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Abstract 
 
Fungal pathogens of humans cause harmful infections and can cause diverse diseases in humans 
which range from superficial skin infections to life-threatening diseases. The opportunistic 
pathogen Candida albicans causes a wide range of diseases primarily in immunocompromised 
individuals. Aspergillus fumigatus is a serious cause of disease in immune deficient patients or in 
those with pulmonary disease (e.g. cystic fibrosis (CF), asthma), and is the second most common 
opportunistic fungal pathogen of humans. Galleria mellonella larvae are an ideal model of 
infection to quickly and easily evaluate the virulence of a range of human fungal pathogens. 
Atorvastatin is a member of the statin drug family which are the main therapeutic agents used to 
decrease high serum cholesterol levels by inhibiting HMG-CoA reductase enzyme. HMG-CoA is 
an enzyme that is responsible for the production of farnesyl diphosphate which is the precursor for 
the production of cholesterol in humans and ergosterol in fungi. The aim of the work presented 
here was to analyse the antifungal activity of a widely prescribed statin (atorvastatin) and assess 
the effect of atorvastatin on the on the virulence of C. albicans and A. fumigatus. The study also 
investigated the effect of atorvastatin on G. mellonella larvae. The results obtained demonstrated 
that atorvastatin has anti-fungal activity and it reduced growth and viability of C. albicans and A. 
fumigatus. Exposure of C. albicans and A. fumigatus to this drug leads to the release of protein, 
amino acids and a reduction in ergosterol synthesis, and increased gliotoxin release in A. fumigatus. 
Proteomic analysis revealed increased abundance of proteins associated with an oxidative stress 
response, ergosterol biosynthesis and secondary metabolites. Atorvastatin can be used to inhibit 
the growth of C. albicans and A. fumigatus in G. mellonella larvae. Atorvastatin was shown to be 
non-toxic to G. mellonella larvae and not to induce an immune response when administered to 
xxvii 
 
larvae. The results presented in this thesis indicate that atorvastatin is non-toxic and capable of 
inhibiting the growth and virulence of C. albicans and A. fumigatus. 
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1    Introduction 
 
1.1 Fungal pathogens of humans 
Fungal pathogens of humans cause harmful infections and thus, are considered to be hidden killers 
(Brown et al., 2012). It has been found that each year these fungal pathogens kill more than 1.5 
million people and affect over a billion people all around the world. However, they are still a  
neglected topic by public health authorities even though most deaths from fungal diseases are 
avoidable (Bongomin et al., 2017). Fungi can cause diverse diseases in humans which range from 
superficial skin infections to life-threatening diseases causing damage to internal organs. Such 
fungal species include dermatophytes, Cryptococcus species, Candida and many more 
(Richardson, 1991, Brown et al., 2012). Fungi causing superficial skin diseases are common and 
can be treated easily but invasive infections caused by fungi tend to possess decreased incidence 
rate and thus, could be life-threatening especially for patients who are diagnosed with AIDS, or 
any autoimmune disorder (Jain et al., 2010). Such patients are known as immunocompromised 
and due to their lower immunity they tend to be more vulnerable to such fungal species than 
healthy individuals (Vargas and Joly, 2002). It has also been determined that the patients who 
receive chemotherapy for treating cancers and those who undergo transplantation of organs such 
as kidney could also develop fatal diseases on exposure to certain fungi (Richardson, 2005). 
Advanced medicine has extensively enhanced the number of immunosuppressed patients who are 
likely to be more vulnerable to invasive fungal pathogens (Pfaller and Diekema, 2007). 
Nevertheless, very few researchers have studied the invasiveness of fungal pathogens in humans 
while most of the researchers have extensively provided information about other microbial 
pathogens including viruses and bacteria. Moreover, enhanced development in the field of 
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medicine has slowed down due to new diagnostic techniques and more potent antifungal drugs 
(Wong et al., 2014).   
1.2 Responses of Host to Fungal infections 
Aspergillus fumigatus, Cryptococcus neoformans and Candida albicans   are the three most 
significant fungal pathogens which cause diseases in human. Primarily, such pathogens are found 
to infect immunocompromised patients as a consequence of intervention therapies which include 
cancer, organ transplant and leukemia or because of immunodeficiency such as HIV and 
neutropenia (Pfaller and Diekema, 2004). This reflects the significance of the defensive property 
of the individual’s immune system in managing and impeding invasive infections. Furthermore, it 
has been observed that in healthy individuals, such fungal pathogens begin to connect with the 
mucosal surfaces of organs ultimately leading to the colonization and commensalism (Boddy, 
2016). However, within the immunocompromised patients, such pathogens are found to cause 
severe infections in the superficial surfaces and could be distributed throughout that causing lethal 
infections (de Melo et al., 2017). In order to counteract such fungal pathogens, the host uses an 
extensive interactive network of chemical signals, cells and proteins disseminated in tissues and 
blood, which together give rise to adaptive and innate immunity (Cavalieri et al., 2018). Invasive 
diseases caused by of filamentous fungi, for example, Aspergillus species produce important 
mortality and morbidity in patients, who are immune compromised with malignancies of 
haematology, transplants of hematopoietic stem cell recipients and patients with the disease of 
chronic granulomatous (Barnes and Marr, 2007, (Richardson, 2005). Fungi can cause infections 
and affect the host immune mechanism due to the expression of various proteins and genes linked 
with their pathogenesis, known as virulence factors (Latgé, 2001). Production of virulence factors 
within aspergilli occurs during their growth in host naturally, these virulence factors defend 
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aspergilli in adverse conditions and increase the spread of Aspergillus infection in human tissue 
(Ben-Ami et al., 2010). 
1.3 Types of Fungal Human Pathogens 
Based on the type of infections caused by each fungus, fungal pathogens of human are categorized 
as follows; 
 1.3.1 Systemic infections 
 
Infections or diseases which prevail deep in the tissues including nervous system and essential 
body organs could be chronic and fatal at the same time. The fungal pathogens causing systemic 
infections tend to enter the human body via open wounds on skin. The fungus is then transmitted 
throughout the human body either through respiratory system or blood circulation causing more 
lethal infections in the internal organs. Such types of fungi are named as saprotrophic fungi which 
grow in the soil (Shoham et al., 2019). 
 
1.3.2 Intermediate infections 
 
Intermediate infections prevail under the skin and remain confined. The prevalence of intermediate 
infections is, however, lower than other types. It is intermediate between systemic and superficial 
infections (Cornely et al., 2017). 
 
1.3.3 Superficial infections 
 
These infections occur when fungi attach either to the skin or appendages including hair and nails. 
These types of fungal pathogens are named as dermatophytes and cause infections such as athlete’s 
foot, ringworms and jock-itch (Reddy, 2017).   
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1.4   C. albicans   
The polymorphic fungus C. albicans is a member of the normal human microbiome. In most 
individuals, C. albicans resides as a lifelong, harmless commensal (Mayer et al., 2013). However, 
it is an opportunistic pathogen for some immunologically weak and immunocompromised people 
(Kim and Sudbery, 2011). Several species of Candida also form candidiasis which is a condition 
in which the fungus grows in an individual. It is also observed in patients with HIV because the 
condition gives the tendency to grow pathogens, which often form infections (Höfs et al., 2016). 
C. albicans biofilm formation initiates with the adhesion of the yeast to the substrate surface, 
followed by cell proliferation, intensive hyphae production and an increase in the extracellular 
matrix (Ribeiro et al., 2017). It is commonly associated with biofilms and can be implanted in 
clinical devices alongside human tissues (Ramage et al., 2006). The increased incidence of 
infection caused by Candida species is mainly due to the increase of the AIDS epidemic, an 
increasingly aged population, higher numbers of  immunocompromised patients and the more 
widespread use of indwelling medical diverse   (YeSudhaSon and Mohanra, 2015). C. albicans   is 
the commonest serious fungal pathogen of humans, variously reported as causing between 250 000 
and 400 000 deaths per annum worldwide as well as extensive morbidity of around 100 million 
episodes of recurrent vaginitis (da Silva Dantas et al., 2016). Candidemia is Candida bloodstream 
infection, also called candidiasis, it is the most common form of invasive candidiasis (Kullberg 
and Arendrup, 2015). In the United States, candidemia is one of the most common causes of 
bloodstream infections in hospitalized patients (Wisplinghoff et al., 2004), and it often results in 
long hospital stays and death. It is also responsible for high medical costs (Morgan et al., 2005). 
Conventional antifungal therapy relies upon the use of polyene, azole or echinocandin drugs but 
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the delivery of appropriate therapy is often problematic due to the appearance of resistance and the 
inherent toxicity of some antifungal therapies (Scorzoni et al., 2017).  
1.4.1 Diseases Caused by C. albicans 
 
C. albicans is the most common type of fungal infection in the human body. The most common 
type of infections and diseases caused by C .albicans includes urinary tract infection, genital yeast 
infection, oral thrush, and mucocutaneous candidiasis which can be identified by focusing on the 
symptoms of diseases and infections (Vila et al., 2017). Other diseases with increased Candida 
infections include HIV for which chemotherapies and steroid medications must be taken by the 
individual facing infection or disease. The immune system of an individual can be weakened by 
illness, stress or some other medications. When an immune system of an organism weakens then 
Candida turns into an aggressive pathogen which causes fungal infections within the body. 
 
1.4.2 Mechanism of action and virulence of C. albicans 
 
C. albicans can cross the host's protective barriers and colonize virtually every internal organ 
causing life-threatening conditions (Johnson et al., 2013). C. albicans penetrates and infects the 
immunocompromised patient by various processes that lead to infection. The fungal cells adhere 
to the surface of epithelial cells in the oral cavity and followed by biofilm formation across it then 
penetrates into the epithelial cells. Once inside the hyphae continues its way through the epithelial 
cells until it gets to the bloodstream. Once in the bloodstream, the fungus can be easily 
disseminated throughout the body and then the fungus can use virulence factors to start growth 
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inside the body.  Virulence factors are traits and adaptations that allow C. albicans to prosper 
within the human body (Odds, 1994).  
1.4.3 Adherence   
 
Virulence factors are the ones that are recognized by various examples of pathogens 
coming from several species like C. albicans, A. fumigatus and others. Interactions of the human 
fungal pathogen with the host tissues are key factors in the pathogenesis of mycoses. According 
to the concept that adherence of microorganisms is a prerequisite for initiation of the infection and 
disease (Fig 1.1A), many studies have sought to identify the fungal adhesins and their respective 
receptors (Tronchin et al., 2008). In order for C. albicans to infect and spread throughout an 
immunocompromised individual, it must be able to adhere to the surface of epithelial cells (usually 
in the oral cavity) so it can develop in order to penetrate the cells and disseminate throughout the 
body (Henriques et al., 2006, Modrzewska and Kurnatowski, 2015). C. albicans possesses an 
extensive repertoire of virulence factors that allow successful colonization and dissemination in 
the host (Mayer et al., 2013) and these include the ability to adhere to host tissue and produce a 
range of enzymes (e.g. secreted aspartyl proteinase, phospholipase, Naglik et al., 2003).  A similar 
process of purging epithelial cells of fungal cells occurs in the urinary tract and vagina, leading to 
a similar adhesion process (Fisher et al., 2011). Yeast adherence to buccal cells was highest and 
the lowest using urinary tract cells, while vaginal epithelium was intermediate (Sandin et al., 
1987).  C. albicans possess a set of unique proteins that allow it to mediate the adhesion process 
to epithelial cells more successfully (Garcia et al., 2011). The mechanisms of adherence 
incorporating adhesins such as ligand-receptor on the yeast cell surface. The well-studied gene 
family agglutinin like sequence (ALS). The genes that encode the ALS family of proteins encode 
glycophosphatidylinositol (GPI)-linked glycoproteins that are used to interact with the epithelial 
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cells to adhere to them.  The ALS3 is particularly important and encodes eight 
glycosylphosphatidylinositol (GPI) cell-surface proteins that are responsible for binding amino 
acids and sugar on an abiotic surface (Cotter and Kavanagh 2000). The most important of the eight 
ALS proteins encoded is Als-3, as it is upregulated during adhesion of C. albicans to oral epithelial 
cells (Murciano et al., 2012). Another adhesion protein is Hwp1, which is hyphae associated GPI-
linked protein that acts as a substrate to the mammalian transglutaminases, covalently linking C. 
albicans to the host cells (Staab et al., 1999). 
 
1.4.4 Invasion 
 
It has been observed that C. albicans  invades epithelial cells (Fig 1.1B)  by two mechanisms which 
include induced endocytosis and active penetration (Maza et al., 2017). The pathogen does not 
rely on active penetration of host cellular mechanism or machinery however it depends upon 
recognition of the cytoskeleton of host. The first action of C. albicans   is to reach the deep tissues 
by breaking the epithelial barrier (Naglik et al., 2011). The interaction of C. albicans is important 
for having commensal growth of the organism along with fungal pathogenicity and host defense. 
In the process of invasion, especially during induced endocytosis, the organism expresses invasins. 
These invasions are in the form of specialized proteins that allows the organism to bind to the host 
cell. These proteins help the organism to engulf the host, while the dead hyphae take up the host 
cell (Cassone, 2015). The invasins have been identified in the process of induced endocytosis: Als-
3 and Ssa-1. Ssa-1 is a cell surface expressed protein which is part of the heat shock family 70 
(Hsp70). Both Als-3 and Ssa-1 bind to E-cadherin and are believed to induce endocytosis through 
a calthrin dependent pathway. Macro-pinocytosis has been mentioned as a potential influencer as 
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well in induced endocytosis of C. albicans (Phan et al., 2007).  By comparing the two processes, 
it has been observed that active penetration is completely opposite of induced endocytosis because 
active penetration is not passive while induced endocytosis is a passive process. Active penetration 
is also driven by fungal adhesion and physical force.  
      1.4.5 Thigmotropism        
Thigmotropism is a directional growth movement that occurs as a mechanosensory response to a 
touch stimulus. Thigmotropism (Fig 1.1B) is involved in the dissemination of hyphae between 
layers of cells and specific directional growth. The weakest area on the cell membrane can be 
sensed through thigmotropism and so the hyphae can penetrate and invade the host cell (Davise et 
al 1999; Kumamoto; 2008). It allows C. albicans to initiate an appropriate response to the surface 
it has attached to whereby attachment to a biotic surface results in invasion and by contact 
attachment to an abiotic surface results in biofilm formation (Mayer et al; 2013). 
 
1.4.6 Biofilm formation 
 
The majority of infections caused by C. albicans are associated with biofilm formation (Fig 1.1C) 
in which the target is an abiotic surface or host cells (Brunke et al., 2016), which is significant for 
the C. albicans to develop and infect the host. Biofilms are mainly the colonies of the organism 
which are encased in extracellular matrix. The growth occurs in a few stages which include 
adherence to host cells, expansion of yeast cells, progression of film, and diffusion of C. albicans 
cells to a new biofilm (Ribeiro et al., 2017). A positive relation between cell surface 
hydrophobicity and biofilm formation has been expounded (Li et al., 2003). This may be mediated 
by cell surface proteins which are encoded by members of the ALS family of adhesin-producing 
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genes and EAP1 (Green et al., 2004). The populations of C. albicans cells were determined 
microscopically in the formation of biofilm. Candida yeast and germ tubes were attached to the 
mucosal surface and consisted of a mixture of closely associated yeast and hyphae surrounded by 
an extracellular matrix (Harriott et al., 2010). The hyphal structure was demonstrated to be an 
essential component for providing the structural integrity and development of characteristic 
multilayered biofilm (Mayer et al., 2013). One feature of biofilms formed by C. albicans is the 
mixture of different morphological forms. Morphological biofilm is a heterogeneous component 
containing a mixture of yeast, hyphae and pseudohyphae forms (Hawser and Douglas, 1994). 
Efflux pumps present in the biofilm are actively pumping out any drug that may come into contact 
with the biofilm and these pumps appear to be found in the biofilm in large quantities (Mukherjee 
et al., 2003). Biofilms in C. albicans have been reported on most medical devices and frequently 
occur on catheters, dentures, voice prosthetics implants and artificial joints (Ramage et al., 2006). 
Recent evidence suggests that biofilms also form on the mucosal surfaces of the mouth and vagina. 
Biofilms of C. albicans form when single cells attach and grow on the surface to form 
microcolonies, which then produce 3-D structure complex that merge together hyphae and an 
exopolymer matrix (Chandra et al., 2001). 
 
1.4.7 Polymorphism and switching 
 
Polymorphism and switching are the ability of an organism to take many forms (Fig 1.1D and 
1.1E). It has been observed that C. albicans is a polymorphic organism that changes its form and 
goes through many morphological transitions between hyphal form, pseudohyphal form, and yeast 
(Neville et al., 2015). The polymorphism of the organism means that it can grow in several forms 
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clinically. There also a different immune response that should be present in the human body 
because C. albicans has various forms and it grows so there should be different immune responses 
for different phases of C. albicans. Hyphae can actively penetrate host tissue allowing them to 
invade the bloodstream and avoid host immune cells such as macrophage (Calderon and Fonzi, 
2001). It is the ability to switch from budding yeast to hyphae that is important for virulence. The 
yeast form can become engulfed by macrophages however it is differentiating into a hyphal form 
and penetrates the macrophages cell membrane allowing escape from the macrophage (Saville et 
al., 2003, Lorenz et al., 2004). It also grows in other forms rather than yeast, pseudohyphae, and 
hyphae which include opaque and white cells which form into chlamydospores (da Silva Dantas 
et al., 2016). White and opaque cells differ in virulence, mating ability, pheromone production and 
competency in evading host defence system. white cells have a key role in internal infection such 
as systemic bloodstream infection whereas opaque colonies are more prevalent in skin infections, 
produces essential for initiation of mating and are more resistant to host neutrophil (Kvaal et al., 
1999; Kolotila and Diamond, 1990). 
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Figure 1.1: Adhesion (A), invasion (B), biofilm formation (C), dimorphism (D), switching (E) 
and fitness traits (F) (Candida albicans pathogenicity mechanisms Mayer et al., 2013). 
 
1.4.8 pH and environmental adaptation 
 
There is an extreme impact of the environment on fungal and bacterial growth. The most important 
thing which is under consideration while focusing on environmental adaptation includes the pH   
(Fig 1.1F) in which the organism grows (Höfs et al., 2016). C. albicans colonizes and infects 
anatomical sites of different pH range, including the oral, gastro-intestinal tracts and the vaginal 
cavity (Davis, 2003) which can cause severe stress to C. albicans. In order to overcome this, C. 
albicans can alter itself in order to adapt to the changing pH environment  (Davis, 2009). C. 
albicans senses and changes itself to the pH of the environment, in addition, it can also dictate 
its extracellular environment. It does this by alkalinizing the surrounding environment,  which 
is nutrient-starved, thereby inducing hyphae formation (Mayer et al., 2012). It has been observed 
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that the acidic pH results in structural loss of an organism, and the outer fibrillar layer reduces in 
size due to acidic pH. Also, acidic pH disrupts the architecture of the structure of an organism. The 
organism requires ambient pH in vaginal mucosa, stomach and GI tract for colonizing (Davis, 
2003). The development in acidic environments include cell wall modifying which results in 
improved chitin and β-glucan exposure at the cell wall periphery (Sherrington et al., 2017). 
1.4.9 Signaling Pathways 
 
Signaling pathways are the molecules that act in a group to control the cell functions such as cell 
death or cell division. For having the responses in the motion of C. albicans, signaling pathways 
are necessary. These are used in MAP kinase pathways that are responsible for sensing 
environmental changes and transducing the signals detected from the cell surface to the interior of 
the cell by sequential protein activation. Activated MAP kinases kinases kinases phosphorylate 
MAP kinases kinases, which in turn phosphorylate MAP kinases (Navarro-Garcia et al., 2001). 
The MAP kinase usually translocates to the nucleus where activation of different transcription 
factors leads to changes in gene expression and/or protein activity, which results in turn in the 
triggering of specific cellular responses required for adaptation (Gustin et al., 1998, (Lengeler et 
al., 2000). In all this molecular interplay, the cell wall has a major role both as a sensor and a 
protector of the living cell. MAP kinase pathways later broken into three which are known as Mck 
1 pathways which activates an oxidative stress response acting along with maintaining the cell 
integrity, Hog1 which is responsible for thermal, oxidative and osmotic stress and Cek 1 which is 
the final pathway for signaling that involves adaptation to thermal stress and maintenance of 
filamentation (Sellam et al., 2019).  
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1.5 Aspergillus fumigatus 
Aspergillus is a species of fungus that lives in soil, plant matter, and household dust. Among the 
species of Aspergillus that are pathogenic towards humans, the most pathogenic, and the primary 
causative agent of aspergillus related infections is A. fumigatus (Morgan et al., 2005). It can also 
produce airborne spores called conidia (Fig 1.2). People can inhale many of these conidia on a 
daily basis. In a healthy individual, the immune system eliminates them from the body without a 
problem. However, it is a serious cause of disease in immunocompromised patients or in those 
with pulmonary disease (e.g. cystic fibrosis (CF), asthma) and conidia can quickly germinate and 
grow in the lung. By increasing in the population of immunocompromised patients A. fumigatus 
has become the second most common opportunistic fungal pathogen of humans (Netea et al., 
2003). 
 
Figure 1.2: Images of A. fumigatus showing hyphae, conidiophore and conidia. 
(https://alunosonline.uol.com.br/biologia/aspergilose-pulmonar.html)  
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1.5.1 A. fumigatus and the Environment 
 
 Mostly A. fumigatus is isolated from a range of substrates in the environment. A. fumigatus 
continues to grow at 37 0C with pH 3.7-7.6 optimally, it can be isolated when soil and decaying 
vegetation range between 12 and 65 0C with the ranges of pH between 2.1 to 8.8 (Kwon-Chung 
and Sugui, 2013). A. fumigatus, like an effective recycler in nature, has adaptable metabolisms 
which fulfill its nutritional need in various environments.  Self-heating heaps of compost are the 
key environmental site for A. fumigatus because of its evident thermo-tolerance. A. fumigatus 
forms small hydrophobic conidia, the head of these conidia forms large numbers of green-grey 
spores with a diameter of 2 to 3 µm makes them float in the environment. Aspergillus conidia is 
found to be 1 to 100 in concentrations that can pass through the clearance mechanism of 
mucocilliary while breathing. Thus, it penetrates the alveoli of lungs (Paulussen et al., 2017).   
 
1.5.2 Diseases caused by A. fumigatus 
 
1.5.2.1 Aspergillosis 
 
Aspergillosis is linked with vast range of disease (Frisvad and Larsen, 2016). Infections related to 
aspergillosis are generally observed in individuals with altered immune mechanism, host elements 
are as crucial as the virulence factors of fungus. Virulence factors serve a key role in the particular 
pathogenesis caused by Aspergillus species, the immune status of the host also serves a major role 
in increasing the fungal virulence factor production in the host (Bodey and Vartivarian, 1989) 
(Tracy et al., 2016). Different physical components are also causing pathogenicity, for example, 
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the capability of fungus to multiply in minute size of conidia, pH of the tissues of the host and at 
optimum temperature (Kwon-Chung and Sugui, 2013). 
1.5.2.2 Invasive Aspergillosis 
 
Invasive Aspergillosis is a kind of pulmonary aspergillosis that can be found in patients with weak 
immune function. It is the most serious kind of aspergillosis that happens once the infection spreads 
quickly from human lungs to skin, heart, kidneys, and brain (Sugui et al., 2015). Invasive 
aspergillosis happens in individuals who have weak immune systems because of the chemotherapy 
for cancer, any disease related to immune system or bone marrow transplantation. Invasive 
aspergillosis can be fatal if left untreated. The signs and symptoms of invasive aspergillosis are 
based on the organs that are affected, generally, they include, eye symptoms, skin lesions, 
headaches, chills and fever, breathlessness, joint or chest pain and hemoptysis (Bruder Nascimento 
et al., 2016). There are various forms of aspergillosis involving pulmonary aspergillosis, 
pulmonary invasive aspergillosis and aspergilloma, notwithstanding the availability of new 
antifungal agents, the morbidity rate due to invasive aspergillosis has increased steadily (Blyth et 
al., 2007). 
1.5.2.3 Allergic Broncho-Pulmonary Aspergillosis (ABPA) 
 
ABPA is a hypersensitive response to the species of Aspergillus (usually A. fumigatus) which 
happens in patients who have cystic fibrosis or asthma. Immune reactions to the antigens of 
Aspergillus cause airway blockage and if it is left untreated, pulmonary fibrosis or bronchiectasis 
can occur. Signs and symptoms include asthma with productive cough, sometimes anorexia and 
fever (Sugui et al., 2015). Diagnosis depends upon imaging tests and history that can be confirmed 
by checking IgE levels and Aspergillus skin testing, specific A. fumigatus antibodies, circulating 
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precipitins. It is treated with corticosteroids, but patients with the condition of the refractory 
disease are treated by itraconazole (Frisvad and Larsen, 2016). 
 
1.5.3 A. fumigatus and virulence factors  
 
Pathogenicity of A. fumigatus is dependent upon various factors of the host (immune status) 
and virulence factors of the pathogen. According to Raksha and Urhekar, (2017) the virulence 
factors that have been recognized for various A. fumigatus include, adhesins, pigments, hydrolytic 
enzymes for example proteases, ribonucleases, phospholipases, restrictocin; catalases, superoxide-
dismutases, mycotoxins and low-molecular-weight non-protein metabolites. Blatzer and Latge, 
(2017) argue that, gliotoxin the main mycotoxin, is among the strong virulence factors, caused by 
A. terrus and A. fumigatus isolates in the samples of patient, although, the formation of aflatoxins 
are mainly observed in the cases of A. flavus. It is noted that mycotoxins are able to serve a key 
role in increasing pathogenesis of aspergillus invasiveness (Bruder Nascimento et al., 2016). It is 
also noted that gliotoxin is formed in vivo in animal tissues infected and affected by A. fumigatus 
as well as it was previously present in patients’ serum with intrusive aspergillosis (Woo et al., 
2017). According to Bruder Nascimento et al., (2016) virulence factors are considered to be 
extremely significant in examining any pathogen which assists in differentiating between species 
which are pathogenic and non-pathogenic. The occurrence of virulence factors within aspergilli 
isolates might provide the invasiveness signals of species from Aspergillus (Paulussen et al., 
2017). With respect to the alterations in virulence factors formed by different species of 
Aspergillus, it can be observed that phospholipase, proteinase, haemolysin, and biofilm formation 
are most significant virulence factors (Ghorbel et al., 2019). A. fumigatus can produce a biofilm in 
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vitro on PS and bronchial epithelial cells with typical characteristics. (Seidler et al., 2008). A 
variety of host components are also activated during aspergillosis which enhance the in vivo 
colonization and biofilm formation by A. fumigatus, like serum components, fetuin A, has been 
recently reported to accelerate the growth of A. fumigatus and facilitate the formation of a thick 
biofilm (Toyotome et al., 2012). It is necessary analysis and understanding of A. fumigatus biofilms 
is necessary to devise newer and better antifungal targets for treating complex A. fumigatus 
biofilm-associated diseases (Kaur and Singh, 2014). 
 
1.5.4   Mycotoxins 
 
Mycotoxins are the toxic compounds that are formed by specific kinds of molds which can form 
mycotoxins on several food items like spices, dried fruits, cereals, and nuts. The growth of mold 
can happen before or after harvesting, on the food itself in humid, damp and warm conditions or 
during storage. Some molds can produce more than one mycotoxin and some mycotoxins are 
produced by more than one fungal species (Zain, 2011).  Contamination by mycotoxins in human 
food and animal feed is a significant worldwide problem because mycotoxins are naturally 
occurring toxic substances (Charoenpornsook and Kavisarasai, 2006). Mycotoxins are secondary 
metabolites produced by fungi, and they can cause mycotoxicosis (diseases and death) in humans 
and animals (Liew and Mohd-Redzwan, 2018). A fumigatus, an important human pathogen, 
produces several mycotoxins including gliotoxin (Hof and Kupfahl, 2009).  
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1.5.5   Gliotoxin 
 
Gliotoxin (Fig. 1.3) is considered to be a significant virulence factor of A. fumigatus. It has 
immunosuppressive characteristics which might suppress and lead to apoptosis in specific immune 
cells, including thymocytes, neutrophils, macrophages, eosinophils, and granulocytes (Hof and 
Kupfahl, 2009). Particularly, neutrophils exposed to gliotoxin produce reduced “reactive oxygen 
species (ROS)” and finish less phagocytic activities and also gliotoxin is considered to interfere 
with the activation of T-cells (Orciuolo et al., 2007). Furthermore, gliotoxin serves as a farnesyl 
transferase inhibitor which inhibits the activity of chymotrypsin of 20S proteasome non-
competitively (Paulussen et al., 2017). In vivo gliotoxin shows anti-inflammatory activity 
(McDougall, 1969). This was explored as an anti-fungal, anti-viral and antibiotic agent (Aljofan 
et al., 2009). Gliotoxin inactivates several enzymes which include glutaredoxin, nuclear factor- κB 
and NADPH oxidase. Nuclear factor- κB inhibition leads to prevent the release of cytokine and 
inflammatory reaction induction (Pahl et al., 1996). The immunosuppressive characteristics of 
gliotoxin are due to bridge of disulfide bond in its structure (Trown and Bilello, 1972). There are 
interactions between the molecules of sulfur which creates thiol groups and bridge of disulfide 
contained in the residues of cysteine, gliotoxin serves by obstructing the residues of thiol in the 
cell-membrane (Kwon-Chung and Sugui, 2009). Also, gliotoxin activates the Bcl-2 family 
member known as Bak to mediate apoptosis (Nguyen et al., 2014). Then, the activated Bak allows 
the ROS release, which produces pores in mitochondrial membrane, such pores enable the 
cytochrome C release that stimulates the cell apoptosis (Pardo et al., 2006).   
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Figure 1. 3: Gliotoxin structure. (https://www.apexbt.com/gliotoxin.html). 
 
1.6 Antifungal drugs 
An antifungal agent is a drug that selectively eliminates fungal pathogens from a host with minimal 
toxicity to the host. An antifungal medication, also known as an antimycotic medication, is a 
pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, 
ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and 
others. The major groups of antifungals are the polyenes, the azoles, and the echinocandin; these 
groups are distinguished primarily by chemical structure and mechanism of action.  The main 
mode of action of azole and polyene antifungal agents is the damage of the cell membrane (Fig. 
1.4).  Sterols are one of the main constituents of the cell membrane and are important in 
maintaining appropriate membrane fluidity and rigidity, and hence, the proper function of the cell 
membrane. Antifungals take advantage of little differences between fungi and humans in the 
biosynthesis of sterols. For most fungi, the predominant membrane sterol is ergosterol (Fig. 1.5). 
Because human cell membranes use cholesterol, instead of ergosterol, antifungal drugs that target 
ergosterol synthesis are selectively toxic.  
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Figure 1. 4: Mechanism of action of antifungal agents. Basic and clinical pharmacology, 13e 
Bertram G. Katzung, Anthony J. Trevor. 
 
 
Figure 1. 5: The prevalent sterol found in human cells is cholesterol however the prevalent sterol 
found in fungi is ergosterol making ergosterol a good target for antifungal drug development. 
(https://courses.lumenlearning.com/cuny-kbcc-microbiologyhd/chapter/mechanisms-of-other-
antimicrobial-drugs/) 
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1.6.1   Azoles 
 
Azoles are the largest class of clinically used antifungal drugs that act mainly by rupturing the cell 
membrane by inhibiting the action of lanosterol 14- α-demethylase enzyme, the enzyme involved 
in the biosynthesis of ergosterol (Odds et al., 2003). This damages the membrane structure and 
disrupts many functions of fungal membrane leading to inhibition of fungal growth (Diaz-Guerra 
et al., 2003).  Ergosterol is the largest sterol component of the fungal cell membrane, and has 
structural differences from human cholesterol, so azoles do not cross react with host cell. The azole 
family includes imidazoles (miconazole, econazole, clotrimazole, and ketoconazole), triazoles 
(fluconazole, itraconazole) and the largest agent voriconazole (second generation, synthetic 
triazole derivative of fluconazole) and posaconazole (hydrated analogue of itraconazole). Many 
azoles are effective both for topical use as well as for the treatment and prophylaxes of invasive 
fungal infection (Utz, 1980).    
 
1.6.2   Polyenes  
 
Polyenes are typically obtained from some species of Streptomyces bacteria (Fj ervik and Zotchev, 
2005).  Polyenes bind to the ergosterol in the fungal cell membrane, which creates hydrophilic 
pores in the cell membrane (Gray et al., 2012). Consequently, the cellular permeability is altered 
and leads to leakage of cytosolic component and, therefore, death (Gray et al., 2012). One of the 
most effective drugs against pathogenic fungi is the polyene amphotericin B (Reeves et al., 2004). 
Amphotericin B’s mechanism of action relies upon the creation of apertures in the fungal cell 
membrane, altering the permeability of the cell and resulting in release of the contents of the cell. 
Amphotericin B has a broad spectrum of action and remains the drug of choice for many forms of 
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deep fungal infection. The Amphotericin B molecules face inwards, creating a pore of about 0.1-
0.4 nm wide, allowing cellular contents to pour out, and hydrogen ions to invade the cell, raising 
the acidity of the cytoplasm (Reeves et al., 2004). The other member of polyene is nystatin, used 
for the topical treatment of oral, oesophageal, gastrointestinal, genital, and cutaneous forms of 
candidiasis (Cirillo et al., 1964).   
 
1.6.3   Echinocandins 
 
Echinocandins are a class of antifungal drugs that target the fungal cell wall. These agents are 
large lipopeptide molecules that are inhibitors of β-(1,3)-glucan synthesis, an action that 
damages fungal cell walls, which lyse easily by osmotic pressure (Denning, 2003). The 
echinocandins family includes caspofungin, micafungin and anidulafungin. Caspofungin is used 
in the treatment of acute invasive candidiasis and as a rescue treatment for invasive aspergillosis  
(Denning et al., 2002). 
 
      1.6.4 Antifungal resistance 
Antifungal agents treat fungal infections by killing or stopping the growth of pathogenic fungi in 
the body. Fungi, like bacteria, can develop antibiotic resistance. Antifungal resistance occurs when 
fungi no longer respond to antifungal agents. Only three types of antifungal drugs currently exist, 
so antifungal resistance can severely limit treatment options. Common antifungal therapy depends 
on the use of polyene, azole or echinocandin drugs but the delivery of appropriate therapy is often 
problematic due to the presence of resistance and the inherent toxicity of some antifungal therapies 
(Scorzoni et al., 2017). Some types of fungi, like Candida auris, can become resistant to all three 
drug types (Ostrowsky et al., 2020).  (Alexander et al., 2013) demonstrated that the Candida 
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isolates with acquired resistance to azoles and echinocandins have been reported more frequently. 
C. glabrata isolates showed no underlying mutations for both echinocandin and azole resistance 
(Spettel et al., 2019). Aldardeer et al., (2020)) showed that the rise in C. parapsilosis resistance to 
fluconazole is alarming. The continuing problems associated with existing antifungal therapies 
(e.g. toxicity, drug resistance) offer the possibility of employing an active, non-toxic therapy such 
as atorvastatin to supplement existing therapies (Galgóczy, 2011; Nyilasi et al., 2010) 
 
1.7   Statins 
 
Statins are the main therapeutic agents used to decrease high serum cholesterol levels and are 
among the most widely prescribed drugs currently on the market (Macreadie et al., 2006). 
Angiographic studies have demonstrated that these compounds reduce the progression and may 
induce the regression of atherosclerosis (Vaughan et al., 2000). They competitively inhibit 3 
hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase by competitively binding to its binding 
sites (Qiu et al., 1991).  HMG-CoA is an enzyme that catalyses the conversion of HGM-CoA to 
mevalonate, which leads to the production of farnesyl diphosphate (Macreadie et al., 2006). 
Farnesyl diphosphate is the precursor for the production of cholesterol in humans or ergosterol in 
plants and eukaryotic microorganisms (Macreadie et al 2006). If the statin-binding site of fungal 
HMG-CoA reductase is like that of human HMG-CoA reductase, it might be expected that statins 
or their derivatives could also be used to inhibit the growth of fungal pathogens through inhibition 
of ergosterol synthesis. Statins have in vitro activities against several human pathogenic fungi, 
including Candida spp., Cryptococcus neoformans, and Zygomycetes (Chamilos et al., 2006). 
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Some of the statins are obtained after fungal fermentation; lovastatin, pravastatin and simvastatin, 
others by synthesis: fluvastatin, atorvastatin, and cerivastatin (Camelia Stancu and Sima, 2001). 
 
1.7.1   Statins mechanism of action  
 
Hypercholesterolemia (high levels of cholesterol), is considered a significant risk factor in 
coronary artery disease. About two-thirds of total body cholesterol is an endogenous synthesis 
(Kriaa et al., 2019), thus the possibility of controlling represents an effective way of lowering 
plasma cholesterol level (Manzoni  and Rollini 2001). Statins (Fig 1.6) selectively inhibit 
hydroxymethyl glutaryl-coenzyme A (HMG-CoA) reductase, the first enzyme in cholesterol 
biosynthesis pathway. The mechanism used by statins to reduce the cholesterol level in the human 
body revolves around the increased uptake and degradation of low-density lipoproteins, also 
known as LDL cholesterol (Bellosta et al., 2000). The liver plays a central role in lipid metabolism, 
serving as the center for lipoprotein uptake, formation, and export to the circulation (Corey and 
Cohen, 2015). Statins target the hepatocytes and inhibit the catalyzing of HMG-CoA reductase by 
not only out-competing HMG-CoA reductase for the active sites, but also by altering the enzyme 
on formation upon binding to the active site. This prevents HMG-CoA reductase from acquiring 
the correct structure necessary to successfully produce cholesterol, making statins very effective 
and specific (Corsini et al., 1999). The inhibition of HMG-CoA then induces the activation of a 
protease that blocks the sterol regulatory element binding proteins (SREBPs) from moving to the 
endoplasmic reticulum to the nucleus. This increases the gene expression of LDL receptors, 
leading to an increase in the number of LDL receptors being produced. Therefore, the reduction 
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of LDL in hepatocytes leads to the increase of hepatic LDL receptors, which in turn reduces the 
amount of LDL within the circulating blood (Sehayek et al., 1994).  
 
 
Figure 1. 6: Mechanism of action of anti-hypercholesteremia (statins). Statins prevent cholesterol 
biosynthesis by inhibiting the conversion of HMG-CoA to mevalonic acid. 
 
1.7.2   Statins Prospect as Antifungals  
 
The fungal equivalent of cholesterol is ergosterol, which is a main component of the cell membrane 
in both C. albicans and A. fumigatus, and just like cholesterol, it depends on the production of 
farnesyl diphosphate (Dhar et al., 2013). The target of statins is the precursors of cholesterol, in 
particular, farnesyl diphosphate. The induced inhibition of farnesyl diphosphate has wider 
modulations than just reducing cholesterol in the human body. Statins are well-known inhibitors 
of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), the key enzyme of the cholesterol 
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synthesis pathway (Maciejak et al., 2013). It could, therefore, be supposed that if statins could 
inhibit cholesterol, they could inhibit the production of ergosterol (Macreadie et al., 2006a). 
Ergosterol, a 5,7-diene oxysterol, is the most abundant sterol in the fungal cell membrane, where 
it regulates permeability and fluidity (Manzoni and Rollini, 2002). Because of its crucial functions, 
unique structural properties, and particular biosynthetic steps, ergosterol is the target of the 
majority of clinically available antifungals. The mode of action of most anti-fungal drugs is to 
target and interact with ergosterol in the fungal cell (Ghannoum and Rice, 1999). Any product that 
can prevent the production of ergosterol would therefore be an invaluable member of the anti-
fungal family and could be used in combination with all the other drugs, as well as potentially on 
its own (Brilhante et al., 2015).  Some previous studies have shown that statins do have an effect 
as antifungal drugs. Macreadie et al., (2006), showed that A. fumigatus and some species of 
Candida show a reduced level of growth once treated with statins. The lower level of growth could 
be due to the fact that the fungi were grown in the presence of statin, leading to a lower level of 
ergosterol (Macreadie et al., 2006a).  Another study (Qiao et al., 2007) confirmed these results, 
suggested that statins have an inhibitory effect on ergosterol in A. fumigatus.   
 
     1.8 Insects as a model for human pathogens 
 
The vertebrate innate immune system has strong structural and functional similarities to the insect 
immune system (Kavanagh and Reeves, 2004,  Renwick et al., 2007). As a result of these 
conserved similarities a wide range of insects have been employed to study the virulence of 
bacterial and fungal pathogens and give results that are comparable with those obtained using 
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vertebrates (e.g., mice) (Lemaitre and Hoffmann, 2007, Ben-Ami, 2011). In recent times more 
interest in in-vivo insect models has come about with the global increase in antibiotic and 
antifungal resistance as a result of more immunocompromised individuals who are susceptible to 
mostly commensal pathogenic organisms that include Candida, Aspergillus, and Cryptococcus 
species (Romani, 2004). Both mammalian and insect models are susceptible to similar pathogens 
and share common infection pathologies (Kemp and Massey, 2007). The insect screening model 
provides an innovative way to simultaneously examine the mechanisms of microbial pathogenicity 
and the activity of potential drug agents without the drawbacks of mammalian models.  This has 
led to a variety of insect host models being established for such purposes. These include the well 
characterised fruit fly Drosophila melanogaster (Lemaitre et al., 1996), wax moth Galleria 
mellonella (Kavanagh and Reeves, 2004) and the silkworm Bombyx mori (Hamamoto et al., 2004) 
(Fig 1.7).  
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Fig. 1.7: Insects used as models for human pathogens.  (A) Drosophila melanogaster; (B) 
Manduca sexta; (C) Galleria mellonella and (D) Bombyx mori (Kemp and Massey, 2007) 
 
1.9   Galleria as an in vivo model 
 
The greater wax moth or honeycomb moth, Galleria mellonella, has become important in many 
different lines of research (Abidalla, 2018). G. mellonella is found throughout the world. G. 
mellonella larvae (range between 1.5 - 2.5 cm) enable an easy means of inoculation with specific 
amounts of drug or pathogen via the pro-leg making G. mellonella more amenable to drug 
pharmacodynamics studies  (Kavanagh and Fallon, 2010). G. mellonella larvae have been 
considered as a viable alternative to other models of infection since they are cheap and require no 
specialist equipment (Kay et al., 2019). In addition to their importance in apiculture, wax moth 
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larvae are widely used as model organisms for studies in insect physiology and human with 
pathogens (Browne and Kavanagh, 2013). G. mellonella larvae were used to assess the virulence 
of C. albicans and to investigate the virulence of pathogenic and non-pathogenic yeast species 
(Cotter et al., 2000). Pathogen virulence and antimicrobial efficacy testing of agents can be 
analysed by using a number of parameters in G.mellonella including the degree of melanisation in 
response to a pathogen, larval death, alterations in fungal burden, changes in haemocyte densities 
and changes in antimicrobial peptide expression (Bergin et al., 2003). Brennan et al., (2002) 
established a positive correlation between the virulence of C. albicans mutants in G. mellonella 
larvae and in BalbC mice and a strong correlation was also established between the virulence of 
A. fumigatus mutants in larvae and mice (Slater et al., 2011). G. mellonella has several innate 
immune similarities to mammals they lack many defined organ systems preventing the full study 
of fungal dissemination and antifungal therapy which is possible in mammals (Kavanagh and 
Fallon, 2010). G. mellonella larvae have also been utilised for assessing the in vivo activity of 
amphotericin B, flucytosine and fluconazole following challenge with C. neoformans (Mylonakis 
et al., 2005) and to evaluate the antifungal properties of novel silver-based compounds (Rowan et 
al., 2009). G. mellonella larvae are now utilized as an infection model for Cryptococcus 
neoformans (Mylonakis et al., 2005) and (London et al., 2006) identified that a number of 
virulence-related genes important in C. neoformans mammalian infections were also involved in 
infection of G. mellonella. 
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1.10    Overall objective:  
 
• Establish the antifungal activity of a widely prescribed statin (Atorvastatin).  
• Assess the effect of atorvastatin on the virulence of C. albicans and A. fumigatus.  
• Analyse the proteomic responses of C. albicans and A. fumigatus to atorvastatin 
exposure.  
• Study the effect of atorvastatin on G. mellonella larvae and analyse the proteomic 
responses to atorvastatin exposure.  
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                                Chapter 2 
Materials and Methods 
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2    Material and method 
 
2.1   Strains used in this work  
2.1.1   Candida albicans strain 
 
A single colony of C. albicans (MEN) (serotype B, wild type originally isolated from an eye 
infection by Dr. D. Kerridge, Cambridge, UK) was transferred to sterile YEPD broth (section 
2.2.1) using a sterile inoculating loop. The flask was re-plugged with cotton wool and incubated 
at 30 0C at 200 x g overnight. 
2.1.2   Aspergillus fumigatus strain 
 
A. fumigatus ATCC 26933, (American Type Culture Collection, Maryland, USA) was used in this 
work. Stocks of A. fumigatus were maintained on malt extract agar (MEA) (Oxoid Ltd 
Basingstoke, UK) (section 2.2.3) at 37 0C and sub-cultured every 4 weeks. Culture was grown in 
different types of media for susceptibility assay, see section 2.2.4 and 2.2.5. 
 
2.1.3   Bacterial strains (S. aureus and E. coli) 
 
S. aureus and E. coli (Clinical isolates) were obtained from St James Hospital, Dublin and were 
transferred aseptically using a sterile loop from a single colony grown on nutrient agar to nutrient 
broth (Oxoid Ltd., Basingstoke, UK) (section 2.2.8) and grown overnight at 37 0C and 100 x g to 
the early stationary phase. 
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2.2 Culture conditions  
 
2.2.1   YEPD [Yeast Extract peptone D-glucose] broth / agar  
 
 YEPD broth was made by dissolving glucose (2% w/v), yeast extract (1% w/v), and 
bacteriological peptone (2% w/v) in deionized water and autoclaving at 1210C for 15 minutes. For 
solid media preparation 2% (w/v) agar was added and autoclaved as described. In some cases, 
antibiotic erythromycin (1 mg/ml) was added to the hand warm agar prior to pouring to control 
bacterial contamination in determining fungal load in Galleria mellonella larvae. This was 
prepared by dissolving 0.1g erythromycin in 1 ml of deionized (di) H2O and transferring the 
erythromycin solution into the hand warm agar solution 100 ml. Once in the agar solution the 
plates were spread as normal and stored at 4 0C in the dark. All erythromycin supplemented plates 
were used within 3 days.  
2.2.2   C. albicans liquid culture and cell harvest 
 
 A colony of C. albicans (MEN) was aseptically transferred to sterile YEPD broth using a sterile 
inoculating loop. The flask was re-plugged with cotton wool and incubated at 30 0C at 100 x g 
overnight. To get a suspension of C. albicans cells, 50 ml culture was transferred to a sterile 50 ml 
tube and centrifuged at 500 x g for 5 minutes.  The cellular pellet was washed twice in sterile PBS 
and the final cell concentration in a 10 ml volume of sterile PBS was ascertained by 
Haemocytometer. 
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2.2.3   Malt Extract Agar (MEA)  
 
Malt extract agar was prepared by adding 50 grams of MEA per liter of deionized water, mixing 
and autoclaving at 121 0C for 15 minutes. Agar was poured into petri-dish once it was hand hot. 
2.2.4   Sabouroud dextrose liquid medium  
 
Sabouroud dextrose powder (30 gram) was dissolved in one litre of distilled water, mixed well, 
and sterilized by autoclaving at 121 0C for 15 minutes. 
2.2.5   Czapek-Dox broth  
 
Czapek-Dox broth powder (35 gram) was dissolved in one litre of deionized water, mixed well, 
and sterilized by autoclaving at 121 0C for 15 minutes 
2.2.6   Nutrient broth (NB)  
 
NB (13 gram) powder was dissolved in 1 liter of distilled water. This was mixed well and sterilized 
by autoclaving at 121 0C for 15 minutes.   
2.2.7   A. fumigatus culture and cell harvest 
 
Stocks of A. fumigatus conidia were grown and maintained on Malt Extract Agar (Oxoid Ltd 
Basingstoke UK) at 37 0C in a thermally controlled incubator for 4 to 5 days. Sterile medium was 
inoculated in a sterile laminar flow hood and A. fumigatus conidial inoculations of 5 x 107 per 100 
ml culture were used. Conidia of A. fumigatus were harvested in a safety cabinet Class II. 10 ml 
PBS-T [0.1% (v/v) Tween 80] was used to wash the plates. Conidia were harvested by 
centrifugation at (2,056 x g) for 5 minutes at room temperature on a Beckmann GS-6 bench 
centrifuge. The supernatant was removed, and the conidial pellet was washed twice in sterile PBS 
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to remove excess Tween 80 and re-suspended in sterile PBS. The concentration of conidia in the 
suspension was determined by counting with a Haemocytometer. 
2.3   General laboratory practice and sterilization procedures  
 
2.3.1   Chemicals and reagents  
 
 All reagents were of the highest purity and were purchased from Sigma Aldrich Ltd, Somerset, 
U.K unless otherwise stated.  
 
2.3.2   Sterilization procedures  
 
All growth culture media were sterilized by autoclaving before use at 1210C and 15 lb/sq.in for 
15 minutes. Any liquid unsuitable for autoclaving was filter-sterilized using a pore size 0.45 and 
0.2 µm (Sarstedt, Nümbrecht, Germany).  All used liquid and solid cultures were autoclaved 
prior to disposal. Laboratory equipment such as micro-centrifuge tubes and pipette tips were kept 
in a sealed container and sterilized by autoclaving at 1210C for 15 minutes prior to use. Semi-
solid agar media were allowed to cool until hand hot, (approximately 45-55ºC) and poured under 
sterile conditions using 9 cm petri-dishes. All work with A. fumigatus was carried out using a 
class II safety cabinet.   
2.3.3   Phosphate buffered saline (PBS)  
 
 One PBS (NaCl 8.0 g/l, KCl 0.2 g/l, Na2HPO4 1.15 g/l, KH2PO4 0.5 g/l, pH 7.3) tablet (Oxoid 
Ltd Basingstoke UK) was dissolved in 100ml deionised water and autoclaved at 1210C for 15 
minutes. PBS was made fresh as required and stored at room temperature.   
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2.4   Preparation of Atorvastatin  
Atorvastatin (20 mg Film-Coated Rowex Ltd) tablets were ground to a powder using a pestel and 
mortar and dissolved in sterile PBS with agitation. The solution was filtered sterilised using 0.45 
μm and 0.02 μm pore filters (Sarstedt, Nümbrecht, Germany).  
 
2.5   Susceptibility of fungal cells to increasing concentrations of atorvastatin 
 
C. albicans was grown to stationary phase in YEPD and cells were counted on a haemocytometer 
and diluted to a cell density of 1 x 106 cells/ml. In the case of A fumigatus conidia were harvested 
in a safety cabinet and a cell suspension was prepared in SAB liquid media. Cells were counted on 
a haemocytometer and were diluted to a cell density of 1 x 105  cells/ml. Using 96 well plates 
(Costar, New York, USA) and a multi-channel pipette, 200µl of the media was placed into each 
well of the first row, this was the control media; growth media (100µl) was placed in each well of 
the other 11 rows. The atorvastatin solution (100µl) was placed in each well of row 12 and then 
serially diluted (50:50) as far as row 3.  Once the drug gradient had been established cells (100µl) 
were added to each well. C albicans plates were incubated at 30 0C   for 24 h and A.  fumigatus 
plates were incubated at 37 0C   for 48 h. Growth was quantified by reading on an absorbance plate 
reader (Synergy HT, Bio-Tek) at 600 nm. 
2.6   Effect of atorvastatin on the viability of C. albicans 
C. albicans cells were incubated in 10 ml PBS supplemented with different concentrations of 
atorvastatin for different time points at 30 0C. An aliquot was removed, serially diluted, and 100μl 
of diluted sample was spread onto YEPD agar plates. Resulting colonies were enumerated and 
expressed as % survival relative to the control.  
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2.7 Analysis of atorvastatin effect on growth of A. fumigatus on solid medium  
 
Malt extract agar was prepared and poured into petri-dish once it was hand hot, different 
concentrations of atorvastatin (1.5, 3, 6 µl) were added to the hand warm agar prior to pouring. A. 
fumigatus (5x106) was inoculated on the center of the plate, incubated at 37 oC for 48, 72 and 96 
h). 
 
2.8   Fluorescence microscopy of fungal cells  
Cells were grown in the presence of a different concentration of atorvastatin for 24 and 72 h for C. 
albicans and A. fumigatus respectively, harvested, washed in PBS and stained with Calcofluor 
white (Sigma) for 15 min at 16 0C on a glass slide. Cells were washed twice (PBS) and a cover 
slide was placed on top.  Cells were viewed with an Olympus BX51 fluorescence microscope at 
magnification x 400.  
 
2.9   Determination of Adherence ability of C albicans 
The adherence of C. albicans to buccal epithelial cells (BECs) was analysed as described (Murphy 
and Kavanagh, 2001). A culture of C. albicans was grown in the presence or absence of 
atorvastatin for 24 h. Cells were counted using a haemocytometer and cells were harvested, washed 
with PBS and re-suspended in 1ml of PBS. Human buccal epithelial cells (BECs) were collected 
from healthy volunteers using sterile tongue depressors by gently scraping the inside of the cheek. 
The BECs (5 x 105) were washed in PBS (500 x g, 5 minutes) and resuspended in 1ml PBS. The 
final solutions of yeast and BECs (1ml each) were mixed together gently to give a ratio of yeast to 
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BECs of 50:1 and placed in an incubator at 30 0C for 2 h. The mixture was then filtered through a 
polycarbonate mesh with a pore size of 20µm and washed with 10ml of PBS. The yeast/BEC 
suspension was smeared onto a clean glass slide and allowed to air dry overnight. The cells were 
heat fixed by passing the slide through the flame of a Bunsen burner a few times. The slides were 
flooded with 1% (w/v) crystal violet and washed with distilled water and allowed dry. The number 
of yeast cells adhering to BECs was counted using a light microscope (HP), and the average 
number adhering per BEC was calculated.   
2.10   Analysis of susceptibility of C. albicans to Trichoderma lysing enzyme preparation. 
Five ml of 24 h C albicans culture were taken, inoculated in 50ml YEPD (1x107) and incubated at 
30 0C for 3- 4 h. Cells were harvested, washed with sterile PBS and centrifuged. C. albicans cells 
were resuspended in MB buffer (0.5 M KCl, 0.1 M NaCl and 0.1 M acetic acid) at PH 5.5. 
Trichoderma lysing enzyme (SIGMA) was added to the cell suspension. 100 µl of the sample were 
taken at different time points (0, 20, 40, 60 and 80 min.), diluted with sterile distilled water 
(1:10000) 100 µl was taken, spread on YEPD plate and incubated at 30 0C for 24 h to count the 
colonies.  
 
2.11   Ergosterol extraction and quantification 
The method of Arthington-Skaggs et al. (1999) was used to extract the sterols with slight 
modifications. One-gram dry weight of each sample was washed twice with sterile PBS and 
resuspended in 3 ml of a solution containing 20% (w/v) KOH (Sigma) and 60% (v/v) ethanol. 
Samples were placed in a heated (85 to 90 0C) shaking water bath for 2 h. N-heptane (2 ml) was 
added to the solution and vortexed for 10 seconds. The top aqueous layer containing ergosterol 
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was separated by centrifugation for 5 min at 3000 xg and collected. Different concentrations of 
ergosterol standard were prepared to produce a standard curve (Fig 2.1). Ergosterol quantification 
was performed using a Gas Chromatograph (Hewlett Packard 5890 series II) with a flame 
ionization detector and a chrompack capillary column (Chrompack International BV, Middleburg, 
The Netherlands). The carrier gas was N2, and the injector and detector temperatures were set at 
320 oC. Ergosterol standards were used to calibrate the instrument. 
 
 
 
Figure 2.1: Standard curve of ergosterol which was generated using samples of known 
concentrations (mg/ml). 
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2.12   Determination of amino acid leakage 
Amino acid leakage from cells exposed to atorvastatin for 0 to 4 h was determined using the 
ninhydrin colorimetric method and expressed in terms of aspartic acid and glutamic acid. Standard 
curves were produced using different concentrations of aspartic acid and glutamic acid (Fig. 2.2 
and Fig 2.3). Ninhydrin (Sigma-Aldrich) was dissolved in ethanol to give a final concentration of 
0.35% (w/v) and 250μl was added to each sample (1 ml) and heated to 95 0C for 4 min followed 
by cooling on ice. The absorbance at 600 nm was recorded on a spectrophotometer (Beckman DU 
640 Spectrophotometer). 
 
 
 
 
Figure 2.2: Standard curve of aspartic acid which was generated using samples of known 
concentrations.  
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Figure 2.3: Standard curve of glutamic acid which was generated using samples of known 
concentrations.  
 
2.13   Bradford assay and protein quantification 
C albicans protein samples were diluted in sterile PBS. Biorad Bradford protein assay reagent was 
diluted in ddH2O (ratio 1:5). Twenty microliters of sample were placed in a 1 ml cuvette. To this 
980µl of diluted Biorad Bradford protein assay reagent was added. The cuvettes were inverted to 
mix the contents and then allowed to incubate for 5 minutes at room temperature before being read 
in a microcentrifuge tube Bio-photometer. The quantity of protein was based on the OD600 
readings.  
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2.14   Assessment of Catalase activity of cells 
Catalase activity was measured as described (Rowan et al., 2009) with slight modifications. 
Protein was extracted from cells as described (section 2.17). Protein extract was added to 1.8 ml 
of 17 mM H2O2 and left at room temperature for 15 minutes. The suspension was centrifuged at 
10,000 x g (Eppendorf centrifuge 5417R) for 1 minute to stop the reaction. The supernatant was 
removed and placed in a clean quartz cuvette. The absorbance at 240 nm was obtained on a 
Beckman DU640 spectrophotometer. A blank consisted of 17 mM H2O2. 
2.15   Galleria mellonella viability assay 
 Liquid cultures of C. albicans were grown to exponential phase. The cells were counted using a 
hemocytometer and 5 x 107 cells were harvested. These cells were washed twice using PBS and 
re-suspended in 1ml of PBS. Culture were diluted to 5 x 107/ml. Thirty G. mellonella larvae, with 
no black spots on their backs (0.02-0.026gm) were selected and placed into three Petri dishes with 
some wood shavings. Ten larvae were injected with 20µl of the cultures (1 x 106/ml) into the last 
left pro-leg of the Galleria, under sterile working conditions using insulin syringe, 10 were injected 
with 20µl of the treated culture and the other 10 larvae were injected with 20µl of the PBS (blank). 
The larvae were incubated overnight at 30 0C. Mortality was assessed by visual inspection and 
lack of movement when gently probed.         
 
2.16   Determination of fungal load in G. mellonella larvae 
 Three larvae inoculated with C. albicans were homogenized using a pestle and mortar in 3 ml of 
sterile PBS. This was serially diluted with PBS, and 100 µl aliquots of the resulting dilutions 
were plated on YEPD plates containing erythromycin (1 mg/ml) to prevent bacterial overgrowth. 
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These plates were incubated at 30 0C for 48 h. The fungal load was calculated as the yeast cell 
density per larva and was based on the number of colonies that grew at specific dilutions. 
 
2.17   Determination of fungicidal activity of hemocytes 
 Larvae were inoculated with 20 µg of atorvastatin and incubated for 0, 20, 40, 60 and 80 
minutes (n = 10). Hemocytes were extracted from larvae and incubated at a density of 1x106/ml 
at 30 0C in PBS in a thermally controlled stirring chamber. Cell free hemolymph opsonized C. 
albicans (2x106 cells) were added and killing was measured as described previously (Sheehan 
and Kavanagh, 2018) by diluting and plating yeast cell suspensions onto YEPD agar plates. 
Plates were incubated and the resulting number of colonies enumerated. Results were calculated 
as the mean (± S.D.) from at least three experiments with colony counts performed in triplicate 
for each sample and expressed as a percentage of the original number at time zero. 
 
2.18   Analysis of the effect of atorvastatin on the growth of A. fumigatus  
SAB culture medium (50 ml) was inoculated initially with 1x105 A. fumigatus conidia/ml. Four 
different concentrations of atorvastatin plus control were used in this experiment. Cultures were 
incubated at 37 0C on a rotary incubator, samples were taken every 72 h, filtered using miracloth, 
and wet hyphae mass was measured (wet weight).   
 
2.19   RP-HPLC Gliotoxin 
Reversed phase HPLC is the most commonly used form of HPLC. Different compounds have 
different retention times. For a particular compound, the retention time will vary depending on the 
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pressure used, the nature of the stationary phase, the exact composition of the solvent and the 
temperature of the column. In this work RP-HPLC was employed to quantify gliotoxin 
concentrations in A. fumigatus culture supernatants.  
 
2.19.1   Buffer used in (RP–HPLC) 
Buffer A.  
(1 L) HPLC grade water was placed in a darkened Duran bottle. 0.1% (v/v) Triflouroacetic acid 
was added and mixed thoroughly. This was made fresh on the day.  
Buffer B.  
HPLC grade acetonitrile (1 L) was placed in a clear Duran bottle. Triflouroacetic acid 0.1% (v/v) 
was added to the bottle and contents of the bottle were mixed thoroughly. This was made fresh on 
the day.  
2.19.2   A. fumigatus gliotoxin extraction and quantification 
 
Seventy-two h A. fumigatus cultures were harvested by filtration using mira-cloth. Chloroform (20 
ml) was added to the same volume of supernatant for each filtrate sample and the solution was 
mixed continually for 2 h. The chloroform was collected and evaporated to dryness in a rotorary 
evaporator. Dried extracts were dissolved in 500 µl methanol (Fisher chemical) and stored at -20 
0C until assayed. Gliotoxin was determined by reversed phase-HPLC (Agilent 1200 Series). The 
mobile phase was acetonitrile (Fisher Chemical), 0.1% (v/v) trifluoroacetic acid (Sigma-Aldrich) 
and deionized-distilled water. Gliotoxin extract (20 µl) was injected onto a C18 Hewlett Packard 
column. Gliotoxin concentrations (50, 100 and 200 ng/ml) were dissolved in methanol (Sigma-
Aldrich) to create a standard curve of peak area versus gliotoxin concentration was constructed 
(Fig 2.4).  
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Figure 2.4: Detection of gliotoxin by RP-HPLC. Gliotoxin detection was performed at 254 nm 
with a retention time of approximately 17.1 minutes. Image shows gliotoxin detection of 1µg/10µl. 
 
2.19.3   Preparation of extracts for detection of gliotoxin by reversed phase HPLC  
 
A standard curve of peak value versus gliotoxin concentration (Fig 2.5) was constructed using 
different concentrations of gliotoxin standards (µg/10µl). 
 
 
Figure 2.5: Standard curve of gliotoxin reference. 
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2.20   Quantification of atorvastatin administered to G. mellonella larvae by  HPLC 
 
Atorvastatin was determined by reversed phase-HPLC (Agilent 1200 Series). The mobile phase 
was acetonitrile (Fisher Chemical), 0.1% (v/v) trifluoroacetic acid (Sigma-Aldrich) and deionized-
distilled water. Atorvastatin extract (20 µl) was injected onto a C18 Hewlett Packard column. 
Atorvastatin concentrations (1, 10 and 100 ng/ml) were dissolved in methanol (Sigma-Aldrich) to 
create a standard curve of peak area versus atorvastatin concentration was constructed (Fig 2.6). 
A standard curve of peak value versus atorvastatin concentration (Fig 2.7) was constructed using 
different concentrations of atorvastatin standards (mg/10ml). 
 
 
 
Figure 2.6: Detection of atorvastatin by RP-HPLC. Atorvastatin detection was performed at 254 
nm with a retention time of approximately 21.9 minutes. Image shows atorvastatin detection of 
1mg/10ml. 
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Figure 2.7: A standard curve of peak value versus atorvastatin concentration was constructed 
using different concentrations of atorvastatin standards (mg/ml). 
 
 
2.21   Whole cell protein extraction from the fungal cells 
 
2.21.1   Whole cell protein extraction from C albicans 
 
 A culture of C. albicans was grown to stationary phase in YEPD broth for 24 h at 30 0C in an 
orbital incubator. A cell suspension was centrifuged at 8000 x g for 10 min, washed twice with 
PBS. Four ml of lysis buffer (6M urea, 2M thiourea, 0.1M Tris-HCL) and supplemented with 
protease inhibitors (aprotinin, pepstatin,A, TLCK, leupeptin) 1 µl/1ml of buffer was added to one 
gm of cell pellet and mix until a viscous liquid consistency was obtained. The viscous liquid was 
sonicated at 50% power, cycle 3 for 15 second. This was repeated three times with the sample 
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being cooled on ice between each sonication. Protein supernatant were obtained by centrifugation 
(10,000 x g 4 0C for 15 min) and pellet was discarded.   
 
2.21.2   Whole cell protein extraction from A. fumigatus  
 
A culture of A. fumigatus was grown in SAB liquid culture media for 72 h at 37 0C in an orbital 
incubator. A 100 ml volume of the culture medium was filtered through 2 layers of Mira-cloth and 
squeezed to dry. Hyphae were left 5 minutes to dry on filter paper. A certain weight of mycelia 
mass was added to 50 ml falcon tube and Snap frozen in liquid nitrogen to break-up by agitation. 
Mycelium (1 gram) was ground to a fine powder using mortar and pestle with liquid nitrogen 
followed by the addition of four ml of protein extraction buffer [0.4 M NaCl, 10mM Tris HCl, 2 
mM EDTA] supplemented with aprotinin, pepstatin, TLCK, leupeptin (1µl/1ml) and ground until 
a viscous liquid consistency was attained. The suspension was sonicated using sonication probe 
(Bandelin sonopulse, Bandelin electronic, Berlin) at 50% power, cycle 3 for 15 second. This was 
repeated three times with the sample being cooled on ice between each sonication. Protein 
supernatant were obtained by centrifugation (10,000 x g 4 0C fore 15 min) and pellet was discarded.   
2.22 Solutions and buffers used for 1D and 2D SDS-PAGE  
Coomassie Blue Stain Solution: 
Brilliant Blue R      2 g  
Methanol               450 ml   
Acetic acid             100 ml   
Made to 1 L with distilled water  
Coomassie De-stain Solution:  
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Acetic acid             100 ml   
Methanol               200 ml   
And 700 ml of distilled were added 
IEF Equilibration (Reducing) Buffer  
30% (v/v) Glycerol (150 ml)  
2% (w/v) SDS (10 g)  
6M Urea (180.1 g)  
50mM Tris HCl (3.94 g)  
Up to 500 ml distilled water, pH adjusted at 6.8, Aliquoted into 20ml (in 50 ml falcon tubes) and 
stored at -20 0C. When using, add 2% DTT (0.4 g), for reducing (2.5% IAA (0.5 g) + few grains 
of Bromophenol Blue) for alkylation.  
IEF Buffer   
8 M Urea (48 g)  
1% (v/v) Triton X100 (1 ml)  
4% (w/v) Chaps (4 g)  
10 mM Tris HCl (0.158 g)   
2 M Thiourea (15.22 g)  
Made up to 100 mls of sterile distilled water Aliquot into 2 ml samples and stored at -20 0C When 
using, add 65 mM DTT (0.2 g) and 0.8% (v/v) Ampholytes (2 µl)  
Running Buffer 10X = Electrode Buffer  
Trizma base   30 g  
Glycine    144 g  
SDS (sodium lauryl sulphate) 10 g  
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Made to 1 L with distilled water, pH should be 8.9, stored at room temp and 1:10 Dilution in 
distilled water = 1X  
1% Agarose (for sealing strips):  
1 g Agarose 100 ml  
10X Running Buffer  
Few grains of Bromophenol Blue  
Heat until boiling and sets when cool.  
200 mM EDTA Solution:  
EDTA (14.89 g)  
Made to 200ml with Distilled water, pH at 7.2 
5X Sample Buffer for 1-D SDS–PAGE.  
SDS      2.0 g  
DTT   1.54 g  
2 ml of [0.2 % (w/v) Bromophenol blue (0.1 g) + 50% (w/v) Sucrose (25 g) made to 50 ml H2O] 
3 M Tris HCl (pH 6.7) 
2.1 ml 200 mM EDTA (pH 7)    
0.5 ml Add deionized water- make up to 20 ml  
Aliquoted to 500 microliters. Stored at -20 0C  
Tris–HCl 1.5 M  
Tris – HCl (1.5 M) was prepared by dissolving 11.8 g Trizma Base (Tris Base) in 50 ml deionised 
water and adjusted to pH 8.9. Following pH adjustment 1.5 M Tris – HCl was filter sterilised 
through a 0.22 µM cellulose filter (Millipore) and stored at 4ºC.  
Tris – HCl 0.5 M  
52 
 
0.5 M Tris-HCl was prepared by dissolving 3.94 g Trizma Base in 50 mls deionised water and 
adjusted to pH 6.8. Following pH adjustment 0.5 M Tris– HCl was filter sterilised through a 0.22 
µM filter (Millipore) and stored at 4ºC.  
Ammonium Persulphate (APS) 10%  
APS (10% w/v) was prepared by adding 0.05 g APS into 0.5 ml of deionized water and vortexing 
to dissolve completely. APS (10% w/v) was prepared fresh every day and kept on ice when not in 
use.  
Sodium Dodecyl Sulphate (SDS) 10% w/v  
Sodium Dodecyl Sulphate (SDS), (10% w/v) was prepared by adding 10 g SDS to 100 mls of 
deionized water and left to stir until all SDS had been solubilized. The solution was stored at room 
temperature after filtration through a 0.22 µM filter. 
 
  
2.23   Preparation of SDS–PAGE mini-gels  
All glass plates were washed in warm soapy water and cleaned thoroughly with 70% ethanol prior 
to use in SDS–PAGE mini-gels, (Mini-Protean II gel casting apparatus). A 12.5% acrylamide gel 
was normally used in experimental procedure. The separating gel separates the proteins from each 
other depending on size therefore aiding visualization. All gels were used within 24 h of setting 
and were allowed to polymerize for at least one h prior to being loaded. Solution component of 
separating gel 12.50%, 1.5 M Tris-HCl 3 ml, deionized water 3.8 ml, 30% Acrylamide 5 ml 10% 
v/v SDS 120 µl, 10% v/v APS 75 µl, TEMED 3 µl. These volumes were sufficient to make 3 mini-
gels.   
53 
 
2.23.1   Loading and voltages of 1-D SDS-PAGE   
 
Protein was extracted from a sample (grown with and without atorvastatin) using method described 
in section 2.17.1. Bradford method was used to calculate the concentration of protein see (2.11) 
and equal concentrations were loaded into the wells of separating gel and run at 50 Volts for 10 
minutes followed by 80 Volts for 120 minutes on (Bio-Rad, CA, USA). Gels were stained with 
Coomassie Blue solution for 5 h and destained with Coomassie destaining solution for 8 h.  
 
2.23.2   Preparation and analysis of 2-D SDS-PAGE   
 
Protein was extracted from a sample as mentioned before. Using the Bradford method, a solution 
of 100 µg/ml protein was prepared and then precipitated by adding three times the volume of ice-
cold acetone and incubated overnight at -20 0C. The precipitated protein was collected by 
centrifugation (12,400 x g) for 30 minutes at 4 0C (Eppendorf centrifuge 5417R). The acetone was 
removed, and the pellet was allowed to air dry. The dried precipitated protein was resuspended in 
250 µl IEF buffer (see 2.18.4) with 0.8% (v/v) IPG buffer, pH 3-10 (G.E. Healthcare BioSciences 
AB, Uppsala, Sweeden;) and few grains of bromophenol blue. The solution was applied to a 13 
cm ImmobilineTM DryStrip pH 3-10 (G.E. Healthcare) and iso-electric focusing was performed 
on an Ettan IPGphor II (Amersham Biosciences, NJ, USA) system using the following program. 
1. Step and Hold   50 Volts 12 h 2. Step and Hold 250 Volts 15 minutes 3. Gradient    8000 Volts 
5 h 4. Step and Hold 8000 Volts 8 h. Following IEF IPG strips were frozen at -80ºC or were 
transferred to equilibration. Strips were initially equilibrated in 5 ml reducing equilibration buffer 
for 15 minutes. Strips were transferred to the 5 ml alkylation buffer for 15 minutes. Following 
equilibration, strips were rinsed in 1X electrode running buffer. Strips were placed on top of SDS-
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PAGE gels and sealed with 1% w/v agarose sealing solution. The top of the gel was sealed with 
molten cooled sealing solution and allowed to set. The second dimension of protein separation was 
achieved by placing the gels in ProteanXi-II vertical electrophoresis cells as per manufacturer’s 
instructions. The inner chamber was filled to the top with 5X electrode running buffer while the 
outer chamber was filled with 2X running buffer. Gels were initially electrophoresed for 1 h at 50 
volts and at 80 volts for the remaining time. Gels were monitored regularly to assess the level of 
electrophoresis and were transferred to a staining dish of Coomassie Blue solution and destained 
with destaining solution, until the blue background was removed.   
 
2.24   In gel trypsin digestion and bioinformatics analysis of LC/MS results.  
 
The method of Shevchenko et al., (2006) was used in processing of bands and spots for LC-MS 
analysis with slight modifications. LC/MS grade acetonitrile 100 % (v/v) was used to wash tubes 
and pipette tips. Following this 30-minute incubation period 500µl of acetonitrile was added for 
10 minutes shaking at room temperature. Samples were centrifuged at 20,000 x g for 10 minutes 
and the supernatant was removed. Gel pieces were placed in 40 µl of 1:1 ammonium bicarbonate 
(100 mM): acetonitrile (100 % (v/v) and incubated with occasional vortexing for one h. The 
supernatant was removed and 40 µl of 100% (v/v) acetonitrile was placed over gel pieces and 
incubated until gel became white and shriveled. Acetonitrile was removed and gel pieces were 
covered with 500 µl 50mM ammonium bicarbonate for 5 minutes. An equal volume of 100% (v/v) 
acetonitrile was added and the pieces were incubated for a further 15 minutes. Supernatant was 
removed and pieces were again covered with acetonitrile until gel became white and shrunk. 
Trypsin (20 µg-Promega) was reconstituted in 100 µl of reconstitution buffer (10 mM ammonium 
bicarbonate containing 10% acetonitrile). This was aliquoted into 10 x10 µL aliquots and to each 
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of these 500 µl of 50 mM Ammonium Bicarbonate was added. The trypsin solution (50 µl) was 
added to each gel piece. This was incubated at 4°C for 1 h and at 37°C overnight. For peptide 
recovery samples were centrifuged at 20,000xg for 10 minutes and supernatant was transferred to 
a fresh 1.5ml tube. Extraction buffer (1:2 5% formic acid (v/v): acetonitrile) was added to the gel 
pieces (50 µl) and incubated at 37°C for further 15 minutes. Samples were centrifuged at 20,000 
xg for 10 minutes and added to the supernatant. Extracts were dried in a vacuum centrifuge 
overnight. Dried peptides were resuspended in 20 µl of 0.1% formic acid and sonicated for 2 
minutes. Samples were filter sterilized and supernatants were added to mass spectroscopy vials 
(Agilent Technologies, USA). Samples were analysed on a 6340 Ion Trap LC/MS spectrometer 
(Agilent Technologies) using BSA as external reference standards. Resulting data were analysed 
using the mascot search engine, (www.matrixscience.com). The mass error tolerance was 1 Da 
allowing for a maximum of no more than 2 missed cleavages. Verification of protein sequences 
was confirmed by blasting the protein sequence on the Uniprot, (www.uniprot.org), and NCBI, 
(www.ncbi.nlm.nih.gov), databases. Identified proteins are listed by their GI number as accessed 
through www.ncbi.nlm.nih.gov.   
 
2.25   Protein methodology for shotgun label free proteomics  
 
2.25.1   Acetone precipitation of protein samples 
 
 Acetone precipitation was used to concentrate protein from a dilute sample and also to purify 
protein samples. The required volume of protein was calculated following Biorad Bradford assay 
quantification (section 2.11). The correct protein volume was aliquoted into a fresh pre-chilled 
microcentrifuge tube and 100% ice cold acetone was added to the tube at a volumetric ratio of 1:3 
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(sample: acetone). Protein was left at -20oC overnight and then precipitated at 13,000 x g for 10 
minutes to pellet protein. All protein pellets were placed upside down to air dry for 5 mins 
following removal of acetone.  
 
2.25.2   In solution digest protocol for overnight peptide digestion for label free  
proteomics.   
 
 The list of buffers used for the in-solution digestion of proteins in preparation for label free 
proteomics are presented below. Buffers were made fresh daily. Protease Max (Promega) was used 
in order for the trypsin (Promega) to digest the protein when using urea and thiourea. All water 
was deionised and was taken fresh before use from the deionised water dispenser.   
 
• Sample Resuspension Buffer (pH to 8.0)  
7.2g Urea, 2M Thiourea, 0.1M Tris-HCL in 20mls diH2O  
• 200mM Ammonium Bicarbonate (AmBic) solution 
0.394g Ammonium bicarbonate in 25ml water   
• 50mM AmBic  
2.5ml 200mM AmBic in 7.5ml water   
• 0.5M Dithiothreitol (DTT)  
0.077g DTT in 1ml 50mM AmBic   
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• 0.55M Iodoacetamide (IAA) (Protect from light)   
0.102g IAA in 1ml 50mM AmBic   
• ProteaseMax solution (1mg/100µl)  
1mg ProteaseMax TM Surfactant Trypsin Enhancer (Promega) in 100µl 50mM AmBic  
• Trypsin solution (0.5µg/µl)  
20µg Sequence grade modified trypsin (Promega) in 40µl trypsin reconstitution buffer (Promega). 
 Following overnight acetone precipitation, the protein samples were centrifuged at 13000 x g for 
10 minutes and allowed to air dry. Pellets were resuspended in 25µl of sample resuspension buffer. 
To aid in pellet resuspension samples were placed in a sonication bath for 5 minutes and vortexed 
for approximately 30 seconds. Protein enumeration was carried out using a Qubit fluorometer, and 
the Qubit protein assay kit (Theremo scientific). Protein concentrations for each sample 
determined by the qubit protein assay were later used to quantify the samples to (1µg µl-1) just 
before they were loaded onto the Q-exactive. One hundred and five microliters of 50mM 
ammonium bicarbonate was added to the samples. Following the addition of 1µl of 0.5M DTT 
samples were incubated at 56 0C for 20 minutes. Samples were allowed cool to room temperature. 
The samples were alkylated by the addition of 2.7µl 0.55M IAA and incubated at room temperature 
in the dark for 15 minutes. One microliter of ProteaseMax solution and trypsin solution were added 
to the samples. The samples were wrapped in tinfoil, incubated for 24 h at 37 0C in an orbital 
shaker.   
2.25.3   Sample clean-up prior to loading on Q-Exactive MS. 
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 The list of buffers used for the sample clean-up for use on Q-exactive using C18 spin columns 
(Thermo Scientific) are listed below. Buffers were made fresh directly before use. All water was 
deionised and was taken fresh before use from the deionised dispenser. The C18 columns are 
designed to trap only 30μg of protein and so is the final step of re-quantification before loading on 
the Q-exactive OrbiTrap. Care was taken to ensure the resin did not reach any flow through.  
• Sample buffer (2% TFA, 20% Acetonitrile)   
200μL Acetonitrile, 20μl TFA in 780μl diH2O   
• Equilibration Buffer (0.5% TFA, 5% Acetonitrile)  
25μl TFA, 250μl Acetonitrile in 4.3ml diH2O    
• Wash buffer (Same as equilibration buffer)   
• Elution buffer (70% Acetonitrile, 30% water)  
700µL Acetonitrile in 300µl diH2O  
• Activation buffer (50% Acetonitrile, 50% water)  
5ml Acetonitrile in 5ml diH2O 
• Loading buffer (0.05% TFA, 2% Acetonitrile)  
Taken straight from the Q-exactive buffer reservoirs.  
 Digested protein samples were briefly centrifuged in a microfuge to collect any condensate, 
straight from the 37 0C incubator following overnight peptide digestion. TFA to a concentration 
of 0.75% of the total volume of sample was added (approximately 0.75μl), vortexed briefly, and 
incubated at room temperature for 5 minutes. Samples were centrifuged at 13000 x g for 10 
minutes to remove any debris that may have formed overnight, and the supernatant transferred to 
a fresh tube. Samples were mixed at a ratio of 3 parts sample:1part sample buffer. PierceTM C-18 
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spin columns (Thermo scientific) were tapped briefly to settle the resin, and the protective caps 
were removed from either end. Holes were pierced in the lid of sterile microcentrifuge tubes to 
place C-18 spin columns into (Fig. 2.8). Resin was activated using 200μl of activation buffer, 
added to the top of the resin, and centrifuged at 1500 x g for 1 minute. Flow through was discarded 
and the process repeated. Equilibration buffer (200μL) was added to the column, spun for one-
minute 1500 x g and the flow through discarded, and repeated once more. Samples were loaded to 
the top of the resin in the C18 column, and a fresh receiver tube placed underneath. Tubes were 
spun at 1500 x g for 1 minute, flow-through collected, and placed back onto the resin. This was 
repeated three times to ensure complete peptide binding to the C18 resin. C18 columns were placed 
in a fresh receiver microcentrifuge tube, and 200μl of wash buffer added. This was then spun at 
1500 x g for one minute, flow through discarded, and the process repeated a total of three times to 
remove containments such as urea and ammonium bicarbonate. Column was placed over a fresh 
receiver tube, this time with the lid open and no hole pierced through the lid, and 20μl of elution 
buffer added to the top of the resin bed. The tubes were spun at 1500 x g for 1 minute, and the 
flow-through untouched. This was repeated a total of three times to obtain a final volume of 60μl 
in the receiver microcentrifuge tube. This was now the cleaned peptide sample. Samples were 
dried down in a SpeedyVac and stored at 20μl until running on the Q-exactive.  
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Figure 2.8: Image shows the C-18 spin placed in a 1.5 ml microcentrifuge tubes.  
 
 
2.25.4 Preparation of sample prior to loading on Q-Exactive mass spectrometer 
   
 The protein concentration of each sample (from Qubit protein assay) was used to determine the 
concentration of sample loading buffer needed to achieve peptide resuspension at a concentration 
of (1 µg/µl). The samples were vortexed for 30 seconds and placed in a water bath for sonication 
for 5 minutes. Following resuspension of the peptide pellet, samples were spun at 13000 x g for 5 
minutes at room temperature to pellet any insoluble material, and 30μl of the supernatant 
transferred to vials (VWR).  
 
2.25.5 Parameters for running samples on Q-Exactive mass spectrometer 
 
One microliter of peptide suspension was eluted onto the Q-Exactive, a high-resolution accurate 
mass spectrometer connected to a Dionex Ultimate 3000 (RSLCnano) chromatography system. 
Peptides were separated by an increasing acetonitrile gradient on a Biobasic C18 PicofritTM 
column (100 mm length, 75 mm ID), using a 180 minutes reverse phase gradient at a flow rate of 
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250 ml /min. All data were acquired with the mass spectrometer operating in automatic data 
dependent switching mode. A high-resolution MS scan (300-2000 Dalton) was performed using 
the Orbitrap to select the 15 most intense ions prior to MS/MS.  
 
2.25.6   Parameters for analysing quantitative results and statistical analysis 
 
Protein identification from the MS/MS data was performed using the Andromeda search engine in 
MaxQuant (version 1.2.2.5; http://maxquant.org/) to correlate the data against a database for G. 
mellonella (Galleria_6_frame_database), depending on the experiment. A combined database for 
the two organisms (Drosophila melanogaster and Bombyx mori) was also used. The following 
search parameters were used: first search peptide tolerance of 20 ppm, second search peptide 
tolerance 4.5ppm with cysteine carbamidomethylation as a fixed modification and N-acetylation 
of protein and oxidation of methionine as variable modifications and a maximum of 2 missed 
cleavage sites allowed. False Discovery Rates (FDR) were set to 1% for both peptides and proteins 
and the FDR was estimated following searches against a target-decoy database. Peptides with 
minimum length of seven amino acid length were considered for identification and proteins were 
only considered identified when more than one unique peptide for each protein was observed. 
Results processing, statistical analyses and graphics generation were conducted using Perseus v. 
1.5.0.31. Label free quantification (LFQ) intensities were log2 -transformed and ANOVA of 
significance and t-tests between the proteomes of control and treated larvae was performed using 
a p value of 0.05 and significance was determined using FDR correction (BenjaminiHochberg). 
Proteins that had non-existent values (indicative of absence or very low abundance in a sample) 
were included in the study only when they were completely absent from one group and present in 
at least three of the four replicates in the second group (referred to as qualitatively differentially 
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abundant proteins). The Blast2GO suite of software tools was utilized to assign gene ontology 
terms (GO terms) relating to biological processes (BP), molecular function (MF) and cellular 
component (CC). Enzyme commission (EC) numbers and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway mapping was performed as part of the Blast2GO annotation pipeline.    
2.26   G. mellonella larval storage and experimental conditions 
 
2.26.1   G. mellonella storage and food 
 
 Sixth instar larvae of the greater wax moth G. mellonella (Lepidoptera: Pyralidae, the Greater 
Wax Moth) (Mealworm Company, Sheffield, England) were purchased and stored in wood 
shavings (Fig 2.9) in the dark at 150C to prevent pupation (Cotter et al., 2000); (Hornsey and 
Wareham, 2011). Larvae weighed 0.22 ± 0.03g and were excluded if there was evidence of 
localised melanisation or infection.  
 
Figure 2.9: Larvae were stored in 9 cm petri-dishes with 0.45 mm Whatmann filter paper inserted 
on the lids and some wood shavings. 
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2.26.2   Inoculation of G. mellonella larvae 
 
 Larvae were injected through the last left pro-leg, with a Myjector U-100 insulin syringe, (Terumo 
Europe N.V., 3001 Leuven, Belgium), while applying mild pressure to the insect to allow the 
opening of pro-legs (Fig 2.10A). In order to administer compounds by the feeding route, a blunted 
Myjector syringe was gently inserted into the mouth of larvae to force-feed 20μl of each solution 
(Mukherjee et al. 2013) (Fig. 2.10B).  
The larvae were kept in 9cm petri-dishes with 0.45 mm Whatmann filter paper inserted on the lids 
and some wood shavings for all experiments. Great care was taken with each injection to maintain 
a high accuracy of drug or pathogen delivery. All in vivo assays were performed on three separate 
occasions using a group size of 10 larvae per dish (unless stated otherwise) and average results 
were calculated. For viability studies larvae were injected with sterile PBS as a control for the 
injection of larvae.  
 
 
Figure 2.10: Administration of a solution to G. mellonella via (A) intra-haemocoel injection 
through the last left pro leg and (B) force feeding. 
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2.27   Extraction of haemocytes from G. mellonella larvae  
 
 Larvae were pierced through the head with a sterile 23G needle and haemolymph was squeezed 
through the head region Fig (2.11) into a pre-chilled microcentrifuge tube. Haemocytes were 
pelleted by centrifugation at 500 x g for 5 minutes and washed in PBS to remove any excess 
haemolymph. Following a further centrifugation step at 500 x g for 5 minutes, the remaining 
supernatant was removed, and the pelleted cells were resuspended gently in 1 ml of PBS 
(supplemented with 0.37% 2-mercaptoethanol).  
Hemocyte density was determined by bleeding 5 larvae (two drops hemolymph (40 µl) / larva) 
into a pre-chilled micro-centrifuge tube to prevent melanization. The collected hemolymph was 
diluted in PBS supplemented with 0.37% (v/v) mercaptoethanol and cell density was assessed with 
a hemocytometer and expressed as hemocytes per ml of hemolymph. Experiments were performed 
on three independent occasions and the means ± SE. were determined.  
 
 
Figure 2.11: Isolated of hemolymph from larvae. 
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2.28   Haemocyte mediated killing using C. albicans as a target 
 
 G. mellonella larvae were administered atorvastatin and incubated at 30 0C for 24 h. Ten larvae 
were bled into 10 ml of cold PBS. The haemocytes were pelleted by centrifugation at 500 x g. Cell 
free haemolymph was poured into a separate container and left on ice. The pelleted haemocytes 
were washed in 10ml of cold sterile PBS, resuspended in 1 ml of PBS and adjusted to 1 x 105 
cells/ml. C. albicans were grown up to the stationary phase in YEPD broth. The cell suspension 
was transferred to a sterile 50 ml universal and centrifuged at 1500 x g. The pellet of C. albicans 
cells was washed in sterile PBS, resuspended in 40ml of PBS, enumerated and adjusted to 2 x 105 
cell/ml. The C. albicans cells were transferred into the container with the cell free haemolymph to 
allow for the opsonization of the cells. The solution of cell free haemolymph and C. albicans cells 
were incubated for 30 mins at 30 0C. The opsonized C. albicans cells were pelleted by 
centrifugation at 1500 x g and resuspended in 1 ml of PBS. Haemocytes (1 x 105 cells/ml) were 
mixed with opsonised C. albicans cells (2 x 105 cells/ml) in a ratio of 1:2 in a stirred chamber at 
30 0C (Bergin et al., 2005). Aliquots were removed at t = 0, 20, 40, 60 and 80 minutes and serially 
diluted (1/100) in ice cold minimal essential medium to quench phagocytosis, prior to plating on 
YEPD agar plates to ascertain fungal viability. The percentage reduction in yeast cell viability was 
calculated based on viability of control which was defined as 100% as t = 0.  
 
2.29   Extraction of G. mellonella haemolymph 
 
 Haemolymph was extracted from G.mellonella larvae by piercing and bleeding through the 
anterior end with a sterile 23G needle (Section 2.5.1) and haemolymph was squeezed into a pre-
chilled microcentrifuge tube containing a few grains of N-phenylthiourea to prevent melanisation. 
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A 1/10 dilution in cold PBS was carried our using a pipette tip with the tip cut off to enable uptake 
of the viscous haemolymph. Haemocytes were pelleted by centrifugation at 1500 x g for 5mins 
and the protein supernatant was transferred to a fresh pre-chilled microcentrifuge tube and stored 
at -20 0C. For protein enumeration and quantification, a further 1/10 dilution of the protein 
supernatant was carried out (1/100 of the original). Protein was then quantified using the Bradford 
assay as mentioned in section 2.11 and adjusted 100µg.  
 
2.30   Statistical analysis of data 
 
All experiments were performed on three independent occasions and results are expressed as the 
mean ± SE.  Statistical significance in growth assay, viability assay, ergosterol quantification and 
leakage experiments was assessed by t-test. Larval survival was assessed by Kaplan-Meier log 
rank. All statistical analysis was performed using GraphPad Prism. Differences were considered 
significant at p ≤ 0.05. 
 
2.31   Data Availability  
 
The MS proteomics data and MaxQuant search output files have been deposited to the 
ProteomeXchange Consortium (Côté et al., 2012) via the PRIDE partner repository with the 
dataset identifier Candida albicans PXD013365, Aspergillus fumigatus PXD015254 and Galleria 
mellonella PXD016067. 
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Chapter 3 
 
Assessment of in vitro and in vivo anti-Candida activity 
of atorvastatin. 
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3.1   Introduction  
 
The yeast Candida albicans is a member of the normal human microbiome. In most individuals, C. 
albicans resides as a lifelong, harmless commensal (Mayer et al., 2013). Although, it is an 
opportunistic pathogen for some immunologically weak and immunocompromised people (Kim 
and Sudbery, 2011). C. albicans  induces a wide range of superficial and life-threatening systemic 
infections in susceptible patients (Mayer et al., 2013).  The yeast C. albicans has a range of 
virulence factors that allow successful colonization and dissemination in the host  and these 
involve the adhesion of the yeast to the host tissue, followed by cell proliferation, production of a 
range of enzymes, biofilm formation and altered phenotype to overcome the host’s immune 
response (Naglik et al., 2003, (Calderone and Fonzi, 2001). Common antifungal therapy depends 
on the use of polyene, azole or echinocandin drugs but the delivery of appropriate therapy is often 
problematic due to the presence of resistance and the inherent toxicity of some antifungal therapies 
(Scorzoni et al., 2017).  Statins (e.g. atorvastatin, lovastatin, pravastatin, simvastatin) are one of 
the most widely prescribed medications and lower cholesterol levels in blood (Nyilasi et al., 2010 
(Galgóczy, 2011).  They competitively inhibit 3 hydroxy-3-methylglutaryl-CoA (HMG-CoA) 
reductase by competitively binding to its binding sites (Istvan, 2002). HMG-CoA is an enzyme 
that catalyses the conversion of HGM-CoA to mevalonate, which leads to the production of 
farnesyl diphosphate (Macreadie et al., 2006b). Farnesyl diphosphate is the precursor for the 
production of cholesterol in humans or ergosterol in plants and eukaryotic microorganisms 
(Macreadie et al., 2006b). Fungal HMG-CoA reductases are also inhibited by statins which results 
in a reduction in the ergosterol content and an inhibition of fungal growth (Nyilasi et al., 2010b).  
Statins inhibit the growth of a wide range of medially important fungi (e.g. Aspergillus fumigatus, 
Candida albicans), but not Candida krusei,  (Galgóczy, 2011) and supplementation of statin-
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containing growth medium with ergosterol lead to recovery of growth indicating that statins 
specifically inhibit the mevalonate pathway (Macreadie et al., 2006b). Prolonged exposure of cells 
of Candida glabrata to statins lead to an increase in the percentage of petite (respiratory deficient) 
mutations in the population suggesting that statins may also affect the integrity of mitochondrial 
DNA (Westermeyer and Macreadie, 2007). Patients on statin therapy display fewer fungal 
infections (Sun and Singh, 2009) thus suggesting that statins may be capable of inhibiting the 
growth of fungi in vivo and so may represent a novel, non-toxic antifungal treatment option 
(Donnino et al., 2009; Spanakis et al., 2010). Statins have in vitro activities against several human 
pathogenic fungi, including Candida spp., Cryptococcus neoformans, and Zygomycetes (Chamilos 
et al., 2006). In addition, administration of statins to patients with severe sepsis (Dobesh et al., 
2009) or bacteremia (Kruger, 2006) resulted in increased survival possibly due to a reduction in 
inflammatory responses (Weitz-Schmidt, 2002). The aim of the work presented here was to 
characterise the effect of atorvastatin on C. albicans and establish its in vitro and in vivo antifungal 
activity using Galleria mellonella larvae. 
 
3.2   Susceptibility assay 
 
3.2.1   Determination of susceptibility of C. albicans to atorvastatin 
 
A susceptibility assay was applied to test the sensitivity of C. albicans against the compound. A 
serial dilution was constructed on the 96-well plate so that the growth of the yeast in different drug 
concentrations can be accurately determined. This test was set up in accordance with procedures 
described in section 2.5 and the concentrations of atorvastatin was 0.75 μg/ml – 195 μg/ml. The 
percentage growth of C. albicans in the presence of atorvastatin was then calculated and is 
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illustrated in (Fig. 3.1). The results revealed that a dose of 96 µg/ml reduced growth by 74.6 ± 0.3 
% at 24 h (p < 0.0001). Concentrations of 12 and 24 µg/ml reduced growth by 11.9 ± 1.1% and 
21.8 ± 0.5 % (p < 0.05) respectively at 24 h. 
 
Figure 3.1: Effect of atorvastatin on growth of C. albicans. C. albicans (initial concentration 104 
cells per well) was exposed to atorvastatin (0.75 μg/ml – 192 μg/ml) in YEPD. Growth (%) was 
calculated by comparing atorvastatin treated C. albicans to control cells after 24 h growth (*; p < 
0.05, **; p < 0.01 ***; p < 0.001). 
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3.2.2   Susceptibility assay of C. albicans to a combination of antifungal drugs and   
atorvastatin. 
 
Susceptibility assays were carried out on C. albicans to test the sensitivity of the yeast to 
amphotericin B (highest concentration = 6.25 μg/ml), caspofungin (3.75 μg/ml), miconazole (250 
μg/ml) or DMSO (25%) stock solutions (Fig 3.2 A, B, C and D) both singly and in combination 
with, atorvastatin (12 μg/ml) in accordance with the protocol set out in method (2.5). The results 
of these tests showed a slight increase in the percentage growth of C. albicans when the 
atorvastatin was combined with amphotericin B, but not miconazole, caspofungin or DMSO. 
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Figure 3. 2A: The percentage growth of C. albicans exposed to a serial dilution of Amphotericin 
B and (0.012 - 6.25 μg/ml) in presence atorvastatin (12 μg/ml). 
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 Figure 3. 2B: The percentage growth of C. albicans exposed to a serial dilution of caspofungin 
(0.014 – 3.75 μg/ml) and in presence atorvastatin (12 μg/ml) 
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Figure 3.2C: The percentage growth of C. albicans in the presence of a serial dilution of miconazle 
(0.97 – 250 μg/ml) and in presence atorvastatin (12 μg/ml). 
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Figure 3. 2D: The percentage growth of C. albicans exposed to a serial dilution of % DMSO 
(0.097 – 25%) in presence atorvastatin (12 μg/ml) 
 
 
 
3.3   Analysis of the effect of atorvastatin on the growth of Escherichia coli or Staphylococcus 
aureus. 
 
The impact of atorvastatin on E. coli and S. aureus growth was evaluated. The results 
showed that atorvastatin has no activity against S. aureus and E. coli (Fig. 3.3 A and B).  
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Figure 3.3 A and B: Effect of atorvastatin on growth of E. coli and S. aureus respectively. 
Bacterial cells (initial concentration 1.5 x106 per well) exposed to atorvastatin (0.75 μg/ml – 192 
μg/ml) in nutrient broth. No inhibition of growth was observed due to atorvastatin treatment by 
comparing atorvastatin treated bacterial cell to control cells after 24 h. 
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3.4   Effect of atorvastatin on the viability of C. albicans 
 
The effect of atorvastatin on the viability of C. albicans was also assessed and the results revealed 
a small fungicidal effect (Fig 3.4). Exposure of cells to 24 µg/ml atorvastatin reduced viability by 
19 ± 1.6 % at 4 h and by 22.5 ± 0.9 % at 24 h.  
 
 
 
Figure 3.4: Effect of atorvastatin (6, 12, and 24 µg/ml) on viability of C. albicans at different time 
points (2, 4 and 24 h), (*; p < 0.05, **; p < 0.01). 
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3.4   Ergosterol extraction and quantification.  
 
Exposure of C. albicans to atorvastatin (12 µg/ml) for 24 h lead to a reduction in the ergosterol 
content of cells (control = 0.063 ± 0.008 µg/ml and treatment = 0.027 ± 0.003 µg/ml (p = 0.04) 
(Fig 3.5).  
 
 
Figure 3.5: Atorvastatin exposure reduced the ergosterol content of C. albicans. Ergosterol 
quantification was performed using a Gas Chromatograph with a flame ionization detector and a 
chrompack capillary column. Ergosterol standards were used to calibrate the instrument. 
Ergosterol content was expressed in terms of mg/ml (*; p < 0.05). 
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3.5   Determination of Amino acid Leakage 
 
Exposure of cells to atorvastatin (12 µg/ml) for up to 4 hr lead to an increase in amino acid (Fig 
3.6) leakage from cells.  Exposure to atorvastatin for 2 h lead to an amino acid concentration of 
1.97 ± 0.09 µg/ml and 1.78 ± 0.1 µg/ml amino acids at 4 h.  
 
 
 
 
 
Figure 3.6: Effect of atorvastatin on release of amino acids from C. albicans. The effect of 
atorvastatin (12 μg/ml) on C. albicans amino acid release was determined by ninhydrin 
colorimetric assay. Atorvastatin treatment resulted in increased amino acid release relative to 
control cells (*; p < 0.05, **; p < 0.01 ***; p < 0.001). 
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3.6   Assessment of protein release  
 
Exposure of cells to atorvastatin (12 µg/ml) for up to 4-h lead to an increase in protein leakage 
from cells (Fig. 3.7). Protein release at 2 and 4 h was 147.7 ± 10.8 and 132.7 ± 18.1 µg/ml, control 
was 57.3 ± 6.2 and 35.67 ± 4.6 µg/ml respectively (p < 0.05).  
 
 
 
 
Figure 3.7: Effect of atorvastatin on protein release from C. albicans. The effect of atorvastatin 
(12 μg/ml) on C. albicans protein release was determined by Bradford protein assay. Atorvastatin 
treatment resulted in increased protein release relative to control cells (*; p < 0.05, **; p < 0.01 
***; p < 0.001). 
 
3.7   Fluorescence microscopy of atorvastatin treated C. albicans 
 
Altered membrane permeability could lead to distortions in the fungal cell wall. Staining cells with 
calcofluor following exposure to atorvastatin revealed increased fluorescence indicating an 
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increase in the chitin content of cells.  Atorvastatin treated cells also appeared larger and 
demonstrated incomplete cell separation (Fig. 3.8).  
 
 
Figure 3.8: Calcofluor staining of C. albicans following exposure to atorvastatin, (Magnification 
x 400). C. albicans cells were exposed to atorvastatin (6, 12 and 24 µg/ml) for 24 h, stained with 
Calcofluor white and visualized with an Olympus BX51 fluorescence microscope. Increased 
fluorescence indicated an increase in the chitin content of cells.   
3.8   Adherence assay of C. albicans 
 
Atorvastatin treated cells demonstrated a reduced ability to adhere to exfoliated buccal epithelial 
cells indicating a possible disruption to the surface of the yeast cell (Fig. 3.9). Control cells 
showed 5.55 ± 0.6 yeast cells adhering per BEC while cells exposed to atorvastatin showed 3.02 
± 0.5 adhering per BEC (p = 0.009). 
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Figure 3.9: The adherence ability of C. albicans following exposure to atorvastatin (12 µg/ml), 
(**; p < 0.01). 
 
3.9   Analysis of susceptibility of C. albicans to cell wall lysing enzyme 
 
Fig. 3.10 shows the % of colony of C. albicans control and atorvastatin (12 µg/ml) treated cultures 
exposed to Trichoderma lysing enzyme (10 mg/ml) (SIGMA). There were no significant changes 
in colony growth of the atorvastatin treated culture compared to control. This result indicates that 
no major alteration in the cell wall susceptibility to degradation.     
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Figure 3.10: Enzyme susceptibility assay of C. albicans of exposed to 10 mg/ml of Trichoderma 
lysing enzyme. Differences in the % growth statistically non-significant (p > 0.05). 
 
 
3.10   Assessment of Catalase activity 
 
 
In the work presented here, determination of the activity of catalase (CAT) was performed on C. 
albicans cells and atorvastatin (6, 12 and 24 µg/ml) treated C. albicans cells which had been 
exposed to17 mM hydrogen peroxide for 30 min. Total (CAT) activity increased to 0.6 ±0.04 % 
and to 0.66 ±0.0 %  at atorvastatin concentration (6 µg/ml) and (12 µg/ml) respectively compared 
to the control (C. albicans) 0.272 ±0.02 % when cells were exposed to 17 mM hydrogen peroxide 
for 30 min (Fig. 3.11).  
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Figure 3.11: Catalase activity of C. albicans protein exposed to 17 mM H2O2 for 20 minutes. 
Differences in the levels of catalase activity were deemed statistically significant at (**; p < 0.01). 
 
3.11   Assessment of toxicity and in vivo antifungal efficacy of atorvastatin 
 
Administration of doses of atorvastatin (4.55 or 9.09 mg/kg) to G. mellonella larvae by intra 
haemocoel injection resulted in no adverse effect over 144 h (Fig 3.12).  Larvae infected with C. 
albicans were subsequently administered a dose of atorvastatin (4.55 or 9.09 mg/kg) 30 minutes 
post-infection. The results indicate increased survival in those larvae given a dose of atorvastatin 
(4.55 or 9.09 mg/kg). Larvae infected with C. albicans showed a survival of 76.8 ± 3.5 % at 72 h 
and 18.1 ± 4.2 % at 144 h. In contrast those larvae administered a dose of atorvastatin 9.09 
mg/kg displayed a survival rate of 94.3 ± 1.96 % at 72 h and 60 ± 6.4% at 144 h (p < 0.05).  
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Figure 3.12: Effect of atorvastatin on viability of G. mellonella larvae infected with C. albicans. 
Larvae injected with atorvastatin (4.55 or 9.09 mg/kg) displayed no decrease in survival. Larvae 
were inoculated with C. albicans (1 × 106 /larva) and followed up 30 mins later with atorvastatin 
(4.55 or 9.09 mg/kg) and incubated at 30 oC. Survival was monitored over 144 h. Atorvastatin 
(4.55 or 9.09 mg/kg) treatment enhanced larval survival relative to non-treated larvae. 
 
 
3.12    Proteomic analysis of the effect of atorvastatin on C. albicans 
 
3.12.1   One-dimensional SDS-PAGE analysis of released protein  
 
In order to ascertain whether atorvastatin induced the release of proteins from C. albicans, cells 
were suspended in PBS, exposed to atorvastatin (12 µg/ml) for 24 h and the released constituents 
were precipitated as described in section 2.17.1. The proteins that were released from C. albicans 
cells by 24 h were collected and placed on ice with protease inhibitors (see 2.17.1). Proteins were 
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resolved on a 1-D SDS PAGE gel and stained with colloidal Coomassie blue (Fig. 3.13). It was 
evident that several proteins were released from the control cells during the 24 h of incubation 
period. When cells were exposed to atorvastatin 12 µg/ml, increased release of protein was evident 
when compared to the control. There was a significant difference in the abundance of band 1 
(hsp72-like protein), 2 (heat shock protein SSA2), 3 (elongation factor 3), 4 
(glycogen/starch/alpha-glucan phosphorylase), 5 (hexokinase), 6 (enolase, partial), 7 (fructose-
bisphosphate aldolase), 8 (Malate dehydrogenase), 9 (enolase, partial), and 10 (peptidylprolyl 
isomerase) (Table 3.1). 
 
 
 
 
 
Figure 3.13 Visualization by 1 D SDS-PAGE of released proteins from C. albicans following 
exposure to atorvastatin 12 µg/ml.  Yeasts were exposed to atorvastatin released proteins were 
precipitated and separated by SDS-PAGE.   
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Table 3.1:  Identities of proteins observed to be altered in intensity following 1-D electrophoresis 
of samples from C. albicans cells in response to atorvastatin 12 µg/ml.  Bands were excised, trypsin 
digested and analysed using LC-MS.  
 
 
3.12.2   Effect of atorvastatin on the protein leakage from C albicans as assessed by 
Two Dimensional SDS-PAGE analysis  
 
Two–dimensional SDS-PAGE was employed in order to further separate the released proteins and 
thus facilitate their identification by LC-MS. Cells were exposed to atorvastatin (12 µg/ml) for 24 
h and the released proteins were collected, separated by 2-D electrophoresis and stained with 
colloidal Coomassie blue (2.18.1). It is obvious that atorvastatin induced the release of a number 
of proteins and a change in spot intensity was observed as shown in (Fig. 3.14). Selected spots 
were excised, washed, trypsin digested and analyzed on LC-MS as described previously (section 
2.20).  Fourteen peptide spots were successfully identified. The spot intensity changed following 
the treatment of cells with atorvastatin. There was a significant increase in the abundance of some 
spots such as spot 2 (enolase, partial), 5 (alcohol dehydrogenase 1), 6 (malate dehydrogenase, 
NAD-dependent) 7 (phosphoglycerate mutase), 8 (fructose-bisphosphate aldolase), 9 (UDP-N-
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acetylglucosamine pyrophosphorylase) and 11 (peptidylprolyl isomerase) (Table 3.2).  A number 
of proteins 1 (adenosine kinase), 4 (malate dehydrogenase1), 13 (phosphoglycerate kinase) showed 
decrease in abundance when C. albicans cells were exposed to (12 µg/ml) atorvastatin for 24 h 
(Table 3.3).  
 
Figure 3.14: Analysis of protein leakage from a control and atorvastatin (12 µg/ml) treated C 
albicans cells by 2D-IEF/PAGE analysis.  
. 
 
 
 
89 
 
 
Table 3.2:  Two Dimensional SDS-PAGE analysis list of identified proteins, using LC-MS, 
leaking from the C. albicans when the culture was exposed atorvastatin (12 µg/ml).  
 
 
The 2D-PAGE gel approach is subject to the restrictions imposed by the gel method, which include 
limited dynamic range, difficulty handling hydrophobic proteins, and difficulty detecting proteins 
with extreme molecular weights and pI values (Zhu et al., 2009). And after the results that we got 
from 2D-PAGE we decided to identify protein by using label-free quantification (commonly 
abbreviated to LFQ) of shotgun proteomics. LFQ techniques allow us to analyse many samples in 
a single experiment and are normally used in the screening and discovery phases of projects. The 
rapid development of label-free quantitative proteomic techniques has provided fast and low-cost 
measurement of protein expression levels in complex biological samples. 
 
3.12.3 Label-free proteomics of response of C. albicans to atorvastatin 
 
Comparative analysis of differential protein abundance in atorvastatin treated C. albicans was 
performed using label-free proteomics. A principal component analysis (PCA) was performed on 
all filtered proteins and identified distinct proteomic differences between the control and statin 
Spot no. Protein name Accession no. Organism Score Coverage Fold change
1 adenosine kinase KGR05046.1 C. albicans P57072 597 28% -1.9
2 enolase, partial AHB86321.1 C. Albicans 837 31% 1.4
3 hypothetical protein MG7_03415 KGU26040.1 C. albicans P34048 244 25% -1.9
4 malate dehydrogenase EEQ43187.1 C. Albicans wo-1 1043 52% -2
5 Alcohol dehydrogenase 1 P43067.1 C albican 393 34% 10.7
6 malate dehydrogenase, NAD-dependent KGQ86444.1 C. albicans P94015 542 46% 2
7 Phosphoglycerate mutase EMG50907.1 C. maltosa Xu316 215 15% 1.7
8 fructose-bisphosphate aldolase XP_722690.1 Candida albicans SC5314 265 15% 2.1
9 UDP-N-acetylglucosamine pyrophosphorylase KGQ85212.1 C. Albicans P94015 588 22% 2.1
10 hypothetical protein MGO_03165 KHC35483.1 C. albicans P76055 87 4% 1.7
11 peptidylprolyl isomerase XP_721313.1 C albicans SC5314 319 24% 2.7
12 54S ribosomal protein L16 XP_009227451.1 Gaeumannomyces tritici R3-111a-1 78 4% 1.7
13 phosphoglycerate kinase XP_711323.1 Candida albicans SC5314 224 10% ̶   4.4 
14 hypothetical protein KGR06433.1 C. albicans P57072 247 12% 7.3
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treated samples (Fig. 3.15). The heat maps also show major differences in the relative abundance 
of proteins in the control and atorvastatin treated cells (Fig 3.16). In total 1575 proteins with two 
or more peptides were identified and 465 proteins were determined to be differentially abundant 
(ANOVA, p < 0.05) with a fold change of >1.5. Of this, 231 were found in higher abundance in 
the atorvastatin treated cells and 234 were present in lower abundance in the treated cells.  A total 
of 74 proteins were present in all three control samples and absent in all three treated samples, and 
a further 57 were present in each replicate of the atorvastatin treatment and absent in all three 
control samples. The volcano plot (Fig. 3.17) shows the relative increase or decrease in abundance 
of proteins in the atorvastatin treated cells compared to the control cells. A variety of proteins were 
increased in abundance in atorvastatin treated cells (Table 3.4) and these included squalene 
monooxygenase ERG1 (4.52 fold), lanosterol synthase (3.30 fold), 3-keto-steroid reductase (2.78 
fold), lanosterol 14-alpha demethylase (2.57 fold) and acetyl-CoA C-acetyltransferase (2.23 fold). 
A number of proteins were decreased in abundance in the treated cells (Table 3.5) and included 
Hsp12p (-6.33 fold), small heat shock protein 21 (-6.26 fold), yeast-form wall Protein1 (-5.68 
fold), Wh11p (-4.93 fold), Acyl-CoA desaturase (-4.88 fold) and heat shock protein SSA1 (-4.40 
fold).   
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Figure 3.15: Shotgun proteomics of responses of C. albicans to atorvastatin (12 μg/ml) after 24 h 
at 30 °C. Principal component analysis of control and atorvastatin treated C. albicans for 24 h 
showing a clear distinction between control and treatment. 
 
 
 
 
 
 
 
Figure 3.16: Shotgun proteomics of responses of C. albicans to atorvastatin (12 μg/ml) after 24 h 
at 30 °C. Two-way unsupervised hierarchical clustering of the median protein expression values 
of all statistically significant differentially abundant proteins from C. albicans control (C1, C3, 
C4) and atorvastatin treated (T1, T2, T4) C. albicans. 
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Figure 3.17: Shotgun proteomics of responses of C. albicans to atorvastatin (12 μg/ml) after 24 h 
at 30 °C. Volcano plot showing the distribution of quantified proteins according to p value (−log10 
p-value) and fold change (log2 mean LFQ intensity difference). Proteins above the horizontal line 
are considered statistically significant (p value < 0.05) and those to the right and left of the vertical 
lines indicate relative fold changes ± 1.5.  
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The volcano plot (Fig 3.18) shows the relative increase in abundance of proteins involved in 
ergosterol biosynthesis in atorvastatin-treated cells compared to non-treated cells, these included 
squalene monooxygenase ERG1 (4.52 fold), lanosterol synthase (3.30 fold), 3-keto-steroid 
reductase (2.78 fold), lanosterol 14-alpha demethylase (2.57 fold), acetyl-CoA C-acetyltransferase 
(2.23 fold) and more proteins listed in Table 3.3. The genomes (KEGG) analysis of proteins that 
showed altered abundance in atorvastatin-treated cells revealed seven proteins that showed 
increased abundance in the fungal steroid pathway (Fig. 3.19). This suggests that the cell may be 
attempting to increase ergosterol biosynthesis or redirect biosynthesis following the inhibition of 
the action of the fungal 3-hydroxy-3-methylglutaryl-CoA reductase. The results were confirmed 
by STRING analysis (Fig. 3.20).  
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Figure 3.18: Volcano plot showing the distribution of quantified ergosterol biosynthesis related 
proteins (blue) according to p value (−log10 p-value) and fold change (log2 mean LFQ intensity 
difference). Proteins above the horizontal line are considered statistically significant (p value < 
0.05) and those to the right and left of the vertical lines indicate relative fold changes ± 1.5.  
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Table 3.3: List of identified ergosterol related proteins, using label-free proteomics leaking from 
the C. albicans when the culture was exposed atorvastatin (12 μg/ml). 
 
No. Protein name  Accession no. Fold change 
1 Squalene monooxygenase ERG1 Q92206        4.52 
2 Lanosterol synthase ERG7 Q04782          3.3 
3 3-keto-steroid reductase ERG27 Q5A888 2.78 
4 Lanosterol 14-alpha demethylase ERG11 P10613 2.57 
5 Acetyl-CoA C-acetyltransferase ERG10 A0A1D8PH52 2.23 
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Figure 3.19: KEGG analysis of proteins changed in abundance in the steroid biosynthesis pathway 
in C. albicans. Proteins which are colored black are differentially abundant in C. albicans treated 
with atorvastatin (12 μg/ml). 
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Figure 3.20: Interaction network analysis of up regulated proteins in atorvastatin (12 μg/ml) 
treated C albicans. Protein interaction information was obtained from the STRING database using 
gene lists extracted for statistically significant differentially abundant (SSDA) proteins of increased 
abundance in treated C albicans. Statistically enriched KEGG and Gene Ontology (GO) terms 
were examined to identify pathways and processes enriched within each set of proteins. 
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Table 3.4: Relative fold changes of proteins increased in abundance of atorvastatin (12 μg/ml) 
treated C. albicans and the number of matched peptides, sequence coverage, and overall intensity. 
Only proteins that had more than two matched peptides and were found to be differentially 
expressed at a level greater than ± 1.5-fold were considered to be in significantly variable 
abundances between control and treated. 
N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean 
LFQ 
intensity 
Fold 
change  
1  Inositol-3-phosphate synthase  31 75 3.66E+09 7.69 
2  Uncharacterized protein  8 57.5 7.98E+08 6.10 
3 
Aromatic-amino-acid:2-oxoglutarate 
transaminase  
16 48.2 5.38E+08 4.88 
4 Squalene monooxygenase  25 64.3 1.12E+10 4.52 
5  Putative serine hydrolase  12 51.9 3.58E+08 4.50 
6 Hgt7p  9 20.1 3.73E+08 4.25 
7  Uncharacterized protein 17 35.3 4.02E+08 3.74 
8 Ribosome biogenesis protein YTM1  12 39.5 1.74E+08 3.62 
9  rRNA-binding ribosome biosynthesis protein 10 24.8 1.68E+08 3.56 
10 Glutamate dehydrogenase  33 81.4 1.91E+10 3.48 
11 
tRNA (adenine(58)-N(1))-methyltransferase 
non-catalytic subunit TRM6  
10 32.7 1.22E+08 3.35 
12  Uncharacterized protein  10 24.7 1.56E+08 3.31 
13 ERG7_CANAL Lanosterol synthase  11 19.2 1.46E+08 3.30 
14  Methylenetetrahydrofolate reductase 18 38.1 3.46E+08 3.20 
15 
Mitochondrial 54S ribosomal protein 
YmL24/YmL14  
8 42.3 1.81E+08 2.92 
16  3-keto-steroid reductase  9 25.4 3.12E+08 2.79 
17 
Carbamoyl-phosphate synthase arginine-
specific small chain  
7 24 1.62E+08 2.71 
18 Protein RMD9, mitochondrial  8 17.9 1.6E+08 2.67 
19 
Bifunctional urea carboxylase/allophanate 
hydrolase 
15 12.7 1.2E+08 2.63 
20 Lanosterol 14-alpha demethylase 42 62.9 8.57E+09 2.58 
21 Extracellular glycosidase CRH11  5 15 1.26E+08 2.51 
22 Predicted GPI-anchored protein 45  5 13.2 1.01E+08 2.46 
23  rRNA-binding ribosome biosynthesis protein  4 20.6 1.32E+08 2.46 
24  Uncharacterized protein  15 44.2 2.06E+08 2.44 
25  Nucleolar GTP-binding protein 2  9 21.2 1.14E+08 2.43 
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N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean 
LFQ 
intensity 
Fold 
change  
26  Putative tRNA acetyltransferase  10 46.6 1.24E+08 2.37 
27  Uncharacterized protein  3 49.4 1.88E+08 2.34 
28  Kinase  6 33.4 1.17E+08 2.33 
29  Exopolyphosphatase  11 39.2 1.28E+08 2.32 
30 
Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
39 65.2 7.28E+09 2.29 
31 
 Arginine biosynthesis bifunctional protein 
ArgJ, mitochondrial 
9 41 2.13E+08 2.27 
32  Tyrosine protein phosphatase  8 12.3 8.53E+07 2.26 
33  54S ribosomal protein L51, mitochondrial  6 48.6 1.05E+08 2.24 
34  Hmx1p  4 14.8 1.29E+08 2.24 
35  Acetyl-CoA C-acetyltransferase  26 76.6 2.60E+10 2.24 
36 Uncharacterized protein  6 18.8 9.83E+07 2.18 
37  Pex7p  6 25.8 9.34E+07 2.17 
38 Utp8p  11 24.7 1.10E+08 2.17 
39  Mitochondrial 54S ribosomal protein YmL27  4 28.6 9.18E+07 2.17 
40 Mitochondrial 37S ribosomal protein MRPS17  8 26.4 1.41E+08 2.10 
41  Survival factor 1  19 63.6 1.69E+09 2.06 
42  Sphingolipid homeostasis protein  4 34.7 9.53E+07 2.06 
43  Phosphoglycerate mutase  7 32.6 7.29E+07 2.03 
44 
 Glycerol-3-phosphate dehydrogenase 
[NAD(+)]  
21 80.1 1.92E+09 2.01 
45 Meiotic recombination directing protein 16 36.5 6.06E+08 1.99 
46 ATP synthase complex assembly protein  6 16.9 9.24E+07 1.98 
47  Uncharacterized protein  5 43.2 1.33E+08 1.98 
48 
Ubiquinone biosynthesis monooxygenase 
COQ6, mitochondrial  
17 37.1 1.28E+09 1.95 
49 Nucleolar GTP-binding protein 1  19 38.3 4.55E+08 1.90 
50  Crd2p  6 73.7 1.65E+08 1.85 
51 Rab geranylgeranyltransferase  4 16.7 8.75E+07 1.84 
52 Uncharacterized protein  4 36 1.49E+08 1.84 
53 NADPH--cytochrome P450 reductase  39 70.9 4.29E+09 1.80 
54  Protoporphyrinogen oxidase  8 26.2 1.24E+08 1.79 
55 Q59KQ1_CANAL Glycerol kinase  15 35.3 3.38E+08 1.75 
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N0. Protein name  
Unique 
peptides 
Sequence 
coverage [%] 
Mean 
LFQ 
intensity 
Fold 
change  
56 
Succinate dehydrogenase [ubiquinone] cytochrome b 
small subunit  
3 26.6 1.05E+08 1.75 
57  Ribosome biogenesis protein NSA2  4 19.9 8.61E+07 1.74 
58 Nucleotidase  10 38.7 2.64E+08 1.66 
59  Phosphopantothenate--cysteine ligase  20 78.7 1.90E+09 1.65 
60 
 Bifunctional acetylglutamate kinase/N-acetyl-
gamma-glutamyl-phosphate reductase  
29 44.2 9.10E+08 1.65 
61  Delta 8-(E)-sphingolipid desaturase  8 20.7 3.14E+08 1.65 
62 Uncharacterized protein  3 18.8 8.48E+07 1.63 
63 Uncharacterized protein  11 21 1.59E+08 1.62 
64  Pre-rRNA-processing protein RIX1  4 8.8 6.51E+07 1.60 
65  O-acyltransferase  4 10.5 1.05E+08 1.57 
66  Tyrosine--tRNA ligase 8 23.8 9.65E+07 1.57 
67  WD repeat-containing protein JIP5  4 14.2 6.62E+07 1.57 
68  NADH-cytochrome b5 reductase 1  15 66 2.78E+09 1.55 
69  tRNA (guanine(26)-N(2))-dimethyltransferase 9 21.8 2.26E+08 1.53 
70 5-3 exoribonuclease 2  9 14 5.20E+07 1.53 
71 Zcf39p OS=Candida albicans 5 10.6 7.82E+07 1.53 
72  ATP-dependent rRNA helicase RRP3  8 21.2 1.55E+08 1.53 
73 Glycerol-1-phosphatase  10 57.9 1.90E+09 1.51 
74 
 tRNA (adenine(58)-N(1))-methyltransferase 
catalytic subunit TRM61  
7 26.9 1.05E+08 1.50 
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Table 3.5: Relative fold changes of proteins decreased in abundance of atorvastatin (12 µg ml) 
treated C. albicans and the number of matched peptides, sequence coverage, and overall intensity. 
Only proteins that had more than two matched peptides and were found to be differentially 
expressed at a level greater than ± 1.5-fold were considered to be in significantly variable 
abundances between control and treated. 
 
N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean 
LFQ 
intensity 
Fold 
change  
1  Hsp12p  11 75.6 2.83E+01 -6.33 
2 Small heat shock protein 21  9 49.2 2.62E+01 -6.33 
3  Yeast-form wall Protein 1  1 3.2 2.76E+01 -6.27 
4  Wh11p  6 78.5 2.54E+01 -5.68 
5 Uncharacterized protein  25 35.2 2.46E+01 -4.93 
6  Acyl-CoA desaturase  24 51.2 2.55E+01 -4.88 
7 Heat shock protein SSA1  49 34.3 2.98E+01 -4.40 
8 Phenylpyruvate decarboxylase  15 35.5 2.52E+01 -4.35 
9 Asr2p  12 47.7 2.50E+01 -4.25 
10 Glyoxalase 3  21 75.4 2.90E+01 -4.22 
11 Uncharacterized protein  7 64.5 2.51E+01 -3.85 
12 Mdg1p  17 38.5 2.65E+01 -3.75 
13 Cip1p  12 56.2 2.57E+01 -3.74 
14 Cdr4p  24 21.3 2.45E+01 -3.71 
15 dehydrogenase 1 12 54.9 2.45E+01 -3.69 
16  Uncharacterized protein  3 29.4 2.42E+01 -3.62 
17 Cytochrome c oxidase subunit VII  1 11 2.49E+01 -3.57 
18 Uncharacterized protein  11 38.7 2.54E+01 -3.39 
19 mRNA-binding translational activator  5 49.1 2.49E+01 -3.36 
20 Csp37p  14 54.5 2.67E+01 -3.35 
21 Phm7p  14 25.8 2.45E+01 -3.22 
22 Uncharacterized protein  6 22.4 2.59E+01 -3.16 
23 Uncharacterized protein  4 64.5 2.63E+01 -3.16 
24 Pst2p  7 70.1 2.44E+01 -3.01 
25 Proline dehydrogenase  11 37.6 2.45E+01 -3.01 
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N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean 
LFQ 
intensity 
Fold 
change  
26 Tricalbin  17 23.1 2.49E+01 -2.88 
27 Arginase  8 31.5 2.44E+01 -2.87 
28 
Pleiotropic ABC efflux transporter of multiple 
drugs CDR1    
16 16.1 2.43E+01 -2.85 
29 Glycogenin glucosyltransferase  12 23.9 2.51E+01 -2.82 
30 Uncharacterized protein  19 21.2 2.51E+01 -2.80 
31  mRNA stability protein  7 61.2 2.39E+01 -2.69 
32 1-pyrroline-5-carboxylate dehydrogenase  22 47.9 2.68E+01 -2.65 
33 Pst1p  3 32.8 2.43E+01 -2.64 
34  Uncharacterized protein  8 40 2.36E+01 -2.64 
35  Uncharacterized protein  7 73 2.43E+01 -2.62 
36  Glycerol-3-phosphate dehydrogenase  16 32.5 2.45E+01 -2.61 
37 ysophospholipase  9 19.1 2.44E+01 -2.60 
38  Uncharacterized protein  14 92.6 2.86E+01 -2.53 
39  Hgt2p  4 7.9 2.45E+01 -2.46 
40  Phosphorelay intermediate protein YPD1  6 37 2.36E+01 -2.38 
41 Putative mannosyltransferase  17 45 2.54E+01 -2.36 
42 Phosphoenolpyruvate carboxykinase  42 82.6 3.15E+01 -2.33 
43  Uncharacterized protein  5 52.7 2.41E+01 -2.29 
44 Uncharacterized protein  8 34.3 2.41E+01 -2.26 
45  Uncharacterized protein  6 21 2.35E+01 -2.26 
46 Uncharacterized protein  6 42.1 2.36E+01 -2.19 
47  Ahp2p  5 57.3 2.48E+01 -2.15 
48  Ifr2p  13 45.5 2.85E+01 -2.12 
49  Serine/threonine/tyrosine protein kinase  5 16.7 2.37E+01 -2.11 
50 Uncharacterized protein  10 45.4 2.45E+01 -2.09 
51  Vtc4p  14 24.3 2.47E+01 -2.08 
52 Uncharacterized protein  9 32 2.38E+01 -2.07 
53  Uncharacterized protein  12 55.3 2.50E+01 -2.06 
54  Glutathione peroxidase 5 33.1 2.35E+01 -2.06 
55 
 Dihydroorotate dehydrogenase (quinone), 
mitochondrial  
16 54.1 2.68E+01 -2.03 
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N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean 
LFQ 
intensity 
Fold 
change  
56  hydrolase  12 43.5 2.59E+01 -2.03 
57  Monothiol glutaredoxin  5 29.7 2.43E+01 -2.01 
58 Ebp1p  28 78.4 2.88E+01 -2.00 
59 Hgt1p  9 16.3 2.65E+01 -1.98 
60 Uncharacterized protein  19 69.1 2.83E+01 -1.98 
61 
Trehalose 6-phosphate synthase/phosphatase 
complex subunit  
32 48.6 2.70E+01 -1.90 
62 Uncharacterized protein  4 38 2.37E+01 -1.88 
63 Uncharacterized protein  5 12.3 2.37E+01 -1.85 
64  Ifg3p  4 20.7 2.31E+01 -1.85 
65  Uncharacterized protein  7 38.3 2.41E+01 -1.79 
66 Vacuolar protein-sorting protein BRO1  8 12.3 2.39E+01 -1.78 
67 ,3-beta-glucanosyltransferase PGA4  8 25.9 2.41E+01 -1.72 
68 
Medium-chain fatty acid ethyl ester 
synthase/esterase  
6 25.6 2.34E+01 -1.71 
69 Uncharacterized protein  27 38.4 2.67E+01 -1.70 
70 
 Putative NADPH-dependent methylglyoxal 
reductase GRP2  
32 85.6 3.11E+01 -1.70 
71  Uncharacterized protein 18 74.7 2.92E+01 -1.67 
72 Uncharacterized protein  10 48.5 2.44E+01 -1.64 
73  Malate synthase  42 76.6 2.88E+01 -1.63 
74  Glycine cleavage system P protein  31 52.8 2.78E+01 -1.62 
75  Putative phosphotransferase  28 63.2 2.71E+01 -1.61 
76  4a-hydroxytetrahydrobiopterin dehydratase  8 88.6 2.64E+01 -1.61 
77  Uncharacterized protein  7 14.3 2.36E+01 -1.60 
78  Uncharacterized protein  2 10.5 2.33E+01 -1.58 
79 Uncharacterized protein  6 61 2.46E+01 -1.58 
80 Xylulokinase  15 47.2 2.60E+01 -1.52 
81  Cytochrome c peroxidase, mitochondrial  20 66.4 2.90E+01 -1.51 
82 Uncharacterized protein  8 16.3 2.38E+01 -1.51 
 
 
 
Blast2GO annotation software was used to group proteins based on conserved GO terms in order 
to identify processes and pathways potentially associated with atorvastatin effect.  GO terms were 
categorized by enzyme classes (EC), biological processes (BP), molecular function (MF) and 
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cellular components (CC). The enzyme classes that altered in abundance of C. albicans treated 
with atorvastatin (12 µg/ml) were; oxidoreductases, transferases, hydrolases, lyases, isomerases 
and ligases (Fig. 3.21). The enzyme class that shows the highest increase in abundance in C. 
albicans exposed to atorvastatin was oxidoreductases enzymes class followed by hydrolase class. 
The increases in BP in atorvastatin C. albicans treatment included proteins labelled as single-
organism cellular process (69 - 81), single-organism cellular process (74 - 93), filamentous growth 
(18 - 20), response to stress (22 - 44), response to chemicals (23-31), cellular response to stimulus 
(33 - 46), catabolic process (15 - 27) and establishment of localization (19 - 32) (Fig. 3.22). The 
significant changes were observed.  
The increases in MF in C. albicans treatment included proteins labelled in small molecule binding 
(36 proteins in control – 39 proteins in treated C. albicans), ion binding (54 - 60), ion binding 
carbohydrate derivative binding (25 - 30), hydrolase activity (27 - 33) and oxidoreductase activity 
(35 - 47) (Fig. 5.23).  Changes were observed. 
The increase in CC in C. albicans treatment included proteins labelled intracellular organelle (100 
proteins in control – 72 proteins in treated C. albicans), ribonucleoprotein complex (27 - 0), 
membrane-bounded organelle (93 - 65), non-membrane-bounded organelle (34 - 18), intracellular 
organelle part (54 - 0), catalytic complex (20 - 0) and cell periphery (25 - 40). The decrease in MF 
in C. albicans treatment included proteins labelled intracellular (128 - 101), intracellular part (126 
- 99), intracellular organelle (100 - 72), membrane-bounded organelle (93 - 65) and catalytic 
complex (20 - 0) (Fig. 3.24). The significant changes were observed. 
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Figure 3.21: Bar chart showing changes to number of proteins involved in various enzyme classes 
at level 3 ontology. Proteins were assigned groups based on involvement in enzyme classes for 
control and atorvastatin treated. Closed bar: control, open bar: treated. 
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Figure 3.22: Bar chart showing changes to number of proteins involved in various biological 
processes at level 3 ontology. Proteins were assigned groups based on involvement in biological 
processes for control and atorvastatin treated. Closed bar: control, open bar: treated. 
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Figure 3.23: Bar chart showing changes to number of proteins given various molecular functions 
at level 3 ontology.  Proteins were assigned groups based on involvement in molecular function 
for control and atorvastatin (12 µg/ml) treated C. albicans. Closed bar: control, open bar: treated. 
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Figure 3.24:  Bar chart showing changes to number of proteins in various cellular components at 
level 3 ontology. Proteins were assigned groups based on involvement in cellular components in 
the total proteome for control and treated. Closed bar: control, open bar: treated. 
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3.14   Discussion 
 
Statins are used to reduce the cholesterol level in the body by inhibiting the action of HMG-Co A 
(3-hydroxy-3-methylglutaryl-CoA) reductase (Manzoni and Rollini, 2002).  Cholesterol in 
mammals and ergosterol in fungi have a similar structure and biosynthetic pathways consequently 
both pathways are sensitive to the same inhibitory effects of statins  (Stancu and Sima, 2001).   
Patients on statin therapy display  less fungal infections therefore prompting the suggestion that 
statins may have potential applications as  anti-fungal agents in vivo (Sun and Singh, 2009) 
(Galgóczy, 2011). This raises the possibility that statins, in addition to being used to control 
cholesterol levels, may also be used in the control of fungal infections either as sole therapies or 
in combination with existing antifungal therapies (Galgóczy, 2011). For example, statins could be 
useful in the treatment of fungal pathogens showing resistance to conventional antifungal agents 
(e.g. azoles). The work presented here evaluated the interaction of atorvastatin with C. albicans 
and demonstrated the in vivo activity of the statin against C. albicans infection in G. mellonella 
larvae. 
The information presented in Macreadie et al. (2006), suggests that statins inhibit the growth of C. 
albicans. This was concluded as C. albicans cultures grown in the presence of statin showed 
reduced growth. A second study, Wikhe et al., (2007), showed that C. albicans that had been 
treated with statin also had inhibited growth through a reduction in ergosterol level. Both of these 
results are based on the growth of C. albicans in solid media that had been treated with statin. 
None the less, both studies show that statin interrupts the production of ergosterol by interacting 
with its precursor farnesyl diphosphate (Macreadie et al., 2006a).  The results presented in this 
research correlate with the results of both previous studies. The determination of susceptibility of 
C. albicans to a serial dilution of atorvastatin (200 µg/ml) stock solution showed that atorvastatin 
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does inhibit the growth of C. albicans. On the other hand, the combination of atorvastatin (12 
µg/ml) and the serial dilution of amphotericin B (6.25 ug/ml), caspofungin (3.75 µg/ml), 
miconazole (250 µg/ml) or DMSO (25 µg/ml) stock solutions showed that no clear different effect 
except with amphotericin B where it has slightly antagonist effect.  
Exposure of C. albicans to atorvastatin reduced growth and also caused a small reduction in 
viability. Ergosterol plays a key role in maintaining the integrity and permeability of the fungal 
cell membrane and reduced levels of ergosterol could indicate a more porous membrane 
(Macreadie et al., 2006b; Song et al., 2016). Statin exposure did lead to an increase in the release 
of amino acid and proteins from cells indicating increased permeability. 
The release of protein from C. albicans following exposure to atorvastatin could indicate a general 
increase in cell permeability thus suggesting the need for the cell to counteract the elevated 
permeability of the cell. In one and two-dimensional analysis the changes in the abundance  
of proteins following exposure of C. albicans to 12 µg/ml atorvastatin indicated the increased 
expression of a number of proteins associated with the oxidative stress response including band1 
(Hsp72), spot and band 2 (Hsp SSA2). Protein related to cell wall, spot 2 enolase protein (1.4 fold) 
cell wall organization or biogenesis and filamentous growth (Reyna-Beltrán et al., 2018), and spot 
5 alcohol dehydrogenase 1 (10.7) cell wall organization or biogenesis filamentous growth and 
pathogenesis (Dagley et al., 2011). However, exposure of C. albicans control and atorvastatin 
treatment to lysing enzyme (Trichoderma) showed no significant changes in wall degradation. this 
indicated that no significant effect of atorvastatin on the cell wall. 
In addition, exposure of C. albicans to atorvastatin increased the activity of catalase enzyme. The 
activation of C. albicans oxidative stress response genes and enzymes following exposure to 
atorvastatin is evidence of the generation of oxidative stress within this medically important yeast. 
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Atorvastatin treated cells displayed elevated levels of chitin, were larger than untreated cells and 
demonstrated incomplete cell division. Interestingly proteomic analysis revealed glutamine-
fructose-6-phosphate aminotransferase (+2.29-fold), an enzyme which plays a role in chitin 
synthesis and hyphal growth, was increased in abundance in atorvastatin treated cells. Adherence 
to host cells is an important virulence factor of C. albicans (Pendrak and Klotz, 1995) and is 
mediated by a variety of specific and non-specific mechanisms. The dominant adherence 
mechanism is mediated by cell wall bound adhesins which attach to host cell receptors and anchor 
the cell in hostile environments to form a focal point for tissue invasion. Exposure of C. albicans 
to atorvastatin lead to a reduction in the adherence ability of cells possibly as a consequence of the 
altered cell wall composition as indicated by the increased calcofluor staining. Proteomic analysis 
revealed decreased abundance of yeast form wall protein (-6.26-fold) which plays a role in 
adherence and promoting dispersal and in Wh11p (-5.68ffold) – a protein involved in biofilm 
formation and pathogenesis.  
A number of proteins involved in the ability of the cell to respond to stress were reduced in 
abundance. Heat shock proteins such as Hsp12p (-6.33-fold), small heat shock protein 21 (-6.33-
fold) and heat shock protein SSA1 (-4.40 fold) were reduced in abundance and these play roles in 
the pathogenicity of the yeast and in its ability to respond to oxidative and osmotic stress. Reduced 
abundance of these protein may have an impact on the cell’s ability to grow and proliferate in vivo. 
Protein such as Cip1p (-3.73-fold), Pst2p (-3.01-fold), pleiotropic ABC efflux transporter (-2.85-
fold) were also reduced in abundance and all play a role in the cell’s response to oxidative stress 
(Brown et al., 2010). 
Proteomic analysis revealed an increase in the abundance of proteins involved in ergosterol 
biosynthesis in atorvastatin-treated cells. In particular squalene monooxygenase (+4.52-fold), 
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lanosterol synthase (+3.30-fold), keto-steroid reductase (+2.78-fold) and lanosterol 14-alpha 
demethylase (+2.57-fold) were all increased in abundance. Atorvastatin treated cells displayed a 
reduced ergosterol content and perhaps the cells responded to statin exposure by attempting to 
increase its biosynthesis.  Statins inhibit  the synthesis of important isoprenoids, e.g. farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate, which are important lipid attachments for the γ 
subunit of heterotrimeric G-proteins (Pella et al., 2005), guanosine triphosphate binding protein 
Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap) (Ghittoni et al., 2005; Liao, 2008; Pella 
et al., 2005). Moreover, statins act as inhibitors of some G-protein actions and Ras or Ras-like 
signalling, which affect several important bioprocesses (Cordle et al., 2005). 
Larvae of G. mellonella can be employed to assess the virulence of fungal pathogens (Brennan et 
al., 2002b; Fuchs and Mylonakis, 2006) and for determining the in vivo activity of antifungal 
agents (Kavanagh and Sheehan, 2018; Maurer et al., 2015). Their use offers the possibility of 
quickly establishing the in vivo toxicity and efficacy of antimicrobial agents without the need to 
resort to the use of mammals in initial screening studies. In the work presented here atorvastatin 
was shown to be non-toxic to larvae and to be able to protect larvae following infection with C. 
albicans.  The doses used in larvae of 50 and 100 μg/ml are equivalent to 4.55 and 9.09 mg/kg, 
respectively. Interestingly, atorvastatin had a negative effect on survival of mice infected 
with C. albicans and followed up with atorvastatin (40 mg/kg) and this was due to decreased INF-
gamma and IL-4 levels in response to C. albicans while the LD50 for atorvastatin is 5000 mg/kg 
in mice (Rahal et al., 2015).  However, other work has demonstrated that pravastatin enhanced 
survival and a decreased fungal burden in C3H/HeN mice infected with C. albicans and the 
potential benefits of statins in the clinic against Candida have been described (Cuervo et al., 2013; 
Forrest et al., 2010; Spanakis et al., 2010; Tashiro et al., 2012). The proteomic results indicated 
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reduced abundance of proteins associated with virulence and stress response (e.g. Hsp12p, ABC 
efflux transporter) in C. albicans and this may have made the cells more susceptible to killing by 
the larval immune response.  
The results presented here indicate that atrovastatin has a profound effect on C. albicans and 
reduced its ability to grow and increases its susceptibility to killing in the G. mellonella larval 
model system.  While the anti-microbial activity of statins is well established this work 
demonstrates how they interact with the fungal proteome to induce their effects and highlight their 
ability to retard proliferation in vivo.  The continuing problems associated with existing antifungal 
therapies (e.g. toxicity, drug resistance) offer the possibility of employing an active, non-toxic 
therapy such as atorvastatin to supplement existing therapies (Galgóczy, 2011; Nyilasi et al., 
2010).  
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Chapter 4 
 
Analysis of impact of Atorvastatin  
on the virulence of A. fumigatus 
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4.1   Introduction  
 
Aspergillus is a species of fungus that lives in soil, plant matter, and household dust. The most 
pathogenic and the primary causative agent of Aspergillus related infections is A. fumigatus  
(Morgan et al., 2005). A. fumigatus is a serious cause of disease in immunocompromised patients 
or in those with pulmonary malfunction. A. fumigatus is widely distributed in the environment and 
produces large numbers of small conidia which are inhaled on a daily basis (O’Gorman, 2011). In 
a healthy individual, the immune system eliminates them from the body without a problem. 
However, it is a serious cause of disease in immunocompromised patients or in patients with 
pulmonary disease like cystic fibrosis (CF) and asthma, conidia can quickly germinate and grow 
in the lung  (Dagenais and Keller, 2009). The fungus can cause three types of disease; Saprophytic 
infection involves the growth of the fungus in the lung and is seen in asthmatic and CF patients. 
Allergic bronchopulmonary aspergillosis occurs when the body reacts to toxins and allergens 
secreted by the fungus as it grows in the thick mucus secretion found in the CF or asthmatic lung. 
Invasive aspergillosis occurs in severely immunocompromised patients and involves the fungus 
growing through viable tissue and disseminating to other sites in the body (Kousha et al., 2011). 
Invasive aspergillosis can have a mortality rate of 80 – 90% and is difficult to diagnose and treat 
(Latgé, 1999). A. fumigatus displays a number of characteristics that facilitate its growth and 
persistence in the lung. The fungus is thermotolerant and can survive temperature up to 45oC 
(Maheshwari et al., 2000). It can produce a wide range of enzymes which may facilitate the 
degradation of tissue and toxins which may play a role in suppressing the local immune response 
(Sales-Campos et al., 2013). In addition, it can withstand the immune response (Chotirmall et al., 
2014). Treatment of aspergillosis involves the use of a range of antifungal drugs. The triazole 
voriconazole is highly effective against A. fumigatus and recommended as first-line treatment 
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(Geißel et al., 2018). Amphotericin B has been widely used for the treatment of invasive 
aspergillosis and, due to its inherent toxicity, is now usually administered in a liposomal 
formulation (Pound et al., 2011). Echinocandins, such as caspofungin, show good efficacy against 
aspergillosis and have the advantages of being well tolerated in vivo (Morris and Villmann, 2006). 
Statins are widely used for the control of cholesterol and display strong antifungal properties ( 
Stancu and Sima, 2001). They inhibit the action of 3-hydroxy-3-methylglutaryl-CoA (HMG-Co 
A) reductase and thus block cholesterol biosynthesis (Bonetti et al., 2003). Consequently, fungal 
cells exposed to statins show reduced ergosterol content (Macreadie et al., 2006a; Wikhe et al., 
2007).  It has been reported that patients on high doses of statins show fewer fungal infections 
prompting the suggestion that statins may represent a well-tolerated antifungal therapy that could 
be used alone or in combination with conventional therapies for the treatment of recalcitrant 
infections.  The aim of the work presented here was to characterize the response of A. fumigatus 
to statin exposure with a view to determining it potential as a novel antifungal therapy. 
 
4.2   Analysis of atorvastatin effect on growth of A. fumigatus on solid medium 
 
In this experiment the growth of A. fumigatus in presence of atorvastatin (1.5, 3 and 6 µg/ml) at 
37 0C was assessed. Growth of A. fumigatus was examined at different time points (48, 72 and 96 
h) by measuring surface area on the solid (malt extract agar) medium. In medium supplemented 
with atorvastatin we observed less growth surface area compared with control after 48 h (Fig. 
4.1A). The surface area was decreased with increased atorvastatin concentration (Fig. 4.1B) this 
indicated that the atorvastatin inhibited the growth of A fumigatus. 
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Figure 4.1: Growth surface area of A. fumigatus on Malt agar plate supplemented with different 
concentrations of atorvastatin (1.5, 3 and 6 µg/ml) incubated at  (A). A bar chart of growth area per square 
centimeter of A. fumigatus vs time (48, 72 and 96 h) (B) (***; p < 0.001). 
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4.3   Susceptibility assay 
 
4.3.1   Susceptibility of A. fumigatus to atorvastatin 
 
Exposure of A. fumigatus conidia (initial density 104/ml) to atorvastatin for 48 h at 37 oC resulted 
in reduced growth. An atorvastatin dose of 6.25 µg/ml inhibited growth by 86.4 ± 2.7 % (p < 
0.0001) while doses of 3.12 and 1.56 µg/ml reduced growth by 83 ± 2 and 47.6 ± 4.7 % (p < 0.002) 
respectively at the same timepoint (Fig 4.2). 
 
Figure 4.2: Effect of atorvastatin on growth of A fumigatus. A, fumigatus (initial concentration 
106/ml) was exposed to atorvastatin SAB culture medium. Growth (%) was calculated by 
comparing atorvastatin treated A. fumigatus to control cells after 48 h growth (**; p < 0.01 ***; p 
< 0.001). 
 
4.3.2   Susceptibility of A. fumigatus to a combination of antifungal drugs and 
atorvastatin 
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Susceptibility assays were carried out on A. fumigatus to test the sensitivity of the fungus to 
amphotericin B (6.25 µg/ml), caspofungin (3.75µg/ml), miconazole (250µg/ml) or DMSO (25%) 
stock solutions (Fig 4.3 A, B, C and D) both singly and in combination with, atorvastatin (3µg/ml) 
in accordance with the protocol set out in method (2.5). The results showed a significant decrease 
in the percentage growth of A. fumigatus when the atorvastatin was combined with amphotericin 
B and DMSO (P>0.05 and P<0.01) respectively increased A. fumigatus growth in combination of 
atorvastatin and miconazole and no significant changes when combined with caspofungin. 
 
 
 
 
Figure 4.3A: The percentage growth of A, fumigatus exposed to a serial dilution of Amphotericin 
B (6.25 µg/ml) stock solution in presence atorvastatin (3 µg/ml).  
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Figure 4.3B: The percentage growth of A. fumigatus exposed to a serial dilution of caspofungin 
(3.75 µg/ml) stock solution and in presence atorvastatin (3 µg/ml). 
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Figure 4.3C: The percentage growth of A. fumigatus exposed to a serial dilution of miconazole 
(250 µg/ml) stock solution and in presence atorvastatin (3 µg/ml). 
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Figure 4.3D: The percentage growth of A. fumigatus exposed to a serial dilution of DMSO (25 %) 
stock solution and in presence atorvastatin (3 µg/ml). 
 
4.4   Effect of atorvastatin with amphotericin B on biomass of A. fumigatus  
 
Exposure of cultures of A. fumigatus to atorvastatin lead to a significant inhibition of a biomass 
accumulation at 72 h. Cultures were pre-grown for 24 h and then supplemented with atorvastatin 
at the concentrations stated for a further 48 h. Biomass was reduced from 3.45 ± 0.13 g/100 ml in 
control to 2.28 ± 0.08 gr/100 ml (p = 0.0018) at a concentration of (1.5 µg/ml) and at a 
concentration of (6 µg/ml) biomass decreased to 0.488 ± 0.04g/100 ml (p < 0.0001) (Fig 4.4 A and 
B).  
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Figure 4.4A and B: The biomass of A. fumigatus exposed to atorvastatin (1.5 and 6 µg/ml). A. 
fumigatus was grown in SAB culture medium at 370C. Biomass was calculated by comparing 
atorvastatin treated A. fumigatus to control cells after 72 h growth (**; p < 0.01 ***; p < 0.01). 
Morphological difference of A. fumigatus cultures that supplemented with atorvastatin (3 µg/ml) 
(B). 
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4.5   Fluorescence microscopy 
 
Staining cells with calcofluor following exposure to atorvastatin (3 µg/ml) for 24 h displayed an 
increase in hyphal condensation and shows thinner hyphae in atorvastatin treatment than in control 
sample (Fig 4.5). 
 
 
 
 
Figure 4.5: Calcofluor staining of A. fumigatus following exposure to atorvastatin. (Magnification 
x 400). A. fumigatus cells were exposed to atorvastatin (3 µg/ml) for 24 hr., stained with Calcofluor 
white and visualized with an Olympus BX51 fluorescence microscope.  
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4.6   Ergosterol extraction and quantification  
 
Exposure of A. fumigatus to atorvastatin (3 µg/ml) for 72 h lead to a reduction in the ergosterol 
content of cells (control = 0.044 ± 0.004 mg/ml and atorvastatin = 0.003 ± 0.0006 (p = 0.008) (Fig 
4.6). 
  
 
Figure 4.6: Atorvastatin (3 µg/ml) exposure reduced the ergosterol content of A. fumigatus. 
Ergosterol quantification was performed using a Gas Chromatograph with a flame ionization 
detector and a chrompack capillary column. Ergosterol standards were used to calibrate the 
instrument. Ergosterol content was expressed in terms of mg/ml (**; p < 0.01). 
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4.7   Atorvastatin induces leakage from A. fumigatus 
 
The effect of atorvastatin on membrane permeability was assessed by quantifying amino acid and 
protein release from cells.  
4.7.1   Determination of Amino acid Leakage 
 
Exposure of cells to atorvastatin (3 µg/ml) for 4 or 6 h lead to an increase in amino acid release 
from cells (Fig 4.7). At 4 h   amino acid release from control cells was 0.14 ± 0.0035 µg/ml but 
from the 3 µg/ml atorvastatin treatment it was 0.5 ± 0.0037 µg/ml. At 6 h exposure the amino acid 
release from control cells was 0.4 ± 0.004 µg/ml and 1.08 ± 0.04 µg/ml (p < 0.003) in the treatment 
3 µg/ml.  
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Figure 4.7: Effect of atorvastatin on release of amino acids from A. fumigatus. The effect of 
atorvastatin (3 μg/ml) on A. fumigatus amino acid release was determined by ninhydrin 
colorimetric assay. Atorvastatin treatment resulted in increased amino acid release relative to 
control cells (*; p < 0.05, **; p < 0.01 ***; p < 0.001). 
 
 
 
4.7.2   Assessment of protein release  
 
Exposure of A.  fumigatus to atorvastatin also lead to increased protein leakage (Fig 4.8). Exposure 
to atorvastatin for 4 h lead to protein concentration of 107.6 ± 5.2 µg/ml in treatment (3 µg/ml) 
compared to 85.6 ± 6 µg/ml in control and after 6 h in control the protein release was 106.8 ± 3.1 
µg/ml compared to 150.5 ± 3.6 µg/ml in treatment (3 µg/ml) (p < 0.02).  
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Figure 4.8: Effect of atorvastatin on release of protein from A. fumigatus. The effect of atorvastatin 
(3 μg/ml) on A. fumigatus protein release was determined by Bradford protein assay. Atorvastatin 
treatment resulted in increased protein release relative to control cells (*; p < 0.05, **; p < 0.01). 
 
 
4.8   Effect of atorvastatin and atorvastatin in combination with amphotericin B on 
Gliotoxin release of A. fumigatus  
 
Atorvastatin exposure induced an increase in the release of gliotoxin from A. fumigatus cultures 
(Fig 4.9). After 72 h growth at 37 °C gliotoxin was 14.04 ± 1.01 ng/ml at an atorvastatin 
concentration of 1.5 µg/ml compared to control which was 4.2 ± 0.6 ng/ml  (p = 0.005) and at an  
atorvastatin concentration of 6 µg/ml the gliotoxin concentrations 47.22 ± 5.06 ng/ml (p = 0.01). 
When A. fumigatus was exposed to atorvastatin in combination with amphotericin B (3 µg/ml and 
(0.4 µg/ml respectively) the gliotoxin release was increased (Fig 4.10). After 72 h growth gliotoxin 
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release increased to 29.06 ± 0.9 ng/ml compared to control which was 10 ± 1 ng/ml (p = 0.005) 
and in atorvastatin concentration of 3 µg/ml the gliotoxin concentration was 33.10± 4.9 ng/ml 
under the same conditions (p = 0.04).  
 
Figure 4.9: Atorvastatin (3 µg/ml) exposure increased the gliotoxin release from A. fumigatus. 
Gliotoxin quantification was performed using a HPLC. The gliotoxin standards were used to 
calibrate the instrument. Gliotoxin content was expressed in terms of ng/ml (*; p < 0.01**; p < 
0.01). 
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Figure 4.10: Atorvastatin and atorvastatin in combination with amphotericin B exposure increased 
the gliotoxin release from A. fumigatus. Gliotoxin quantification was performed using a HPLC. 
The gliotoxin standards were used to calibrate the instrument. Gliotoxin content was expressed in 
terms of ng/ml (*; p < 0.01**; p < 0.01). 
 
4.9   Label-free proteomic analysis of response of A. fumigatus to atorvastatin  
 
Proteomic analysis of A. fumigatus cultures exposed to atorvastatin (3 µg/ml) revealed 25915 
peptides representing 1360 proteins and 128 proteins which represented by 2596 peptide were 
determined in different abundance with fold change of > 1.5 of which 83 were increased in 
abundance and 45 were decreased in abundance. These proteins were subsequently used to 
statistically analyse the total differentially expressed group after imputation of the zero values as 
described and were then included in statistical analysis after data imputation. A principal 
component analysis (PCA) (Fig. 4.11) was performed on all filtered proteins and clearly 
distinguished the control and atorvastatin treated A. fumigatus samples. The heat maps also show 
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major differences in the relative abundance of proteins in the control and atorvastatin treated cells 
(Fig. 4.12).   The volcano plot shows the relative distribution of these proteins (Fig. 4.13). Of the 
proteins increased in abundance (Table 4.1) the most notable were: socyanide synthase A (+ 8.52 
fold), glutathione S-transferase family protein (+ 8.43 fold), kynureninase 2 (4.48 fold), and 
nonribosomal peptide synthetase fmpE (+3.06 fold).  And proteins decrease in abundance (Table 
4.2) the main peptides decreased were O-methyltransferase (-3.68 fold), aflatoxin B1(-2.86 fold), 
allergen Asp f 15 (-2.45 fold) and GNAT family acetyltransferase, (-2.25 fold). The results were 
confirmed by STRING analysis (Fig. 4.14).  
 
 
 
Figure 4.11: Principal component analysis of control and atorvastatin treated A. fumigatus for 24 
h showing a clear distinction between control and treatment. 
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Figure 4.12: Two-way unsupervised hierarchical clustering (B) of the median protein expression 
values of all statistically significant differentially abundant proteins from A. fumigatus control (C1, 
C3, C4) and atorvastatin treated (T5, T7, T8) A. fumigatus. 
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Figure 4.13: Volcano plot showing the distribution of quantified proteins according to p value 
(−log10 p-value) and fold change (log2 mean LFQ intensity difference). Proteins above the 
horizontal line are considered statistically significant (p value < 0.05) and those to the right and 
left of the vertical lines indicate relative fold changes ± 1.5.  
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Table 4.1: Relative fold changes of proteins increased in abundance in atorvastatin (3 µg/ml) 
treated A. fumigatus and the number of matched peptides, sequence coverage, and overall intensity. 
Only proteins that had more than two matched peptides and were found to be differentially 
expressed at a level greater than +1.5-fold were considered to be in significantly variable 
abundances between control and treated. 
N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean LFQ 
intensity 
Fold 
change  
1 
Pyoverdine/dityrosine biosynthesis family 
protein 
68 82.7 3.54E+10 8.52 
2 Glutathione S-transferase family protein 23 84.8 2.27E+10 8.43 
3 ThiJ/PfpI family protein 19 79.2 3.78E+09 5.18 
4 Kynureninase  25 76.3 2.34E+09 4.49 
5 Uncharacterized protein 26 37.1 1.23E+09 4.41 
6 Nonribosomal peptide synthetase fmpE  26 27.3 7.36E+08 3.06 
7 Amidase, putative  15 33.1 1.52E+09 2.78 
8 Glutamate carboxypeptidase, putative 10 25.6 3.98E+08 2.56 
9 Kinesin-like protein 20 50.3 9.62E+08 2.28 
10 Ubiquitin-protein ligase (Tom1), putative 46 17.8 7.80E+08 2.24 
11 Lipase/esterase, putative 9 48.2 3.66E+08 2.12 
12 Polyketide synthase, putative 55 35.7 3.48E+09 2.11 
13 Carbon-nitrogen family hydrolase, putative 16 74.5 3.51E+09 2.05 
14 Heat shock protein Hsp30/Hsp42, putative 6 38.3 1.51E+09 2.02 
15 Phosphatidylinositol transporter, putative 15 54.1 1.16E+09 2.00 
16 Methionine aminopeptidase  23 54.9 1.80E+09 1.83 
17 
Phospho-2-dehydro-3-deoxyheptonate 
aldolase  
12 52.3 3.83E+08 1.80 
18 IMP-specific 5'-nucleotidase 12 34.7 4.61E+08 1.80 
19 Mitochondrial pyruvate carrier 5 54.4 4.17E+08 1.79 
20 
U6 small nuclear ribonucleoprotein 
(Lsm3), putative 
3 74.7 5.87E+08 1.77 
21 HAD superfamily hydrolase, putative 5 30.2 4.88E+08 1.76 
22 ABC multidrug transporter Mdr1  25 26.2 7.22E+08 1.74 
23 Amino acid oxidase fmpA  43 73 7.09E+09 1.74 
24 Trehalase 21 39.2 7.25E+08 1.73 
25 
5-demethoxyubiquinone hydroxylase, 
mitochondrial  
6 33.9 2.60E+08 1.73 
26 Transcriptional activator 7 28 5.01E+08 1.63 
27 Alcohol dehydrogenase, putative  35 80.9 3.35E+10 1.62 
28 1,3-beta-glucanosyltransferase Bgt1  8 32.8 5.06E+08 1.61 
29 Psi-producing oxygenase A 67 67.6 8.87E+09 1.55 
30 Uncharacterized protein 9 30.1 3.67E+08 1.54 
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Table 4.2: Relative fold changes of proteins decreased in abundance in atorvastatin (3 µg/ml) 
treated A. fumigatus and the number of matched peptides, sequence coverage, and overall intensity. 
Only proteins that had more than two matched peptides and were found to be differentially 
expressed at a level greater than -1.5-fold were considered to be in significantly variable 
abundances between control and treated. 
N0. Protein name  
Unique 
peptides 
Sequence 
coverage [%] 
Mean LFQ 
intensity 
Fold 
change  
1 O-methyltransferase  15 55.6 1.03E+09 -3.69 
2 
 Haloalkanoic acid dehalogenase, 
putative  
15 92.4 2.39E+09 -3.00 
3 
 Aflatoxin B1-aldehyde reductase 
GliO-like, putative  
13 52.9 4.44E+08 -2.86 
4 Allergen Asp f 15  5 40.1 1.07E+09 -2.46 
5  Malate synthase  33 59 3.68E+09 -2.41 
6 
 GNAT family acetyltransferase, 
putative  
24 88.3 2.63E+09 -2.26 
7  GMC oxidoreductase, putative  26 50.5 3.32E+09 -2.23 
8 alcohol dehydrogenase, putative  21 58.1 2.16E+09 -1.53 
9 
NADH-dependent flavin 
oxidoreductase, putative  
9 38.9 6.52E+08 -1.51 
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Figure 4.14: Interaction network analysis of up regulated proteins in atorvastatin (3µg/ml) treated 
A. fumigatus. Protein interaction information was obtained from the STRING database using gene 
lists extracted for statistically significant differentially abundant (SSDA) proteins of increased 
abundance in treated A. fumigatus. Statistically enriched KEGG and Gene Ontology (GO) terms 
were examined to identify pathways and processes enriched within each set of proteins. 
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Blast2GO annotation software was used to group proteins based on conserved GO terms in order 
to identify processes and pathways potentially associated with atorvastatin effect.  GO terms were 
categorized by enzyme classes (EC), biological processes (BP), molecular function (MF) and 
cellular components (CC).  
The enzyme classes that altered in abundance of A. fumigatus treated with atorvastatin (3 µg/ml) 
were; oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases (Fig. 4.15). The 
enzyme class that shows the highest decrease in abundance in A. fumigatus exposed to atorvastatin 
was lyase enzymes class followed by hydrolase enzymes.  
In the BP,  the most changed process in atorvastatin A. fumigatus treatment included proteins 
labelled as cellular metabolic process (45 proteins in control – 21 proteins in treated A. fumigatus), 
primary metabolic process (45 – 16), nitrogen compound metabolic process (39 - 17), biosynthesis 
process (28 - 10) and small molecule metabolic process (21 - 13) (Fig. 4.16). The results showed 
a significant change of biological process. The changes in MF in A. fumigatus treatment included 
proteins labelled in ion binding (32 proteins in control – 20 proteins in treated A. fumigatus), small 
molecule binding (22 - 14), drug binding (18 - 5), hydrolase activity (26-8) and transferase activity 
(26 -16) (Fig. 4.17).  Changes were observed in abundance of molecular function.  
The changes in CC in A. fumigatus treatment included proteins labelled intracellular part (47 
proteins in control – 17 proteins in treated A. fumigatus), intracellular organelle (26 - 10), 
ribonucleoprotein complex (7 - 2), membrane-bounded organelle (93-65), membrane-bounded 
organelle (22 - 8) and intracellular organelle part (17-5) (Fig. 4.18). The results displayed a 
difference in protein abundance according to cell component.  
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Figure 4.15: Bar chart showing changes to number of proteins involved in enzyme classes at level 
3 ontology. Proteins were assigned groups based on involvement in biological processes for 
control and atorvastatin treated. Open bar: control, closed bar: treated. 
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Figure 4.16: Bar chart showing changes to number of proteins involved in various biological 
processes at level 3 ontology. Proteins were assigned groups based on involvement in biological 
processes for control and atorvastatin treated. Open bar: control, closed bar: treated. 
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Figure 4.17:  Bar chart showing changes to number of proteins in various cellular components at 
level 3 ontology. Proteins were assigned groups based on involvement in cellular components in 
the total proteome for control and treated.  
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Figure 4.18: Bar chart showing changes to number of proteins given various molecular functions 
at level 3 ontology.  Proteins were assigned groups based on involvement in molecular function 
for control and atorvastatin (3µg/ml) treated A. fumigatus. Open bar: control, closed bar: treated. 
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4.10   Effect of statin on Galleria infected with A. fumigatus 
 
Atorvastatin (9.09mg/kg) treatment of G mellonella larvae infected with A fumigatus showed a 
significant increase in survival of the larvae (Fig. 4.19).  After 2 h, infected larvae displayed an 
increase in survival by 43.3 % ± 3.3 and after 4 h to 36.6 % ± 6.6 compared to non-treated sample 
3.3 % ± 3.3.  
 
 
 
Figure 4.19: Effect of atorvastatin on viability of G. mellonella larvae infected with A fumigatus. 
Larvae administered a dose of with atorvastatin (9.09 mg/kg) displayed no decrease in survival. 
Larvae were inoculated with A fumigatus (1 × 106/larva) and followed up 30 mins, 2 h, or 4 h later 
with atorvastatin (9.09 mg/kg). Atorvastatin treatment enhanced larval survival relative to non-
treated larvae. 
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4.11   Discussion 
Statins, 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, belong 
to a group of drugs that are able to inhibit a key enzyme in the cholesterol biosynthesis (Kotyla, 
2010) (Corsini et al., 1998). Sterols are constituents of the cellular membranes that are essential 
for their normal structure and function (de Souza and Rodrigues, 2009). Cholesterol in mammals 
and ergosterol in fungi have similar structure and biosynthetic pathways consequently both 
pathways are sensitive to the same inhibitory effects of statins  (Camélia Stancu and Sima, 2001).  
Patients on statin therapy display  less fungal infections thereby encourage the suggestion that 
statins may have potential effects as  anti-fungal agents in vivo (Sun and Singh, 2009) (Galgóczy, 
2011). Statins exhibit antifungal properties in vitro, but the concentrations used in these 
experiments are dramatically high, and also statins have effects on fungal physiology beyond direct 
growth inhibition (Bergman and Björkhem-Bergman, 2013). This raises the possibility that statins, 
in addition to being used to control cholesterol levels, may also be used in the control of fungal 
infections either as sole therapies or in combination with existing antifungal therapies (Galgóczy, 
2011). They also have synergistic interactions with antimicrobial agents (Sun and Singh, 2011).  
The information presented in Qiao et al., (2007), suggests that statins do inhibit the growth of A. 
fumigatus. This was concluded as A fumigatus cultures grown in the presence of statin showed 
reduced growth. A second study,(Macreadie et al., 2006a), showed that A. fumigatus that had been 
treated with statin also had inhibited growth through a reduction in ergosterol level. Both of these 
results are based on the growth of A. fumigatus in solid media that had been treated with statin. 
None the less, both studies show that statin interrupts the production of ergosterol by interacting 
with its precursor farnesyl diphosphate (Macreadie et al., 2006).  The results of this study correlate 
with the results of both previous studies.  
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The work presented here evaluated the interaction of atorvastatin with A. fumigatus and 
demonstrated the in vivo activity of the statin against A fumigatus infection in G. mellonella larvae. 
The determination of susceptibility of A. fumigatus to a serial dilution of atorvastatin (200 µg/ml) 
stock solution showed that atorvastatin does inhibit the growth of A. fumigatus. however the 
combination of atorvastatin (3 µg/ml) and the serial dilution of amphotericin B (6.25 ug/ml), 
caspofungin (3.75 µg/ml), miconazole (250 µg/ml) or DMSO (µg/ml) stock solutions showed a 
significant decrease in the percentage growth of A. fumigatus when the atorvastatin combined with 
amphotericin B and DMSO P>0.05 and P<0.01 respectively, increase in A. fumigatus growth in 
combined of atorvastatin and miconazole  and in terms of caspofungin no significant changes. 
These results indicated that the atorvastatin has a synergistic effect in combination with 
amphotericin B against A. fumigatus. Sterol analysis conducted during this project showed that 
atorvastatin does inhibit the amount of ergosterol produced. Results present a reduction in the 
amount of ergosterol produced from A. fumigatus that were treated with atorvastatin (3ug/ml) at 
72 h in liquid cultures compared to nontreated culture. This would support Macreadie et al., (2006), 
in suggesting that statin does inhibit ergosterol synthesis in A. fumigatus, and therefore the growth. 
Statins reduce cholesterol biosynthesis in vivo (Matilde Manzoni and Rollini, 2002). Exposure of 
A. fumigatus to atorvastatin reduced fungal growth and induced increased membrane permeability 
as evidenced by increased release of protein and amino acids. Maximum amino acid and protein 
leakage occurred in the 3 µg/mL treatment at 6 h and this concentration may be optimal for this 
effect. Analysis of the fungal biomass produced from liquid cultures of A. fumigatus treated with 
atorvastatin showed that the biomass decreased in response to increase in the atorvastatin 
concentration, this indicate that the A. fumigatus are sensitive to atorvastatin. In addition, staining 
cells with calcofluor following exposure to atorvastatin (3 µg/ml) for 24 h showed an increase in 
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hyphal condensation and shows thinner hyphae in atorvastatin treatment than in the control sample. 
This indicates that the cells under stress and started to protect themselves by changing the 
biological process to withstand the environment changes. 
Cultures treated with atorvastatin also released elevated levels of gliotoxin, which also has been 
observed in A. fumigatus exposed to amphotericin B and may indicate an oxidative stress response 
(Reeves et al., 2004). A. fumigatus under stress, produces more gliotoxin than if it was not under 
stress (Belkacemi et al., 1999).  Depletion of the intracellular gliotoxin concentration may increase 
the biosynthesis of the toxin to recover the lost gliotoxin in order to restore the redox balance 
within the cell. (Schrettl et al. 2010). This phenomenon of gliotoxin leakage has the potential to 
contribute to elevated levels of pulmonary damage and immunosuppression (Tsunawaki et al., 
2004). It is possible that administration of atorvastatin to patients may lead to eventual fungal cell 
death but that before this is achieved internal gliotoxin would be released from cells and the cells 
could have the opportunity to commence synthesizing more toxins to recover that which is lost 
into the surrounding tissue. Previous work that examined the response of A. fumigatus to 
amphotericin B illustrated the ability of cells to recover from antifungal therapy even though they 
appeared incapable of replicating in culture thus highlighting the possibility of continued cell 
survival in the presence of fungicidal concentrations of drug (Liao et al., 1999). An analysis of 
gliotoxin in A. fumigatus control and atorvastatin (6 µg/ml) treatment would give an idea of the 
atorvastatin increased stress in the cells. The results display that the sample treated with 1.5 and 6 
µg/ml of atorvastatin for 72 h produced more gliotoxin in the treated samples compared to the 
control sample. Exposure A. fumigatus to atorvastatin in combination with amphotericin B 
(0.4µg/ml) under the same conditions, results in less gliotoxin release in the case of atorvastatin 
and more gliotoxin release in case of exposure only to amphotericin B. The result illustrates that 
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A. fumigatus appears to overcome the presence of atorvastatin and is capable of produce gliotoxin 
and also the results indicate that A. fumigatus cells more sensitive to gliotoxin release in the case 
of atorvastatin treatment. Proteomic analysis revealed an increased abundance of a range of 
proteins involved in dealing with oxidative stress, including pyoverdine/dityrosine biosynthesis 
(+8.52-fold), 5 demethoxyubiquinone hydroxylase, mitochondrial (+1.74-fold) and alcohol 
dehydrogenase (+1.61fold).  In Saccharomyces cerevisiae, dityrosine is a major component of the 
spore wall surface and plays a role in the resistance of ascospores to environmental stress (Neiman, 
2005). Furthermore, the glutathione Stransferase family protein is increased in abundance (+8.43-
fold), and this protein functions to detoxify xenobiotics. The fumipyrrole biosynthetic (fmpE) 
protein was also increased in abundance (+3.06-fold). Deletion of fmpE in A. fumigatus resulted 
in reduced growth and sporulation of the mutant strains but virulence was not altered as compared 
to the WT strain in a murine infection model (Macheleidt et al., 2015). A range of heat shock 
proteins, such as Hsp30/Hsp42 (+2.02-fold), also increased in abundance in response to 
atorvastatin. Heat shock proteins play an important role in adaptation of the fungal cell to 
environmental  and chemical stresses (Tamayo et al., 2013).  A. fumigatus heat shock proteins are 
also immune-dominant and elicit strong humoral immune responses (Kumar et al., 1993). 
Proteomic analysis also revealed the reduced abundance of a number of peptides associated with 
virulence, including aflatoxin B1 (-2.86-fold) and allergen Asp f 15 (-2.45-fold). Asp f 15 is cell-
wall associated and its decreased abundance could be due to an altered cell-wall composition as a 
result of an altered membrane composition. Statins inhibit the growth of A. fumigatus and 
supplementation of media with ergosterol or cholesterol blocked the growth-inhibiting effect of 
atorvastatin, thus indicating the specificity of statins for the mevalonate synthesis pathway 
(Macreadie et al., 2006a). However, another study found that statins were fungistatic against A. 
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fumigatus, but the MICs were greater than the clinically achievable concentrations (Qiao et al., 
2007). Furthermore, a variety of Candida strains that were resistant to fluconazole and nystatin 
were all sensitive to atorvastatin (Esfahani et al., 2019). Atorvastatin combined with fluconazole 
improved cryptococcosis caused by Cryptococcus gattii and mice treated with atorvastatin had 
increased survival and better clinical outcomes; this was mediated via modifications in the capsule 
and cell membrane in the presence of a statin that induced cell death within phagocytes (de Queiroz 
Ribeiro et al., 2017).  
Larvae of G. mellonella can be employed to assess the virulence of fungal pathogens (Brennan et 
al., 2002,  Fuchs and Mylonakis, 2006) and for determining the in vivo activity of antifungal agents 
(Kavanagh and Sheehan, 2018; Maurer et al., 2015). Their use displays the chance of quickly 
establishing the in vivo toxicity and effectiveness of antimicrobial agents without the need to resort 
to the use of mammals in initial screening research. In the work presented here atorvastatin was 
shown to be non-toxic to larvae and to be able to protect larvae following infection with A. 
fumigatus.  The doses used in larvae was 9.09 mg/kg. The results presented here indicate that 
atorvastatin has a profound effect on A. fumigatus and reduced its ability to grow and increases its 
susceptibility to killing in the G. mellonella larval model system.  While the anti-microbial activity 
of statins is well established this work demonstrates how they interact with the fungal proteome to 
induce their effects and highlight their ability to retard proliferation in vivo.  The continuing 
problems associated with existing antifungal therapies (e.g. toxicity, drug resistance) offer the 
possibility of employing an active, non-toxic therapy such as atorvastatin to supplement existing 
therapies (Galgóczy, 2011; Nyilasi et al., 2010a). 
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Chapter 5 
 
Analysis of the effect of Atorvastatin 
 on Galleria mellonella larvae 
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5.1   Introduction 
 
Galleria mellonella, the greater wax moth or honeycomb moth, is a moth of the family Pyralidae 
(Park et al., 2017).  The moth is spread throughout the world, including Asia, Europe and North 
America (Park et al., 2017). The size of the G. mellonella larvae (range between 1.5 - 2.5 cm) 
enables an easy means of inoculation with specific amounts of drug or pathogen via the pro-leg 
(Fig. 2.6) making G. mellonella more amenable to drug pharmacodynamics studies  (Kavanagh 
and Fallon, 2010).  Wax moth (G. mellonella) larvae are economic, survive at 37°C and require 
no specialist equipment, they are considered as a viable alternative to other models of infection 
(Kay et al., 2019). Their economic importance has led to a number of investigations on their 
biology, molecular biology, ecology, physiology, and behavior. Wax moth larvae are widely used 
as model organisms for research in insect physiology and human pathogens (Browne and 
Kavanagh, 2013). In G. mellonella,  antimicrobial effects and pathogen virulence testing can be 
analysed by using a number of parameters including the degree of melanisation in response to a 
pathogen, larval death, quantification of fungal load, changes in haemocyte densities and changes 
in antimicrobial peptide expression (Bergin et al., 2003). G. mellonella are able to be use in vivo 
as models as they have a high throughput (Cotter et al., 2000) and can be incubated between 30 - 
37oC enabling possible temperature-dependent virulence factors to be studied (Mowlds and 
Kavanagh, 2008). It is also possible to evaluate phagocytic cell function and immune responses to 
set the virulence of pathogens (Cotter et al., 2000). This initial concept in the study of fungal 
virulence was developed further by Brennan et al., (2002) with the discovery of a direct correlation 
between the virulence of C. albicans mutants in BalbC mice and G. mellonella larvae. G. 
mellonella larvae were used to assess the virulence of C. albicans and to investigate the virulence 
of pathogenic and non-pathogenic yeast species (Cotter et al., 2000). Slater et al., (2011) 
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demonstrated a strong correlation between the virulence of A. fumigatus mutants in larvae and 
mice. Fallon et al., (2011) and Renwick et al., (2007) established the actions of 
immunosuppressive molecules such as gliotoxin and fumagillin released from the fungus A. 
fumigatus on phagocytic functions. The immune system of G. mellonella shows functional and 
structural similarities to the innate immune response of mammals (Mylonakis et al., 2005) (Browne 
and Kavanagh, 2013) (Binder et al., 2016) and (Kay et al., 2019). G. mellonella larvae have also 
been utilized for assessing the in vivo activity of amphotericin B, flucytosine and fluconazole 
following challenge with C. neoformans (Mylonakis et al., 2005) and to evaluate the antifungal 
properties of novel silver-based compounds (Rowan et al., 2009). Maguire et al., (2016) 
established that G. mellonella larvae may be used as a model to assess the relative toxicity of food 
preservatives. Administration of silver nitrate (Rowan et al., 2009), glucan (Mowlds et al., 2010) 
or caspofungin (Kelly and Kavanagh, 2011) to G. mellonella larvae induces a nonspecific immune 
response which operates in parallel with the antifungal activity of the introduced agent. Caffeine 
is metabolized in a similar way in G. mellonella larvae to that in mammals and results in a variety 
of behavioral and developmental alterations (Maguire et al., 2017). Clearly the use of G. 
mellonella is a highly advantageous approach in the study and research of microbial pathogenesis 
and chemotherapy however the characterization of alterations to the immunological profile of 
larvae is warranted in order to fully utilize this model. This chapter studied the effect of atorvastatin 
on G. mellonella larvae and analysed the proteomic responses to atorvastatin exposure. 
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5.1.1 Melanisation 
The melanisation reaction is a common response to parasite entry in invertebrate animals, 
especially arthropods, is due to the activity of an oxidoreductase, phenoloxidase. Prophenoloxidase 
shows similar sequence regions to vertebrate complement proteins C3 and C4 (Söderhäll and 
Cerenius, 1998). The prophenoloxidase activating system in a non-self-recognition system that 
leads to the deposition of melanin on microbial surfaces. The recognition of foreign material such 
as lipopolysaccharides by pathogen recognition receptors activates the phenoloxidae cascade. 
Monophenyl L-dopa oxygen oxidoreductase, also known as phenoloxidase, is an enzyme that 
catalyses the oxidization of phenols to quinones. These quinones are then polymerized non-
enzymatically to melanin (Söderhäll and Cerenius, 1998). 
5.1.2. Haemocytes 
Haemocytes are found freely in the haemolymph or adhering to internal organs like the fat body 
or the digestive tract of the insect and can be rapidly mobilised upon breach of the cuticle or entry 
of a pathogen. In order for phagocytic cells to engulf and kill pathogens, haemocytes must first 
recognize invading pathogens and this pathogen recognition mechanism shows further similarities 
in both insects and mammals (Kavanagh and Reeves, 2004). Phagocytosis in insects is known to 
be lectin mediated and is similar to what occurs in human neutrophil (Kavanagh and Reeves, 
2004). The insect haemocyte shows structural and functional similarities to the mammalian 
neutrophil in that both can phagocytose and neutralize engulfed pathogens through the generation 
of superoxide and the secretion of lytic enzymes in the process known as degranulation (Renwick 
et al., 2007, Browne et al., 2013). 
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5.2   Effect of atorvastatin on C. albicans infected G. mellonella  
  
The effect of atorvastatin on C. albicans infected G. mellonella is presented (Fig.5.1 A and B). At 
24 h the average survival of larvae in negative control group was 100% and in case of atorvastatin 
treated group was 67.83 ± 0.16 % compared to positive control which was 19.5 ±0.5 %. After 48 
h the average survival of larvae of the negative control group was 95.8 ±.089 and in case of 
atorvastatin treated group was 46.83 ± 0.16 compared to positive control which was 3.07 ± 0.3 % 
at the same time. The results displayed that the atorvastatin decreased ability of C. albicans to kill 
G. mellonella larvae (Fig 5.1 A). 
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Figure 5.1A: Effect of atorvastatin on viability of G. mellonella larvae infected with C. albicans. 
Viability was monitored over 96 h.  Larvae injected with atorvastatin (12 µg/ml) treated C. 
albicans culture displayed decrease in ability to kill G. mellonella larvae. Atorvastatin treatment 
enhanced larval survival relative to non-treated larvae. (***; p < 0.0001). 
 
 
Figure 5.1B: Effect atorvastatin on G. mellonella larvae infected with C. albicans and extent of  
melanisation over 48 h. Group 1 (10 larvae) negative control were injected with 20µl PBS, group 
(10 larvae) positive control were injected with 20µl C. albicans cells (1x10
6
) and group 3 (10 
larvae) were injected with C. albicans cells (1x10
6
) and atorvastatin (12 µg/ml). 
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5.3   Quantification of atorvastatin of injected G. mellonella larvae by using HPLC 
 
Atorvastatin concentration in larvae was determined by reversed phase-HPLC (Agilent 1200 
Series). Atorvastatin extract (20 µl) was injected onto a C18 Hewlett Packard column. The results 
showed that the quantity of atorvastatin was decreased. The two groups of larvae that are 
administered atorvastatin (5 and 10 mg/ml), the atorvastatin concentration after 6 h became 0.205 
and 0.279 mg/ml respectively compared to the samples of zero time which were 2.76  and 5.86 
mg/ml respectively (Fig. 5.2). The results demonstrated that a significant interaction between 
treatment and time, due to the possible metabolism of atorvastatin by G. mellonella larvae. 
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Figure 5.2: G. mellonella inoculated by intra-hemocoel injection with atorvastatin (5 and 10 
mg/ml). Atorvastatin quantification was performed using a HPLC. The standards atorvastatin was 
used to calibrate the instrument. (***: P<0.001). 
 
5.4   Determination of fungal load in G. mellonella larvae  
 
Larvae were inoculated by intra-hemocoel injection with 5 x 105 yeast cells of control and treated 
culture and incubated at 30 0C as described in chapter two.  At different time point (1, 2, 3,4 and 
24 h), 3 larvae were homogenized using a pestle and mortar in 3 ml of sterile PBS. This was serially 
diluted with PBS, and 100 µl aliquots of the resulting dilutions were plated on YEPD plates 
containing erythromycin and incubated at 30 0C. After incubation of 48 h the results (Fig. 5.3) 
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showed that the decrease in the cell density of atorvastatin treatment sample compared to the 
control sample. The yeast cell density in infected larvae at 1h was 5.6 x 104 ± 3.1 x 103/ml 
compared to the control growth which was 6.4 x 104± 2.8 x 103/ml. By 24 h was 6.2 x 105 ± 2.4 x 
104/ml   relative to control 7.8 x 105 ± 3.5 x 104/ml. The result indicated that the atorvastatin 
inhibits growth of C. albicans. 
 
 
Figure 5.3: Determination of fungal load in G. mellonella larvae. Survival of larvae and 
fluctuations in fungal cell density in C. albicans infected larvae. All values are the mean ± SE of 
three independent replicates. (***; p< 0.001). 
 
5.5   Determination of haemocyte density 
 
Larvae were inoculated by intra-hemocoel injection with different concentration of atorvastatin 
(25, 50, 100, and 200 µg/ml) and were incubated at 30 0C for 24 h. The results demonstrated no 
significant changes in haemocyte density following administration of atorvastatin (25 and 100 
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µg/ml). At atorvastatin (50 and 200 µg/ml) the haemocyte number was 83 ±3.6 x 105 and 86.3 ± 
5.5 x 105 respectively compared to control 62.6 ± 4.3 x 105 (Fig. 5.4). The results showed a small 
increase in number of haemocytes compared to the control.   
 
 
Figure 5.4: The effect of atorvastatin on hemocytes densities of G. mellonella larvae. Larvae were 
inoculated by intra-hemocoel injection with different concentration of atorvastatin (25, 50, 100, 
and 200 ug/ml) and were incubated at 30 0C for 24 h. Changes in haemocyte density in response 
to Atorvastatin. (*; p < 0.05) 
 
5.6   Determination of response of atorvastatin treated C. albicans cell to haemocytes. 
 
C. albicans cells were grown in the presence of atorvastatin (12µg/ml) for 24 h. Hemocytes were 
extracted from larvae and incubated at a density of 1 × 105/ml at 30oC in PBS in a thermally 
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controlled stirring chamber. Cell free hemolymph opsonized C. albicans (2 × 105 cells) was added 
and killing was measured as described previously by diluting and plating yeast cell suspensions 
onto YEPD agar plates. Plates were incubated, and the resulting number of colonies enumerated. 
Results (Fig. 5.5) displayed that the significant increase in percent C. albicans viability of 
atorvastatin treatment relative to non-treatment. After 20 min the percentage of viability increased 
from 53.83 ± 5.199 % of C. albicans control sample to 76.70 ± 5.205 % of treated sample (p<0.05). 
And at 60 min increased to 55.74 ± 6.356 % % compared to control which was 32.85 ± 2.891 was 
(p<0.05). 
 
Figure 5.5: Response of atorvastatin (12µg/ml) treated C. albicans cell to hemocytes at different 
time points (0, 20, 40, 60 and 80 minutes). Results displayed that the percent of colony count were 
decreased by time. (*: p< 0.05). 
 
0 20 40 60 80 100
0
20
40
60
80
100
120 C. albicans
Atorvastatin 12g/ml
*
* *
Time (min)
%
 v
ia
b
il
it
y
 C
. 
a
lb
ic
a
n
s
159 
 
 
5.7   Label-free Proteomic analysis of response of G. mellonella to atorvastatin  
 
5.7.1   Administration of atorvastatin to G. mellonella larvae by intra haemocoel 
injection 
 
Proteomic analysis of atorvastatin injected G. mellonella larvae revealed 1601 peptides 
representing 112 proteins and only one protein was determined in different abundance with fold 
change of > 1.5 of which, this protein was increased in abundance. The peptides were subsequently 
used to statistically analyse the total differentially expressed group after imputation of the zero 
values as described and were then included in statistical analysis after data imputation. A principal 
component analysis (PCA) (Fig. 5.6) was performed on all filtered proteins and clearly 
distinguished the control and atorvastatin treated G. mellonella larvae samples. The heat maps also 
show major differences in the relative abundance of proteins in the control and atorvastatin treated 
cells (Fig. 5.7).   The volcano plot shows the relative distribution of these proteins (Fig. 5.8). The 
only protein increased in abundance (Table 5.1) was apolipophorins (+ 5.66-fold).  
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Figure 5.6: Principal component analysis of control G. mellonella larvae and intra haemocoel 
atorvastatin injected G. mellonella larvae for 24 h showing a clear distinction between control and 
treatment. 
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Figure 5.7: Two-way unsupervised hierarchical clustering of the median protein expression values 
of all statistically significant differentially abundant proteins from G. mellonella control (5, 7 and 
8) and intra haemocoel atorvastatin injected G. mellonella larvae (17, 18 and 20). 
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Figure 5.8: Volcano plot showing the distribution of quantified proteins according to p value 
(−log10 p-value) and fold change (log2 mean LFQ intensity difference). Proteins above the 
horizontal line are considered statistically significant (p value < 0.05) and those to the right and 
left of the vertical lines indicate relative fold changes ± 1.3.  
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Table 5.1: Relative fold changes of proteins increased in abundance of intra haemocoel 
atorvastatin injected G. mellonella larvae and the number of matched peptides, sequence coverage, 
and overall intensity. Proteins had more than two matched peptides and were found to be 
differentially expressed at a level greater than ± 1.5-fold were considered to be in significantly 
variable abundances between control and treated larvae. 
N0 Protein name  
Unique 
peptides 
Sequence coverage 
[%] 
Mean LFQ 
intensity 
Fold 
change  
1 Apolipophorins 3 22.1 3.57E+10 5.66 
 
 
5.7.2   Administration of atorvastatin to G. mellonella larvae by force feeding 
 
Proteomic analysis of atorvastatin force feeding G. mellonella larvae revealed 1785 peptides 
representing 132 proteins and 21 proteins were determined in different abundance with fold change 
of > 1.5 of which 1 were increased in abundance and 20 were decreased in abundance. These 
proteins were subsequently used to statistically analyse the total differentially expressed group 
after imputation of the zero values as described and were then included in statistical analysis after 
data imputation. A principal component analysis (PCA) (Fig. 5.9) was performed on all filtered 
proteins and clearly distinguished the control and atorvastatin treated G. mellonella larvae samples. 
The heat maps also show major differences in the relative abundance of proteins in the control and 
atorvastatin treated cells (Fig. 5.10).   The volcano plot shows the relative distribution of these 
proteins (Fig. 11). The only one protein increased in abundance (Table 5.2) was Hexamerin storage 
srotein PinSP1 (+ 2.9-fold). And proteins decrease in abundance (Table 5.3) the main peptides 
decreased were Diazepam binding inhibitor-like protein (- 3.8-fold), Cecropin-D-like peptide (- 
3.54-fold) and Carboxylesterase (- 3.1-fold). 
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Figure 5.9: Principal component analysis of control G. mellonella larvae and atorvastatin force 
fed G. mellonella larvae for 24 h showing a clear distinction between control and treatment. 
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Figure 5.10: Two-way unsupervised hierarchical clustering of the median protein expression 
values of all statistically significant differentially abundant proteins from G. mellonella control (9, 
11 and 12) and atorvastatin force fed G. mellonella larvae (13, 15 and 16). 
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Figure 5.11: Volcano plot showing the distribution of quantified proteins according to p value 
(−log10 p-value) and fold change (log2 mean LFQ intensity difference). Proteins above the 
horizontal line are considered statistically significant (p value < 0.05) and those to the right and 
left of the vertical lines indicate relative fold changes ± 1.3.  
 
 
 
Table 5.2: Relative fold changes of proteins increased in abundance of atorvastatin force fed G. 
mellonella larvae and the number of matched peptides, sequence coverage, and overall intensity. 
Proteins had more than two matched peptides and were found to be differentially expressed at a 
level greater than ± 1.5-fold were considered to be in significantly variable abundances between 
control and treated larvae. 
N0. Protein name  
Unique 
peptides 
Sequence 
coverage 
[%] 
Mean LFQ 
intensity 
Fold change  
1 Hexamerin storage protein PinSP1 76 78.7 2.0326E+11 2.90 
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Table 5.3: Relative fold changes of proteins increased in abundance of atorvastatin force fed G. 
mellonella larvae and the number of matched peptides, sequence coverage, and overall intensity. 
Proteins had more than two matched peptides and were found to be differentially expressed at a 
level greater than ± 1.5-fold were considered to be in significantly variable abundances between 
control and treated larvae. 
N0. Protein name  
Unique 
peptides 
Sequence 
coverage [%] 
Mean LFQ 
intensity 
Fold 
change  
1 Uncharacterized protein 12 34.8 8.03E+09 -4.60 
2 
Diazepam binding inhibitor-like 
protein  3 25.9 3.46E+09 -3.89 
3 Cecropin-D-like peptide 2 14.5 2.28E+09 -3.54 
4 Uncharacterized protein 7 31.8 2.43E+09 -3.42 
5 Carboxylesterase  13 57 3.75E+09 -3.14 
6 Gustatory receptor    4 26.4 1.94E+09 -2.95 
7 Alpha-crystallin    11 40.4 2.91E+09 -2.64 
8 Lysozyme-like protein 1 9 18.9 1.45E+09 -2.63 
9 Gloverin   2 28.8 1.20E+09 -2.47 
10 Heat shock protein hsp21.4      5 15 1.21E+09 -2.43 
11 Yellow-d 12 26.9 1.94E+09 -2.24 
12 Inducible serine protease inhibitor 2 3 9.8 6.27E+10 -2.15 
13 Beta-1,3-glucan recognition protein   21 45.5 3.87E+09 -1.99 
14 Hdd1-like protein 5 56.9 4.23E+08 -1.90 
15 Apolipophorins 2 26.6 1.87E+10 -1.87 
16 Beta-galactosidase 23 35.1 1.43E+10 -1.83 
17 Similar to CG10638-PA  17 37.4 2.91E+09 -1.79 
18 Odorant-binding protein 7 18.2 7.48E+09 -1.59 
19 Peptidoglycan recognition protein  11 56 1.28E+10 -1.53 
20 Protease inhibitor 1 3 21.2 4.73E+09 -1.52 
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5.8 Discussion  
Statins are the main therapeutic agents used to decrease high serum cholesterol levels and are 
among the most widely prescribed drugs currently in the word (Macreadie et al., 2006a). The sterol 
in plants and eukaryotic microorganisms is ergosterol (Macreadie et al., 2006c). The statins might 
be expected that statins or their derivatives could also be used to inhibit the growth of fungal 
pathogens through inhibition of ergosterol synthesis. Statins have in vitro activities against several 
human pathogenic fungi, including Candida spp., Cryptococcus neoformans, and Zygomycetes 
(Chamilos et al., 2006). Wax moth (G. mellonella) larvae are widely used as model organisms for 
researches in insect physiology and human with pathogens (Browne and Kavanagh, 2013). In G. 
mellonella,  antimicrobial effects and pathogen virulence testing of agents can be analysed by 
using a number of parameters including the degree of melanisation in response to a pathogen, 
larval death, quantification of fungal load, changes in haemocyte densities and changes in 
antimicrobial peptide expression (Bergin et al., 2003).  
The results presented here show that the atorvastatin decreased in the ability of C. albicans to kill 
G. mellonella larvae relative to non-treated. Presence of atorvastatin increased the survival of G. 
mellonella larvae by 50 % comparable to non-treated and this indicates that atorvastatin has in vivo 
effect to inhibit the C. albicans infected G. mellonella larvae. HPLC analysis of atorvastatin 
administrated G. mellonella larvae displayed a considerable interaction between atorvastatin 
concentration and time of extraction, there was a reduction in atorvastatin concentration by 
increase the time. This reduction due to the possibility of atorvastatin metabolism by G. mellonella 
larvae. In this study atorvastatin (5 and 10 mg/ml) were used, and atorvastatin extracted for 
detection at (zero, 0.5, 2 and 6 h) post-administration of atorvastatin, and the HPLC analysis at 
these two concentrations showed a significant decrease in atorvastatin concentration (p < 0.001).  
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this indicates that the atorvastatin metabolized in G. mellonella larvae in a similar manner to that 
in mammals. In the fungal load of C. albicans in G. mellonella larvae experiment there was a slow 
rate of growth of treated larvae. Results showed that the decrease in the C. albicans cell density of 
atorvastatin treatment sample compared to the control sample (P<0.001). This indicate that the 
atorvastatin inhibits growth of C. albicans in vivo. In order to characterize the changes in the 
hemocyte population in larvae, larvae were administered a different concentrations of atorvastatin 
which produced a rise in hemocyte density at atorvastatin concentration of (50 ug/ml and 200 
ug/ml), this elevation of hemocyte possibly due to the release of sessile hemocytes normally 
attached to the fat body and inner surface of the hemocoel of larvae (Bergin et al., 2003) (Sheehan 
and Kavanagh, 2018). In addition, the of response of atorvastatin treated C. albicans cell to 
hemocytes displayed that the significant increase in percent C. albicans viability of atorvastatin 
treatment relative to nontreatment samples. Shotgun proteomics was employed to analyse the 
response of G. mellonella larvae to atorvastatin. Atorvastatin administration was done by intra 
haemocoel injection and by force feeding. In the proteomic analysis of intra-haemocoel injection 
of atorvastatin showed that only one protein has a different in abundance by more than 1.5-fold. 
This protein was apolipophorins which increase in abundance by (5.22-fold). This protein is major 
component of lipophorin, which mediates transport for various types of lipids in hemolymph acts 
by forming lipoprotein particles that bind lipoproteins and lipids (Sundermeyer et al., 1996). 
Proteomic analysis of G. mellonella administered the atorvastatin by force feeding displayed 21 
proteins were different in abundance by more than 1.5-fold. Only one protein that increase in 
abundance this protein was Hexamerin storage protein PinSP1(2.9-fold). In insects,  tope kind of 
proteins are storage proteins or hexamerins accumulate to serve as sources of amino acids during 
metamorphosis and reproduction (Zhu et al., 2002).  
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A number of immune related proteins were decreased in abundance in larvae administered 
atorvastatin including Cecropin-D-like peptide (-3.54 fold), which is an innate immune response 
protein,  killing of cells of other organism and antibacterial activity (Mak et al., 2001), and 
Lysozyme-like protein 1 (- 2.63 fold) has immune response and antimicrobial activity (Gandhe et 
al., 2007). Proteins related to stress like Heat shock protein hsp21.4 (-2.42-fold).  And also, some 
of decreased protein related to fungal cell wall such as Beta-1,3-glucan recognition protein (-1.99-
fold) which has strong specific affinity for β-1,3-glucan, a component of the fungal cell wall. Its 
interaction with  initiates the activation of the prophenoloxidase cascade, which is an important 
defense system in invertebrates of many species (Ochiai and Ashida, 2000).  
Proteomic analysis revealed only two proteins that increase and 20 protein that decreases in 
abundance in both ways of atorvastatin administration (intra-haemocoel injection and by force-
feeding) by 1.5-fold or more. Changes in proteomic analysis of G. mellonella larvae implies that 
no significant stress effect of atorvastatin. This possibly indicates that the atorvastatin is nontoxic 
on the G. mellonella larvae. 
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General discussion 
 
Fungal pathogens of humans cause harmful infections and thus, are considered to be hidden killers 
(Brown et al., 2012). Fungi can cause diverse diseases in humans which range from superficial 
skin infections to life-threatening diseases causing damage to internal organs. Invasive infections 
caused by fungi could be life-threatening especially for patients who are diagnosed with 
autoimmune disorder (Jain et al., 2010).   
Statins are the main therapeutic agents used to decrease high serum cholesterol levels and are 
among the most widely prescribed drugs currently on the market (Macreadie et al., 2006). They 
inhibit (HMG-CoA) reductase enzyme (Qiu et al., 1991).  HMG-CoA is an enzyme that catalases 
the conversion of HGM-CoA to mevalonate, which leads to the production of farnesyl diphosphate 
which is the precursor for the production of cholesterol in humans or ergosterol in plants and 
eukaryotic microorganisms (Macreadie et al., 2006). If the statin-binding site of fungal HMG-CoA 
reductase is like that of human HMG-CoA reductase, it might be expected that statins or their 
derivatives could also be used to inhibit the growth of fungal pathogens through inhibition of 
ergosterol synthesis. It could, therefore, be supposed that if statins could inhibit cholesterol, they 
could inhibit the production of ergosterol (Macreadie et al., 2006).  
 G. mellonella  larvae have been considered as a viable alternative to other models of infection 
since they are cheap and require no specialist equipment (Kay et al., 2019). G. mellonella larvae 
were used to assess the virulence of C. albicans and to investigate the virulence of pathogenic and 
non-pathogenic yeast species (Cotter et al., 2000). G. mellonella has several innate immune 
similarities to mammals they lack many defined organ systems preventing the full study of fungal 
dissemination and antifungal therapy which is possible in mammals (Kavanagh and Fallon, 2010). 
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G. mellonella larvae have also been utilised for assessing the in vivo activity of amphotericin B, 
flucytosine and fluconazole following challenge with C. neoformans (Mylonakis et al., 2005). 
The aim of this study was to determine the antifungal activity of atorvastatin and its effect on C. 
albicans and A. fumigatus by using  G. mellonella larva as a model of infection and also to analyze 
the impact of atorvastatin on G. mellonella larvae. 
The main results from Chapter 3 showed that the atorvastatin reduced growth and also caused a 
small reduction in viability. However, the combination of atorvastatin, amphotericin B, 
caspofungin and, miconazole showed that no clear different effect. Ergosterol plays a key role in 
maintaining the integrity and permeability of the fungal cell membrane and reduced levels of 
ergosterol could indicate a more porous membrane (Macreadie et al., 2006b; Song et al., 2016). 
Statin exposure did lead to an increase in the release of amino acid and proteins from cells 
indicating increased permeability. The release of protein from C. albicans following exposure to 
atorvastatin could indicate a general increase in cell permeability thus suggesting the need for the 
cell to counteract the elevated permeability of the cell. Atorvastatin lead to a reduction in the 
adherence ability of cells possibly as a consequence of the altered cell wall composition as 
indicated by the increased calcofluor staining. Proteomic analysis revealed decreased abundance 
of yeast form wall protein which plays a role in adherence and promoting dispersal and in Wh11p 
protein a protein involved in biofilm formation and pathogenesis. In addition, atorvastatin 
increased the activity of catalase enzyme. Activation of C. albicans oxidative stress response genes 
and enzymes following exposure to atorvastatin is evidence of the generation of oxidative stress. 
Several proteins involved in the ability of the cell to respond to stress were reduced in abundance 
such as Hsp12p and small heat shock protein which play roles in the pathogenicity of the yeast and 
in its ability to respond to oxidative and osmotic stress. Reduced abundance of these protein may 
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have an impact on the cell’s ability to grow and proliferate in vivo. Proteins such as Cip1p, Pst2p 
and pleiotropic ABC efflux transporter were also reduced in abundance and all play a role in the 
cell’s response to oxidative stress (Brown et al., 2010). The proteomic analysis also revealed an 
increase in the abundance of some proteins involved in ergosterol biosynthesis in treated cells. In 
particular squalene monooxygenase and lanosterol synthase, were increased in abundance. 
Atorvastatin treated cells displayed a reduced ergosterol content and perhaps the cells responded 
to statin exposure by attempting to increase its biosynthesis.  Statins inhibit  the synthesis of 
important isoprenoids, e.g. farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are 
important lipid attachments for the γ subunit of heterotrimeric G-proteins (Pella et al., 2005), 
guanosine triphosphate binding protein Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap) 
(Ghittoni et al., 2005; Liao, 2008; Pella et al., 2005). Moreover, statins act as inhibitors of some 
G-protein actions and Ras or Ras-like signaling, which affect several important bioprocesses 
(Cordle et al., 2005). 
Larvae of G. mellonella can be employed to assess the virulence of fungal pathogens (Brennan et 
al., 2002; Fuchs and Mylonakis, 2006) and for determining the in vivo activity of antifungal agents 
(Kavanagh and Sheehan, 2018; Maurer et al., 2015). Their use offers the possibility of quickly 
establishing the in vivo toxicity and efficacy of antimicrobial agents without the need to resort to 
the use of mammals in initial screening studies. In the work presented here atorvastatin was shown 
to be non-toxic to larvae and to be able to protect larvae following infection with C. albicans.  The 
doses used in larvae of 50 and 100 μg/ml are equivalent to 4.55 and 9.09 mg/kg, respectively. 
The results also displayed that atorvastatin has a profound effect on C. albicans and reduced its 
ability to grow and increases its susceptibility to killing in the G. mellonella larval model system.  
While the anti-microbial activity of statins is well established this work demonstrates how they 
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interact with the fungal proteome to induce their effects and highlight their ability to retard 
proliferation in vivo.   
 
The experiments in Chapter 4 showed that exposure of A. fumigatus to atorvastatin resulted in a 
reduction in growth and rescued viability as measure in G. mellonella larvae. These results 
indicated that the atorvastatin has a synergistic effect in combination with amphotericin B against 
A. fumigatus. And in terms of miconazole and caspofungin no significant changes. Sterol analysis 
conducted during this project showed that atorvastatin does inhibit the amount of ergosterol 
produced. This would support Macreadie et al., (2006), in suggesting that statin does inhibit 
ergosterol synthesis in A. fumigatus, and therefore the growth. Atorvastatin increased membrane 
permeability of A. fumigatus as evidenced by increased release of protein and amino acids.  
Cultures treated with atorvastatin also released elevated levels of gliotoxin, which also has been 
observed in A. fumigatus exposed to amphotericin B and may indicate an oxidative stress response 
(Reeves et al., 2004).  A. fumigatus under stress, produces more gliotoxin than if it was not under 
stress (Belkacemi et al., 1999).  Depletion of the intracellular gliotoxin concentration may increase 
the biosynthesis of the toxin to recover the lost gliotoxin in order to restore the redox balance 
within the cell (Schrettl et al. 2010).  
The results displayed that the sample treated with atorvastatin produced more gliotoxin in the 
treated samples compared to the control sample. The result illustrated that A. fumigatus appears to 
overcome the presence of atorvastatin and is capable of produce gliotoxin, and the results indicate 
that A. fumigatus cells are more sensitive to gliotoxin release in the case of atorvastatin treatment. 
 Proteomic analysis revealed an increased abundance of a range of proteins involved in dealing 
with oxidative stress, including pyoverdine/dityrosine biosynthesis 5 demethoxyubiquinone 
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hydroxylase, mitochondrial and alcohol dehydrogenase.  In Saccharomyces cerevisiae, dityrosine 
is a major component of the spore wall surface and plays a role in the resistance of ascospores to 
environmental stress (Neiman, 2005). Furthermore, the glutathione Stransferase family protein is 
increased in abundance, and this protein functions to detoxify xenobiotics. The fumipyrrole 
biosynthetic (fmpE) protein was also increased in abundance. Deletion of fmpE in A. fumigatus 
resulted in reduced growth and sporulation of the mutant strains but virulence was not altered as 
compared to the WT strain in a murine infection model (Macheleidt et al., 2015). A range of heat 
shock proteins, such as Hsp30/Hsp42, also increased in abundance in response to atorvastatin. 
Heat shock proteins play an important role in adaptation of the fungal cell to environmental  and 
chemical stresses (Tamayo et al., 2013). Proteomic analysis also revealed the reduced abundance 
of a number of peptides associated with virulence, including aflatoxin B1 and allergen Asp f 15. 
Asp f 15 is cell-wall associated and its decreased abundance could be due to an altered cell-wall 
composition as a result of an altered membrane composition. Statins inhibit the growth of A. 
fumigatus and supplementation of media with ergosterol or cholesterol blocked the growth-
inhibiting effect of atorvastatin, thus indicating the specificity of statins for the mevalonate 
synthesis pathway (Macreadie et al., 2006a). However, another study found that statins were 
fungistatic against A. fumigatus, but the MICs were greater than the clinically achievable 
concentrations (Qiao et al., 2007). Furthermore, a range of  Candida strains  that were resistant to 
fluconazole and nystatin were all sensitive to atorvastatin (Esfahani et al., 2019). Atorvastatin 
combined with fluconazole improved cryptococcosis caused by Cryptococcus gattii and mice 
treated with atorvastatin had increased survival and better clinical outcomes; this was mediated via 
modifications in the capsule and cell membrane in the presence of a statin that induced cell death 
within phagocytes (de Queiroz Ribeiro et al., 2017).  
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As discussed before use of G. mellonella displays the chance of quickly establishing the in vivo 
toxicity and effectiveness of antimicrobial agents. In this study atorvastatin was shown to be non-
toxic to larvae and to be able to protect larvae following infection with A. fumigatus.  The doses 
used in larvae was 9.09 mg/kg. The results presented here indicate that atorvastatin has a profound 
effect on A. fumigatus and reduced its ability to grow and increases its susceptibility to killing in 
the G. mellonella larval model system.  While the anti-microbial activity of statins is well 
established this work demonstrates how they interact with the fungal proteome to induce their 
effects and highlight their ability to retard proliferation in vivo.  The continuing problems 
associated with existing antifungal therapies (e.g. toxicity, drug resistance) offer the possibility of 
employing an active, non-toxic therapy such as atorvastatin to supplement existing therapies 
(Galgóczy, 2011, Nyilasi et al., 2010a). 
The results of chapter 5 showed that the atorvastatin decreased in the ability of C. albicans to kill 
G. mellonella larvae relative to the control.  The presence of atorvastatin increased the survival of 
G. mellonella larvae by 50 % compared to non-treated and this indicates that atorvastatin has in 
vivo effect to inhibit the C. albicans infected G. mellonella larvae. HPLC analysis of atorvastatin 
administrated G. mellonella larvae displayed a considerable interaction between atorvastatin 
concentration and time of extraction, there was a reduction in atorvastatin concentration over time. 
This reduction may be due to the possibility of atorvastatin metabolism by G. mellonella larvae. 
This result indicates that the atorvastatin metabolized in G. mellonella larvae in a similar manner 
to that in mammals. In the fungal load of C. albicans in G. mellonella larvae experiment there was 
a slow rate of growth of yeast cells in treated larvae. Results showed that the decrease in the C. 
albicans cell density of atorvastatin treatment sample compared to the control sample (P<0.001). 
This indicate that the atorvastatin inhibits growth of C. albicans in vivo. In order to characterize 
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the changes in the hemocyte population in larvae, larvae were administered a different 
concentrations of atorvastatin which produced a rise in hemocyte density at atorvastatin 
concentration of (50 ug/ml and 200 ug/ml), this elevation of hemocyte possibly due to the release 
of sessile hemocytes normally attached to the fat body and inner surface of the hemocoel of larvae 
(Bergin et al., 2003) (Sheehan and Kavanagh, 2018). Shotgun proteomics was employed to analyse 
the response of G. mellonella larvae to atorvastatin. Atorvastatin administration was done by intra 
haemocoel injection and by force feeding. Proteomic analysis revealed only two proteins that 
increased and 20 protein that decreased in abundance in both ways of atorvastatin administration 
(intra-haemocoel injection and by force-feeding) by 1.5-fold or more. Changes in proteomic 
analysis of G. mellonella larvae imply that there was no significant stress effect of atorvastatin. 
This possibly indicates that the atorvastatin may be nontoxic on the G. mellonella larvae. 
In conclusion, the results presented in this thesis indicate that atorvastatin is non-toxic and capable 
of inhibiting the growth and virulence of C. albicans and A. fumigatus. While statins are widely 
used to control cholesterol this work and that of others (Nyilasi et al., 2010, Cabral et al., 2013) 
indicates they may be used alone or in conjunction with conventional antifungal agents to control 
fungal pathogen in vivo and may represent a novel, non-toxic antifungal therapy with a distinct 
mode of action.  
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